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1. Summary
Schizophrenia is a complex heritable psychiatric disorder, which is characterised
by positive and negative symptoms, and cognitive deficits. This thesis
focusses on the glutamate hypothesis of schizophrenia, which is based on the
hypofunction of N-methyl-D-aspartate (NMDA) receptors. This hypothesis is
thought to explain the negative symptoms and cognitive deficits better than the
dopamine hypothesis based on the observed beneficial effect of NMDA receptor
modulators on these symptoms. NMDA receptors require both glutamate
and co-agonist such as glycine or D-serine to function normally. D-serine is
degraded in the brain by the D-amino acid oxidase (DAO) enzyme. Thus,
DAO can regulate the function of NMDA receptors via D-serine breakdown.
One molecular explanation proposed for the NMDA receptor hypofunction is
increased DAO activity leading to decreased D-serine which ultimately results
in NMDA receptor hypofunction. The cause of increased DAO activity in
schizophrenia has been proposed to be due to its interaction with the DAO
activator (DAOA/G72). DAOA has been reported to both increase and decrease
DAO activity. Thus, the effect of DAOA on DAO activity is still controversial.
Despite 15 years of research in the field of DAOA, the exact function of DAOA,
its expression pattern in the human brain and its interaction with DAO is yet to
be elucidated.
The main objectives of this thesis were (i) to understand DAO and DAOA
mRNA and protein expression pattern trajectories across six brain regions during
development and aging in the human post-mortem brains, (ii) to re-evaluate
association of DAO and DAOA single nucleotide polymorphisms (SNPs)
with schizophrenia by conducting meta-analysis of case-control schizophrenia
association studies, (iii) to assess DAO and DAOA SNPs as predictive genetic
and endophenotype markers for transition to schizophrenia-spectrum disorders
in at-risk for psychosis individuals, and (iv) to determine the effect of DAOA on
DAO and NMDA receptor activity in human cell lines.
In the post-mortem study (study I), human post-mortem samples from six brain
regions (ages: 16 weeks of gestation to 91 years) with no neuropathological
evidence of neuropsychiatric disorders were used. We found a higher DAO
mRNA levels in the cerebellum, whereas lower DAO protein levels in the
cerebellum compared to other brain regions studied (brainstem, amygdala,
striatum, thalamus, and frontal cortex), which might suggest post-transcriptional
regulation. Furthermore, DAOA protein was detectable in all brain regions
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studied, whereas DAOA mRNA was undetectable in these brain regions, which
might suggest a tightly regulated or extremely localised DAOA expression.
We found a positive correlation between DAO and DAOA proteins in all
brain regions studied except in the frontal cortex, which provides evidence for
simultaneous expression of these proteins. Moreover, in silico DNA methylation
data downloaded from Gene Expression Omnibus (GEO) datasets showed
that DAO and DAOA CpG sites in the cerebellum were significantly more
methylated than in the frontal cortex, which might explain the brain-region
specific differential DAO and DAOA expression.
In the meta-analysis study (study II), we performed a systematic literature search
which resulted in 20 DAO and 23 DAOA case-control schizophrenia association
studies that fulfilled the inclusion criteria. We re-evaluated the association of 8
DAO and 12 DAOA SNPs with schizophrenia. Out of these SNPs, only one DAO
(rs4623951), and two DAOA (rs778293 and rs3916971) SNPs were significantly
associated with schizophrenia. This systematic meta-analysis is the most
updated one for the association of DAO and DAOA SNPs with schizophrenia.
The at-risk for psychosis study (study III) included a 3-year prospective
study cohort of 185 individuals (ages: 13-35 years) at clinical risk for
psychosis, who were followed-up at 6, 12, 24, and 36 months for conversion
to schizophrenia-spectrum disorders. We assessed whether DAO (rs3918347,
rs4623951) and DAOA (rs778293, rs3916971, rs746187) SNPs could predict
conversion as well as whether they show association with Research Domain
Criteria (RDoC, a non-disease-based dimensional approach) domains, namely,
negative valence system (anxiety, hopelessness) and cognitive systems
(perception disturbances, disorganised symptoms). We found that DAOA
rs746187 CC versus CT+TT genotype carriers (T-allele: risk for schizophrenia)
and DAOA rs3916971 TT versus TC+CC genotype carriers (T-allele: protective
against schizophrenia) experienced nominally more hopelessness and more
visual perception disturbances, respectively. Furthermore, DAO rs3918347
GA+AA genotype carriers experienced nominally more auditory perception
disturbances than GG genotype carriers (G-allele: risk for schizophrenia).
Moreover, DAO and DAOA SNPs did not emerge as predictive markers for
conversion to schizophrenia-spectrum disorders at 36 months follow-up in
at-risk for psychosis population. We found that the schizophrenia risk G-allele
of DAO rs3918347 nominally increased the risk for ultra-high risk (UHR) for
psychosis individuals with attenuated positive symptoms syndrome (APSS).
Our results suggest that DAO and DAOA SNPs might be predictive markers for
endophenotypes such as RDoC negative valence and cognitive systems in at-risk
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for psychosis population.
In the cell culture study (study IV), we used human neuroblastoma SH-SY5Y,
human astrocytoma 1321N1, and human embryonic kidney HEK293 cells.
DAO activity was measured based on the release of hydrogen peroxide and
its interaction with Amplex Red reagent in all three cell lines co-transfected
with DAO and DAOA plasmid constructs. NMDA receptor activity was
measured using whole-cell patch-clamp recording in HEK293 cells that were
stably transfected with NMDA receptor subunits NR1 and NR2A (NR1/NR2A
HEK293) and transiently transfected with DAOA plasmid construct. In silico
experiments were performed using Molecular Dynamics simulations. We found
that DAOA increased DAO activity only in human kidney-like HEK293 cells,
but DAOA had no effect on DAO activity in human neuron-like SH-SY5Y and
human astrocyte-like 1321N1 cells. This might be because of different signalling
pathways, different compartmentalization of DAO and DAOA proteins and
lower DAO and DAOA overexpressed protein levels in 1321N1 and SH-SY5Y
cells compared to HEK293 cells. Furthermore, DAOA had no effect on NMDA
receptor activity in NR1/NR2A HEK293 cells. The simulation experiments
showed that DAOA makes human DAO (hDAO) holoenzyme [hDAO with
flavin adenine dinucleotide (FAD)] more flexible and misfolded than hDAO
apoprotein (hDAO without FAD), that might be suggestive of inactivating effect
of DAOA on hDAO, which is not consistent with our DAO activity results.
Thus, the interactions between DAO and DAOA still needs to be elucidated in a
more realistic in vitro cellular model that recapitulates the complex signalling of
tripartite synapse.
In summary, the performed studies showed that DAO and DAOA genes
are highly regulated at the level of transcription, and have brain-specific
expression patterns varying with age, which might suggest that these genes
are important for brain development. Furthermore, DAO and DAOA SNPs
might emerge as predictive markers for endophenotypes such as negative
symptoms and cognitive deficits in at-risk for psychosis population. Moreover,
the role of DAOA in the NMDA receptor hypofunction pathway is still obscure
and needs to be elucidated with the hope that DAOA might emerge as a
therapeutic target for the treatment of negative symptoms and cognitive deficits
in schizophrenia.
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2. Zusammenfassung
Schizophrene Sto¨rungen sind komplexe psychiatrische Erkrankungen, die
meistens in der Adoleszenz oder im jungen Erwachsenenalter beginnen,
zum grossen Teil genetisch bedingt sind und durch sogenannte “positive”
(z.B. produktive Symptome wie Halluzinationen oder Wahn) und “negative”
Symptome (z.B. Defizite und Reduktion im Antrieb und Affekt), sowie kognitive
Defizite charakterisiert sind. Die vorliegende Dissertation konzentriert sich
auf die Glutamathypothese der Schizophrenie, die auf einer Hypofunktion
der N-Methyl-D-Aspartat-(NMDA)-Rezeptoren basiert. Es wird vermutet,
dass die Dysfunktionen im glutamatergen System die Entwicklung von
“negativen Symptomen” und “kognitiven Defiziten” besser erkla¨rt als
die sogenannte Dopaminhypothese. Diese Annahme basiert u.a. auf den
beobachteten positiven Auswirkungen von NMDA-Rezeptor-Modulatoren auf
die erwa¨hnten Symptome. NMDA-Rezeptoren beno¨tigen sowohl Glutamat als
auch Co-Agonisten wie Glycin oder D-Serin fu¨r eine normale Funktion. Im
Gehirn wird D-Serin durch das Enzym D-Aminosa¨ureoxidase (DAO) degradiert.
Folglich kann DAO die Funktion des NMDA-Rezeptors durch den Abbau von
D-Serin regulieren. Eine mo¨gliche molekulare Erkla¨rung fu¨r die Hypofunktion
des NMDA-Rezeptors ist eine gesteigerte DAO-Aktivita¨t, die zu reduzierter
D-Serin-Aktivita¨t fu¨hrt, was schliesslich eine NMDA-Rezeptor-Hypofunktion
generieren kann. Die Ursache fu¨r die erho¨hte DAO-Aktivita¨t bei schizophrenen
Sto¨rungen wird in der Interaktion von DAO mit dem DAO-Aktivator
(DAOA/G72) vermutet. Es wurde beschrieben, dass DAOA die DAO-Aktivita¨t
sowohl steigern als auch vermindern kann. Bis heute wird der Effekt von DAOA
auf die DAO-Aktivita¨t noch immer kontrovers diskutiert. Obwohl DAOA schon
seit vielen Jahren Gegenstand der Forschung ist, ist seine exakte Funktion,
das Expressionsmuster im menschlichen Gehirn und die Interaktion mit DAO
weiterhin ungekla¨rt.
Ziel dieser Dissertation war einerseits Verla¨ufe und Beziehungen von DAO-
und DAOA-mRNA- sowie DAO- und DAOA-Protein-Expressionsmuster in
sechs verschiedenen Hirnregionen im Verlaufe der Entwicklung und des
Alterungsprozesses im menschlichen Gehirn mittels post-mortem Gehirnproben
zu verstehen. Andererseits sollte der Zusammenhang von DAO- und
DAOA-Einzelnukleotid-Polymorphismen (SNPs, engl. single nucleotide
polymorphism) und schizophrenen Sto¨rungen mittels einer Metaanalyse von
Fall-Kontroll-Assoziationsstudien neu bewertet werden. Dies um DAO- und
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DAOA-SNPs als pra¨diktive genetische und endopha¨notypische Marker fu¨r die
Transition von Risikopatienten zu einer Schizophrenie-Spektrumssto¨rung zu
bestimmen. Ein weiteres Ziel war es, den Effekt von DAOA auf DAO und die
NMDA-Rezeptor-Aktivita¨t in menschlichen Zelllinien zu ermitteln.
Fu¨r die erste Fragestellung (Studie I) wurden post-mortem Proben aus
sechs verschiedenen Hirnregionen (Alter: 16. Schwangerschaftswoche
bis 91 Jahre) verwendet, bei denen keine neuropathologischen Hinweise
fu¨r eine neuropsychiatrische Erkrankung vorhanden waren. Wir fanden
ho¨here DAO-mRNA-Levels und gleichzeitig tiefere DAO-Protein-Levels
im Cerebellum, verglichen mit den anderen untersuchten Hirnregionen
(Hirnstamm, Amygdala, Striatum, Thalamus und frontaler Kortex), was
mo¨glicherweise auf eine post-transkriptionale Regulation hindeutet.
Ausserdem war das DAOA-Protein in allen untersuchten Hirnregionen
nachweisbar. DAOA-mRNA hingegen konnte in diesen Regionen nicht
nachgewiesen werden, was auf eine streng regulierte oder extrem lokalisierte
DAOA-Expression hindeuten ko¨nnte. Die DAO- und DAOA-Proteine zeigte
in allen untersuchten Hirnregionen ausser im frontalen Kortex eine positive
Korrelation, was auf eine gleichzeitige Expression dieser beiden Proteine
hinweist. Ausserdem haben in silico DNA-Methylierungsdaten, die vom
Gene-Expression-Omnibus-(GEO)-Datensatz heruntergeladen wurden, gezeigt,
dass DAO- und DAOA-CpG-Motive im Cerebellum signifikant sta¨rker
methyliert sind als im frontalen Kortex. Dies erkla¨rt mo¨glicherweise die
regionenspezifisch unterschiedliche DAO- und DAOA-Expression.
Fu¨r die Metaanalyse (Studie II) erfolgte eine systematische Literaturrecherche,
die 20 DAO- und 23 DAOA-Fall-Kontroll-Schizophrenie-Assoziationsstudien
ergab, welche die Einschlusskriterien erfu¨llten. Es wurden Assoziationen von
8 DAO- und 12 DAOA-SNPs mit Schizophrenie beurteilt. Von diesen SNPs
waren ein DAO- (rs4623951) und zwei DAOA-SNPs (rs778293 und rs3916971)
signifikant mit schizophrenen Sto¨rungen assoziiert. Diese systematische
Metaanalyse ist die aktuellste Studie zur Assoziation von DAO- und
DAOA-SNPs mit schizophrenen Sto¨rungen.
Die klinische Studie (Studie III) beinhaltete eine dreija¨hrige prospektive
Kohortenstudie von 185 eingeschlossen Individuen (Alter: 13-35 Jahre) mit einem
klinischen Risiko fu¨r schizophrene Sto¨rungen, die nach 6, 12, 24 und 36 Monaten
auf Anzeichen und Symptome fu¨r eine Schizophrenie-Spektrumssto¨rung
untersucht wurden. Ziel war die Untersuchung, ob DAO-SNPs (rs3918347,
rs4623951) und DAOA-SNPs (rs778293, rs3916971, rs746187) die Entwicklung
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der Erkrankung vorhersagen ko¨nnen und ob sie eine Assoziation mit folgenden
Research-Domain-Criteria-(RDoC)-Doma¨nen (einem nicht-krankheitsbasierten,
dimensionalen Ansatz) “negatives Valenzsystem” (Angst, Hoffnungslosigkeit)
und “kognitive Systeme” (Wahrnehmungssto¨rungen, desorganisierte
Symptome) zeigen. Wir stellten fest, dass DAO rs746187 CC-Alleltra¨ger
versus CT- und TT-Alleltra¨ger (z.B. T-Allel: erho¨htes Risiko fu¨r schizophrene
Sto¨rungen) und DAOA rs3916971 TT-Alleltra¨ger versus TC- und CC-Alleltra¨ger)
eine nominal sta¨rkere Hoffnungslosigkeit und visuelle Wahrnehmungssto¨rung
erlebten. Ausserdem erfuhren DAO rs3918347 GA- und AA-Allelstra¨ger nominal
ha¨ufiger an auditiven Wahrnehmungssto¨rungen als GG-Merkmalstra¨ger.
Daru¨berhinaus stellten sich die DAO- und DAOA-SNPs nicht als pra¨diktive
Marker fu¨r die Entwicklung einer Schizophrenie-Spektrumssto¨rung in der
Risikopopulation nach 36 Monaten heraus. Wir stellten jedoch fest, dass das
Schizophrenierisiko-G-Allel von DAO rs3918347 das Risiko fu¨r ultra-high risk
(UHR) bei Psychosepatienten mit attenuated positive symptoms syndrome
(APSS) nominal erho¨ht. Unsere Ergebnisse weisen mo¨glicherweise darauf hin,
dass DAO- und DAOA-SNPs zwar keine generellen pra¨diktiven Marker fu¨r die
Entwicklung von schizophrenen Sto¨rungen sind, aber pra¨diktive Marker fu¨r
gewisse Endopha¨notypen, beispielsweise fu¨r RDoC-Doma¨nen des negativen
Valenzsystems und des kognitiven Systems bei Psychose-Risikopopulationen
darstellen ko¨nnten.
In der Zellkulturstudie (Studie IV), wurden menschliche SH-SY5Y
Neuroblastoma-Zellen, menschliche 1321N1 Astrozytom-Zellen, und
menschliche HEK293 embryonale Nierenzellen verwendet. Die DAO-Aktivita¨t
wurde mittels freigegebenen Wasserstoffperoxids und dessen Interaktion
mit dem Amplex-Red-Reagenz in allen drei Zelllinien, die mit DAO-
und DAOA-Plasmidkonstrukten co-transfiziert wurden, gemessen. Die
NMDA-Rezeptoraktivita¨t wurde mit dem whole-cell-patch-clamp-Verfahren
in HEK293-Zellen gemessen, die mit den NMDA-Rezeptor-Untereinheiten
NR1 und NR2A (NR1/NR2A HEK293) stabil transfiziert und mit dem
DAOA-Plasmidkonstrukt transient transfiziert wurden. In silico Experimente
wurden mit Molekulardynamik-Simulationen durchgefu¨hrt. Wir stellten
fest, dass DAOA die DAO-Aktivita¨t nur in humanen embryonalen
HEK293-Nierenzellen erho¨ht war, nicht aber in humanen neuronalen
SH-SY5Y-Zellen und humanen 1321N-Astrozytenzellen. Dies ko¨nnte
mo¨glicherweise aufgrund verschiedener Signalwege, unterschiedlicher
Kompartimentierung von DAO- und DAOA-Proteinen, sowie tieferer DAO-
und DAOA-Proteinu¨berexpression in 1321N1-Zellen und SH-SY5Y-Zellen
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im Vergleich zu HEK293-Zellen bedingt sein. Des Weiteren hatte
DAOA keinen Effekt auf die NMDA-Rezeptor-Aktivita¨t in NR1/NR2A
HEK293-Zellen. Die Simulationsexperimente zeigten, dass DAOA das humane
DAO-(hDAO)-Holoenzym [hDAO mit Flavin-Adenin-Dinukleotid (FAD)]
flexibler zu machen scheint und auch eine sta¨rkere Dysfunktion in der
Faltung verursachen ko¨nnte als das hDAO-Apoprotein (hDAO ohne FAD),
was auf einen inaktivierenden Effekt von DAOA auf hDAO hinweist. Der
letztgenannte Befund erscheint jedoch nicht konsistent mit unseren Resultaten
zur DAO-Aktivita¨t. Daher sollte die Interaktion zwischen DAO und DAOA
weiter untersucht werden z.B. mittels eines noch geeigneteren “in vitro
Zellmodells”, das die komplexe Zellkommunikation von tripartiten Synapsen
realistisch abbildet.
Zusammengefasst zeigen die vier durchgefu¨hrten Studien, dass die DAO-
und DAOA-Gene auf transkriptioneller Ebene stark reguliert sind und
hirnspezifische Expressionsmuster aufweisen, die altersabha¨ngig variieren,
was darauf hindeutet, dass diese Gene wichtig fu¨r die Gehirnentwicklung
sind. DAO- und DAOA-SNPs als pra¨diktive Marker fu¨r Endopha¨notypen, wie
negative Symptome und kognitive Defizite in Psychoserisiko-Populationen
sollten repliziert werden. Aufgrund der bisherigen und hier vorgelegten
Studien erscheint die Rolle von DAOA fu¨r die Entwicklung einer NMDA
Rezeptorhypofunktion noch immer unklar und sollte weiter erforscht werden,
in der Hoffnung, dass DAOA mo¨glicherweise als ein therapeutisches Target
zur Behandlung von negativen Symptomen und kognitiven Defiziten bei
schizophrenen Sto¨rungen dienen kann.
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3. General Introduction
3.1 Schizophrenia: symptomatology, diagnostic criteria, and
epidemiology
Schizophrenia is a severe, chronic, and debilitating psychiatric disorder. It
is characterised by positive symptoms such as delusions, hallucinations,
and thought disorder, and negative symptoms such as affective flattening
or blunting, avolition, apathy, anhedonia, alogia, and asociality (Crow, 1985;
Andreasen, 1995; van Os and Kapur, 2009; Stahl, 2013). Although cognitive
deficits such as impairments in attention, memory, and executive functions are
not formally recognised as part of the diagnostic criteria for schizophrenia,
numerous studies use this symptom subcategory in schizophrenia research
(Elvevag and Goldberg, 2000; Fioravanti et al., 2012; Stahl, 2013).
The diagnosis of schizophrenia still relies on the examination of the mental
state through a clinical interview and observation of patient’s behaviour
because of the absence of biological markers for schizophrenia. The diagnostic
guidelines for schizophrenia are provided by two major classification systems,
namely Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) (American Psychiatric Association, 2013) and 10th revision of the
International Classification of Diseases (ICD-10) (World Health Organization,
1992). According to DSM-5 criteria, Schizophrenia Spectrum and Other
Psychotic Disorders include schizophrenia (295.90), other psychotic disorders
(298.80 and 298.90), and schizotypal personality disorder (295.40) (American
Psychiatric Association, 2013). In ICD-10 criteria, schizophrenia (F20) includes
paranoid schizophrenia (F20.0), hebephrenic schizophrenia (F20.1), catatonic
schizophrenia (F20.2), undifferentiated schizophrenia (F20.3), post-schizophrenic
depression (F20.4), residual schizophrenia (F20.5), simple schizophrenia (F20.6),
other schizophrenia (F20.8), and unspecified schizophrenia (F20.9) (World
Health Organization, 1992). There are some major differences between ICD-10
and DSM-5 criteria for schizophrenia. ICD-10 criteria puts greater emphasis
on Schneiderian first-rank symptoms (Schneider, 1959), classic schizophrenia
subtypes, non-dimensional assessment of schizophrenia, and 1-month duration
for the diagnosis of schizophrenia. However, DSM-5 criteria eliminated special
emphasis on Schneiderian first-rank symptoms, deleted classic schizophrenia
subtypes, added a dimensional assessment to characterise the heterogeneity of
schizophrenia, and 6-month duration for the diagnosis of schizophrenia (Barch
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et al., 2013; Tandon, 2014).
Schizophrenia is a serious public health problem, which affects more than 21
million people worldwide (World Health Organisation, 2016). The incidence
of schizophrenia varies from 0.1 to 0.4 per 1000 population (Jablensky et al.,
1992). The lifetime prevalence of this disorder is estimated to be 0.3-0.7%
(McGrath et al., 2008). Schizophrenia is a major burden for the healthcare
systems worldwide, which accounts for 1.5-3% healthcare expenses in developed
countries (Knapp et al., 2004). The economic burden of schizophrenia in the
United States of America (USA) in the year 2013 was estimated to be between
$134.4 billion and $174.3 billion, which included direct health costs (24%),
direct non-health care costs (6%), and indirect costs (75%) (Cloutier et al., 2016).
Thus, the economic burden of the disorder highlights the need for effective
pharmacological interventions to increase the stability and performance of
schizophrenia patients which in turn would help in addressing the healthcare
costs.
3.2 Treatment of schizophrenia
The current treatment of schizophrenia involves both pharmacotherapy and
psychotherapy (Huhn et al., 2014). The antipsychotic medications are the
first-line of pharmacotherapy in schizophrenia (Patel et al., 2014). Antipsychotics
are classified into two groups, namely first-generation antipsychotics (typical
antipsychotics) that emerged in the 1950s and second-generation antipsychotics
(atypical antipsychotics) that emerged in the 1980s (Leucht et al., 2009).
First-generation antipsychotics (e.g., chlorpromazine, haloperidol) are dopamine
D2 receptor antagonists, which are effective in reducing positive symptoms of
schizophrenia. However, these first-generation antipsychotics are ineffective and
may exacerbate negative symptoms and cognitive impairment of schizophrenia,
and also cause adverse effects such as extrapyramidal symptoms (tremor,
rigidity, dystonia, bradykinesia), hyperprolactinemia, and cognitive dulling
(Li et al., 2016). Second-generation antipsychotics (e.g., clozapine, risperidone,
aripiprazole) are a combination of dopamine D2 receptor and serotonin 5-HT2A
receptor antagonists that are effective against positive symptoms, but less
effective against negative symptoms and cognitive impairment in schizophrenia.
These second-generation antipsychotics have reduced the propensity to cause
extrapyramidal symptoms and hyperprolactinemia than first-generation
antipsychotics, however, they can still cause adverse effects such as weight
gain and metabolic disorders (Divac et al., 2014). Many schizophrenia patients
(around 10-30%) fail to respond to antipsychotic treatment, some patients are
non-compliant due to adverse effects, and antipsychotic responders are still
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incapable of living a normal productive life due to persistence of negative
symptoms and cognitive impairment (Fenton et al., 1997; Galuppi et al., 2010;
Hasan et al., 2012). Thus, there is an urgent need to develop new drugs for the
treatment of negative symptoms and cognitive impairment in schizophrenia.
3.3 Aetiology of schizophrenia
3.3.1 Genetic factors
Schizophrenia is a complex heritable disorder with non-Mendelian inheritance.
The heritability of this disorder is around 60-80% (Pepper and Cardno, 2014).
The best known genetic risk factors for schizophrenia are single nucleotide
polymorphisms (SNPs) and copy number variations (CNVs) (Harrison,
2015). Genome-wide association studies (GWAS) have provided unequivocal
evidence for common SNPs contributing to schizophrenia risk. A study by
the Psychiatric Genetics Consortium (PGC) involving 21,000 cases and 38,000
controls identified 22 loci, which contain SNPs with genome-wide significance
for schizophrenia (Ripke et al., 2013). This study estimated that over 8,000 SNPs
independently contribute to schizophrenia, and which together will explain
over 50% of the genetic predisposition (Ripke et al., 2013). A new analysis from
the PGC involving 37,000 cases and 113,000 controls identified over 100 loci
(implicating about 600 genes) with genome-wide significance for schizophrenia
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).
Thus, schizophrenia is a highly polygenic disorder (Lee et al., 2012). Most of
the schizophrenia-associated SNPs are in the non-coding regions of DNA (e.g.,
intergenic or intronic), which makes identifying the biological basis for these
SNPs very challenging (Harrison, 2015). Each schizophrenia-risk SNP was found
to have a very small effect size on schizophrenia risk (Harrison, 2015). In contrast
to schizophrenia-associated SNPs, each CNV was found to be extremely rare but
penetrant, which confers significantly increased risk for the disorder (Kirov et al.,
2014). Many CNVs associated with schizophrenia occur de novo (Xu et al., 2011)
and the others are inherited. The extent to which CNVs contribute to the overall
aetiology of schizophrenia is unknown. Nowadays, there is increasing empirical
and bioinformatic evidence of schizophrenia implicated genes converging upon
biochemical pathways and networks (Harrison, 2015).
3.3.2 Environmental factors
The aetiology of schizophrenia cannot be explained completely by genetic risk
factors, which are highlighted by the fact that concordance rates in monozygotic
twins are around 50% (Cardno and Gottesman, 2000). This lack of complete
concordance in monozygotic twins suggests that schizophrenia is caused not
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only due to dysfunctional genes but also due to gene activation or silencing by
the environmental factors (Stahl, 2013). The environmental factors that increases
the risk for schizophrenia include maternal malnutrition during famine,
maternal infections (e.g., rubella, Toxoplasma and herpes simplex virus type
2), maternal obstetric complications (e.g., placental pathology, diabetes, rhesus
incompatibility, pre-eclampsia or bleeding), abnormal foetal development (e.g.,
low birth weight, congenital malformations or reduced head circumference),
delivery complications (e.g., uterine atony, asphyxia or emergency caesarean
section), season of birth, advanced paternal age, childhood trauma, social
factors (e.g., parental separation or loss, social exclusion), urban environment,
migration, and substance abuse (Stilo et al., 2011). These environmental factors
might activate or silence a gene through epigenetic modifications such as DNA
methylation, histone modifications, and microRNAs leading to the development
of schizophrenia (Feil and Fraga, 2012; Alelu´-Paz et al., 2016).
3.3.3 Gene-environment interplay
Schizophrenia is caused by both nature (i.e., genetics) and nurture (i.e.,
environment or epigenetics) (Rapoport et al., 2012; Stahl, 2013). During brain
development, multiple genetic risk factors for schizophrenia might interact
with a wide range of environmental insults triggering a complex cascade of
pathophysiological process such as gene and protein expression impairment
leading to changes in neuro-circuits resulting in inefficient information
processing which ultimately manifests as behavioural, cognitive, and emotional
deficits of the disorder (Horva´th and Mirnics, 2009; Pishva et al., 2014).
3.4 Stages of schizophrenia
The psychotic features of schizophrenia emerge in late adolescence or early
adulthood, with a peak between ages 18 and 25 years (Insel, 2010). The onset of
psychotic features of schizophrenia is preceded by a broad range of symptoms.
A clinical staging of schizophrenia helps in mapping out the whole spectrum
of the disorder from earliest signs to chronic psychosis, thus providing a guide
for prevention and specialized treatment (Fava and Kellner, 1993; McGorry,
1995; McGorry et al., 2006). In the handful of clinical staging models proposed
for schizophrenia, the pre-psychotic phase of the disorder was taken as a
single clinical entity known as prodrome which was a heterogeneous group
(Fava and Kellner, 1993; Lieberman et al., 2001). Subsequently, McGorry
and colleagues proposed a model that underwent various updates which
attempted to subdivide the pre-psychotic phase of the disorder into homogenous
subgroups (McGorry, 1995; McGorry et al., 2006; Agius et al., 2010; McGorry
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et al., 2010, 2014; McGorry and Nelson, 2016). The McGorry model comprises
of five stages, namely stage 0: increased risk of psychotic disorder with no
current symptoms, stage 1a: mild/nonspecific symptoms, stage 1b: moderate
subthreshold symptoms, stage 2: onset of the first episode of psychosis, stage
3a: incomplete remission from the first episode of care, stage 3b: recurrence or
relapse of the psychotic disorder, stage 3c: multiple relapses when worsening in
clinical extent and objective presence of the impact of the disorder, and stage 4:
severe, persistent or unremitting disorder (McGlashan et al., 2010). The clinical
high risk for psychosis (CHR) state includes individuals in McGorry’s stages 1
and 2. A recent study proposed a 4-stage model for psychosis prodrome, which
is based on the notion that increased symptom severity leads to an increased risk
of developing psychosis: stage 1: primarily negative type symptoms and early
risk factors with the absence of attenuated positive symptoms, stage 2: mild to
moderate attenuated form of positive symptoms, stage 3: severe attenuated form
of positive symptoms, and stage 4: presence of only one positive symptom of
psychotic intensity (Carrio´n et al., 2016). These clinical staging of schizophrenia
has improved the possibility of early identification and intervention at the stage
of CHR for psychosis to limit the progression of the disorder.
Individuals at CHR for psychosis are identified by two complementary
approaches, namely the high risk (HR) and the ultra-high risk (UHR) criteria.
The HR criteria based on basic symptoms, which comprises of two partially
overlapping risk entities, the cognitive-perceptive basic symptoms (COPER) and
the cognitive disturbances (COGDIS) (Schultze-Lutter et al., 2012, 2015). The
UHR criteria include attenuated positive symptoms syndrome (APSS), brief
limited intermittent psychotic symptoms (BLIPS), and a combination of a risk
factor for psychosis and a recent functional decline (McGlashan et al., 2010). Both
these approaches have been used in the early recognition of psychosis studies to
predict the transition rate to schizophrenia (Gee and Cannon, 2011; Fusar-Poli
et al., 2012).
3.5 Neurodevelopmental model of schizophrenia
Schizophrenia is hypothesized as an end stage of abnormal neurodevelopmental
processes that began years before the actual onset of the disorder, which is why it
is widely accepted as a neurodevelopmental disorder (Insel, 2010; Rapoport et al.,
2012). Despite many years of research in the field of schizophrenia, the complex
factors preceding the onset of psychosis is not yet completely understood.
Normal cortical development involves proliferation, migration, arborization
(circuit formation), and myelination. Proliferation and migration occur mostly
during the prenatal period, whereas arborization and myelination also occur
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throughout the first two decades of postnatal life (Insel, 2010). Longitudinal
neuroimaging studies in healthy controls have demonstrated that changes in
grey-matter density occur until mid-twenties with the prefrontal cortex being
the last to mature (Figure 1a) (Paus et al., 2008). This progressive reduction
of grey-matter density is thought to be due to combined effects of pruning of
neuronal circuits and deposition of myelin (Insel, 2010). During adolescence and
early adulthood, there is an increase in inhibitory and decrease in excitatory
synapses in the prefrontal cortex (Figure 1a). It has been hypothesised that
this trajectory of cortical development is defective i.e., reduced elaboration of
inhibitory pathways and excessive pruning of excitatory pathways leading to
altered excitatory-inhibitory balance in the prefrontal cortex of individuals who
develop schizophrenia (Figure 1b) (Insel, 2010).
The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA)
Consortium has analysed neuroimaging data from approximately 2,000
schizophrenia patients collected from 17 research groups around the world as
part of the ENIGMA Schizophrenia Working Group (Thompson et al., 2014;
van Erp et al., 2016; Walton et al., 2017a,b). These meta-analyses found that
schizophrenia patients had significantly smaller hippocampus, amygdala,
thalamus, nucleus accumbens, and intracranial volumes as well as larger
pallidum and lateral ventricle volumes compared to healthy controls (van
Erp et al., 2016), positive symptoms were related to cortical thinning in the
superior temporal gyrus (Walton et al., 2017a), and negative symptoms were
related to cortical thinning in the medial orbitofrontal cortex (Walton et al.,
2017b). The ENIGMA Schizophrenia Working Group is actively working on
analysing longitudinal neuroimaging data in first-episode schizophrenia patients
that might help in understanding defective cortical development trajectories
hypothesised in the neurodevelopmental model of schizophrenia.
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Figure 1: Neurodevelopmental model of schizophrenia. (a) Normal cortical development in
humans from prenatal period until 25 years of age, and (b) Defective cortical development from
ages 5 to 25 years in children who transition to schizophrenia (Insel, 2010).
3.6 Neurochemical hypotheses of schizophrenia
Schizophrenia is a multifactorial psychiatric disorder, but the exact cause of the
disorder remains unclear. Dysfunctions in neurotransmitter pathways such as
dopamine, glutamate, gamma-aminobutyric acid (GABA), and serotonin have
been implicated in the pathophysiology of schizophrenia (Eggers, 2013; Brisch
et al., 2014; Hu et al., 2015; Chang et al., 2016), which will be explained further in
the following sections.
3.6.1 Dopamine hypothesis of schizophrenia
The dopamine hypothesis was proposed based on two fundamental
observations. First, the psychostimulants such as amphetamine and cocaine
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that blocked the reuptake of dopamine, and increased dopamine at the synaptic
cleft induced positive symptoms of schizophrenia in healthy volunteers and
exacerbated these symptoms in schizophrenia patients (Bunney et al., 1973;
Lieberman et al., 1987; Einhorn et al., 1988; Prus, 2017; Satel and Edell, 1991).
Secondly, the antipsychotic medications that block dopamine D2 receptors
relieved the positive symptoms of schizophrenia (Creese et al., 1976; Peroutka,
1980; Kapur et al., 2000). There are four main dopamine pathways in the brain,
namely mesolimbic (from ventral tegmental area in the brainstem to nucleus
accumbens in the ventral striatum), mesocortical (from ventral tegmental area
to prefrontal cortex), nigrostriatal (from substantia nigra to basal ganglia or
striatum), and tuberoinfundibular (from hypothalamus to anterior pituitary)
(Stahl, 2013). The two key dopamine pathways implicated in the pathology
of schizophrenia are mesolimbic and mesocortical pathways. The dopamine
hypothesis states that the hyperactivity of dopamine neurons in the mesolimbic
pathway mediate positive symptoms of schizophrenia, and hypoactivity of
dopamine neurons in the mesocortical pathway mediate negative symptoms
and cognitive impairment in schizophrenia (Stahl, 2013).
3.6.2 Serotonin hypothesis of schizophrenia
Involvement of serotonergic pathways in the pathophysiology of schizophrenia
was based on the observation that lysergic acid diethylamide (LSD), a
5-hydroxytryptamine (5-HT) serotonin receptor agonist, induced or exacerbated
schizophrenia-like symptoms in humans (Roth and Meltzer, 1995). The
hypothesis states that schizophrenia is caused by the chronic widespread
stress-induced serotonergic overdrive in the cerebral cortex, especially in the
anterior cingulate cortex (ACC) and dorsolateral frontal lobe. This serotonergic
overdrive might lead to disruption in glutamate signalling ultimately leading to
synaptic atrophy and grey matter loss. Positive symptoms might be caused by
normal dopamine input to impaired ACC, and negative symptoms and cognitive
impairment might be caused by frontal lobe hibernation (Eggers, 2013).
3.6.3 Glutamate hypothesis of schizophrenia
The glutamate hypothesis of schizophrenia was proposed based on the
observation that N-methyl-D-Aspartate (NMDA) receptor antagonists such as
phencyclidine and ketamine produced positive symptoms, negative symptoms,
and cognitive deficits very similar to symptoms of schizophrenia in healthy
volunteers, and also exacerbated all these symptoms in schizophrenia patients
(Javitt, 1987; Javitt et al., 1991; Krystal et al., 1994; Lahti et al., 1995; Malhotra
et al., 1997; Umbricht et al., 2000). Antipsychotics, dopamine D2 receptor
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antagonists are effective against positive symptoms but have little effect on
negative symptoms and cognitive deficits (Javitt, 2010). In a study comparing
the effect of amphetamine (dopamine reuptake blocker) and ketamine (NMDA
receptor antagonist) in healthy controls, the authors reported that both these
drugs induce positive symptoms, however, only ketamine induces negative
symptoms and cognitive deficits (Krystal et al., 2005). Furthermore, individuals
with NMDA receptor autoimmune encephalitis (antibodies against NR1A
subunit) present with symptoms similar to schizophrenia (Dalmau et al., 2007,
2008, 2011). Lastly, meta-analyses have reported that NMDA receptor agonists
D-serine and glycine, and glycine transporter type 1 inhibitor sarcosine reduce
total and negative symptoms as an adjunct to antipsychotic medications (Singh
and Singh, 2011). Based on all these findings, the glutamate hypothesis is
thought to explain the negative symptoms and cognitive deficits better than the
dopamine hypothesis.
The glutamate hypothesis is also known as NMDA receptor hypofunction
hypothesis of schizophrenia. There are several glutamate pathways in
the brain. The cortico-brainstem glutamate pathway projects from cortical
pyramidal neurons in the prefrontal cortex to brainstem neurotransmitter
centres (raphe nucleus, locus coeruleus, ventral tegmental area, substantia
nigra). This glutamate pathway is hypothesised to be a key pathway in the
pathology of schizophrenia as it can regulate dopamine neurons in the ventral
tegmental area (Stahl, 2013). The hypoactive NMDA receptors on cortical GABA
interneurons of the cortico-brainstem glutamate pathway might cause excessive
glutamate release in the ventral tegmental area leading to hyperactivity of
mesolimbic dopamine pathway mediating positive symptoms of schizophrenia.
The hypoactive NMDA receptors on cortical GABA interneurons of the
cortico-brainstem glutamate pathway might cause excessive glutamate release
in the ventral tegmental area leading to activation of GABA interneurons
which in turn inhibits the mesocortical dopamine neurons mediating negative
symptoms and cognitive dysfunction in schizophrenia. Thus, the glutamate
neurons innervate mesolimbic dopamine neurons directly leading to mesolimbic
hyperactivity, whereas they innervate mesocortical dopamine neurons indirectly
via GABA interneurons leading to mesocortical hypoactivity (Stahl, 2013). As the
current thesis mainly focusses on the glutamate hypothesis based on the NMDA
receptor hypofunction, the molecular basis of this theory will be discussed in the
next section.
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3.7 Molecular basis of NMDA receptor hypofunction in
schizophrenia
3.7.1 N-methyl-D-aspartate (NMDA) receptors
NMDA receptors are voltage dependent ionotropic glutamate receptors. To
date, seven different NMDA receptor subunits belonging to three subfamilies
are identified in humans, namely one NR1 subunit, four different NR2
subunits (NR2A, NR2B, NR2C, NR2D), and two NR3 subunits (NR3A, NR3B).
Functional NMDA receptors are heterotetramers composed of two obligatory
glycine-binding NR1 subunits combined with two regulatory glutamate-binding
NR2 subunits (Collingridge et al., 2009; Paoletti et al., 2013). NMDA receptors
are organised into amino-terminal domains and ligand-binding domains on
the extracellular side of the membrane, a transmembrane domain spanning
the membrane which defines the ion channel pore, and an intracellular
carboxy-terminal domain within the cytoplasm (Figure 2) (Traynelis et al.,
2010; Lee et al., 2014). NMDA receptors are blocked by magnesium at resting
state, which prevents calcium influx. NMDA receptors are Hebbian-like
coincidence detectors, which require three events to occur at the same time:
glutamate binding to the NR2 subunit, glycine/D-serine binding to the NR1
subunit, and membrane depolarization to remove magnesium block that open
an ion conductive pore to let calcium into a neuron to trigger post-synaptic
glutamatergic neurotransmission (Mayer et al., 1984; Nowak et al., 1984; Lee
et al., 2014). This NMDA receptor mediated calcium signalling plays a crucial
role in neural development and synaptic plasticity (Lau et al., 2009).
3.7.2 D-serine
D-serine, a co-agonist of NMDA receptors, is a D-amino acid. It is found at much
higher concentrations in the brain than in the periphery. It is synthesised from
L-serine by the pyridoxal phosphate (PLP) dependent serine racemase (SRR)
enzyme and is presumed to be degraded by both SRR and D-amino acid oxidase
(DAO/DAAO) enzymes (Figure 3a) (Wolosker et al., 2008; Sacchi, 2013). D-serine
is a co-agonist of NMDA receptors, which binds to the strychnine-insensitive
glycine modulatory site on the NR1 subunit of the NMDA receptors (Figure 2)
(Mothet et al., 2000). D-serine was found to have three times higher affinity
to NMDA receptors than glycine. This higher affinity of D-serine than glycine
was explained through a crystallography experiment which found D-serine
displaces a water molecule from the NR1 binding site and makes three additional
hydrogen bonds with this site of the NMDA receptors (Furukawa and Gouaux,
2003).
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Figure 2: NMDA receptor complex. An extracellular domain includes binding sites for glycine
or D-serine on the NR1 subunit, and glutamate on the NR2 subunit, a transmembrane domain
defining the ion-channel pore blocked by magnesium, and an intracellular domain for binding of
signalling molecules (Kalia et al., 2008).
3.7.3 D-amino acid oxidase (DAO)
The human DAO gene is located at the chromosome 12q24, which comprises of
eleven exons. It encodes for a ∼39 kDa protein of 347 amino acids (Verrall et al.,
2010). This gene has been shown to have 8 splice variants, out of which only 4
variants have been shown to be protein coding, that encodes for proteins of sizes
∼39 kDa, ∼31 kDa, ∼19 kDa, and ∼22 kDa (Uhle´n et al., 2015; McLaren et al.,
2016).
DAO is a flavoenzyme, which catalyses the oxidation of D-amino acids through
concomitant reduction of flavin adenine dinucleotide (FAD), producing the
corresponding imino acid, which is further hydrolyzed to yield ammonia
and corresponding α-keto acid. During FAD re-oxidation, hydrogen peroxide
is produced (Verrall et al., 2010). FAD-bound DAO was found to be active,
whereas FAD-unbound DAO was found to be inactive (Caldinelli et al., 2009;
Terry-Lorenzo et al., 2014). FAD binding is weaker in human DAO compared to
DAO from other species, which provides human DAO with a potential means to
regulate DAO activity in humans (Caldinelli et al., 2009). DAO oxidises D-amino
acids with small, neutral side chains such as D-serine, D-alanine, D-proline, and
D-Leucine (Molla et al., 2006b; Verrall et al., 2010). The main substrate of DAO in
the brain is D-serine as it is by far the most abundant D-amino acid in the brain
(Bendikov et al., 2007; Verrall et al., 2010).
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DAO is widely distributed in the human central nervous system (CNS). DAO is
generally considered as a hindbrain enzyme, which is enriched in the cerebellum
and the brainstem (Sacchi et al., 2012). DAO activity was robustly detected in
the human cerebellum (Kapoor et al., 2006). However, DAO activity has been
detected in the human forebrain in some studies (Madeira et al., 2008; Sasabe
et al., 2014), albeit only at a small fraction compared to the human cerebellum
(Verrall et al., 2010). DAO mRNA and protein are mainly detected in the human
liver, kidney, and brain (Verrall et al., 2007; GTEx Consortium, 2015; Uhle´n et al.,
2015). In the human brain, both DAO mRNA and protein are highly expressed
in the cerebellum than in other brain regions (GTEx Consortium, 2015; Uhle´n
et al., 2015). Furthermore, DAO is not solely present in glial cells, but there is
evidence that DAO is also present in neurons (Verrall et al., 2007, 2010). Initially,
DAO was thought to be present only in peroxisomes (De Duve and Baudhuin,
1966), however presence of extra-peroxisomally active DAO has been reported
both in glial cells (Sacchi et al., 2008, 2011) and neurons (Popiolek et al., 2011).
3.7.4 D-amino acid oxidase activator (DAOA/G72)
The human DAO activator (DAOA/G72) is a primate specific gene, which is
located at chromosome 13q33 and comprises of seven exons (Sacchi et al., 2016).
It encodes for a∼20 kDa protein of 153 amino acids (Benzel et al., 2008). This gene
has been shown to have 12 splice variants, out of which only 4 variants have been
shown to be protein coding, that encodes for proteins of sizes ∼20 kDa, ∼20 kDa,
∼10 kDa, and ∼15 kDa (Uhle´n et al., 2015; McLaren et al., 2016).
Several lines of evidence suggest that DAOA interacts with DAO. However, the
effect of DAOA on DAO has been controversial to date. Some studies have found
DAOA to be an activator of DAO (Chumakov et al., 2002; Chang et al., 2013).
However, in another study, DAOA was found to be an inhibitor of DAO (Sacchi
et al., 2008). A study also found no effect of DAOA on DAO (Kvajo et al., 2008).
Therefore, future studies with physiological levels of DAOA and DAO will be
required to conclusively comment whether DAOA is an activator or inhibitor of
DAO.
The expression pattern of DAOA mRNA and protein in the human brain is not
yet fully characterised. Only earlier studies have detected DAOA mRNA in the
human brain (Chumakov et al., 2002; Korostishevsky et al., 2006). However,
recent studies could not replicate these findings of DAOA mRNA expression
in the human brain (Benzel et al., 2008; GTEx Consortium, 2015). Furthermore,
DAOA protein was detected in the human cerebellum and the cerebral cortex
(Uhle´n et al., 2015), and in the human amygdala (Kvajo et al., 2008). On the
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contrary, a study could not detect DAOA protein in these human brain regions
(Benzel et al., 2008). DAOA protein has been shown to localise in mitochondria
and cause mitochondrial dysfunction (Kvajo et al., 2008; Sacchi et al., 2011; Otte
et al., 2014).
3.7.5 Genetic association of DAO and DAOA with schizophrenia
A landmark study (Chumakov et al., 2002) identified DAO and DAOA as
putative risk genes for schizophrenia. This study identified four DAO SNPs
(rs211902, rs3918346, rs3741775, rs3918347, all intronic) and six DAOA SNPs
(rs3916965, rs3916967, rs2391191, rs778293, rs3918342, rs1421292) to be associated
with schizophrenia. Subsequently, these and many other DAO and DAOA SNPs
have been examined in many case-control and family association studies of
schizophrenia. These studies were included in the SchizophreniaGene (SzGene)
meta-analysis, which showed a significant association of 24 genetic variants in
16 different genes with schizophrenia (Allen et al., 2008). In this meta-analysis,
one DAO SNP (rs4623951) and two DAOA SNPs (rs778293, rs3916971) were
significantly associated with schizophrenia (Allen et al., 2008). A mega-analysis
conducted by the PGC combining GWAS data from 17 separate studies with
a total of 9,394 cases and 12,462 controls identified seven significant SNP loci
for schizophrenia, but none of the loci were within DAO and DAOA gene
regions (Schizophrenia Working Group of the Psychiatric Genomics Consortium,
2014). A recent GWAS by the PGC involving 37,000 cases and 113,000 controls
identified around 108 schizophrenia associated loci, and again none were within
DAO and DAOA gene regions with genome-wide significance (p ≤ 5×108).
Nevertheless, in this GWAS, DAO SNPs (rs2111902, rs3918346, rs3741775,
rs3918347, rs2070586, and rs2070587) showed nominal association (p<0.05)
with schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014). Therefore, DAO and DAOA remain as candidate genes for
schizophrenia because of their role in glutamatergic signalling.
3.7.6 Roles of DAO and DAOA in NMDA receptor
hypofunction
The NMDA receptor hypofunction theory proposed in schizophrenia is based
on the observations in schizophrenia patients of increased DAO activity leading
to decreased D-serine which in turn results in NMDA receptor hypofunction
(Figure 3b). Human post-mortem studies have shown that there is increased
DAO activity in the cerebellum of schizophrenia patients compared to healthy
controls (Kapoor et al., 2006; Burnet et al., 2008). There is also evidence for
decreased D-serine in serum and cerebrospinal fluid (CSF) of schizophrenia
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patients compared to healthy controls (Hashimoto et al., 2003, 2005; Bendikov
et al., 2007; El-Tallawy et al., 2017). There is post-mortem evidence for a
significant decrease in NMDA receptor subunits, mainly NR1 mRNA and
protein in the prefrontal cortex of schizophrenia patients compared to controls
(Weickert et al., 2013; Catts et al., 2016). A study found increased DAOA
mRNA and protein levels in schizophrenia brains (Korostishevsky et al.,
2006), which wasn’t replicated in the subsequent study (Benzel et al., 2008).
Furthermore, studies have reported increased DAOA protein levels in the
plasma of schizophrenia patients compared to healthy controls (Lin et al., 2014;
Akyol et al., 2017), which was not replicated in a recent study (Ishiwata et al.,
2017). Thus, the effect of DAOA on DAO activity and in general the role of
DAOA in schizophrenia is yet to be elucidated.
Figure 3: Molecular basis of NMDA receptor hypofunction theory proposed in schizophrenia.
(a) A normal tripartite synapse showing synthesis of D-serine (green triangles) from L-serine
(L-ser) by serine racemase (SRR), degradation of D-serine by DAO into alpha-keto acid (Aka),
ammonia (NH3), hydrogen peroxide (H2O2), and NMDA receptors (NMDAR) requiring both
D-serine and glutamate (yellow circles) for glutamatergic neurotransmission (Verrall et al., 2010).
(b) Proposed NMDAR hypofunction molecular cascade in schizophrenia showing increased DAO
activity leading to decreased D-serine, and finally NMDAR hypofunction, and an unclear effect
of DAOA/G72 on DAO.
3.8 DAO and DAOA as targets for the treatment of
schizophrenia
The current antipsychotics that are dopamine D2 receptor antagonists used in
the treatment of schizophrenia are more effective against positive symptoms
than against negative symptoms and cognitive impairment in schizophrenia
(Lally and MacCabe, 2015). Thus, there is an urgent need to develop novel
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and more efficacious medications to ameliorate negative symptoms and
cognitive impairment in schizophrenia. In the search for developing novel
drugs for schizophrenia, many studies have focussed on testing NMDA receptor
modulators such as D-serine and glycine as adjunctive therapy to the ongoing
antipsychotic treatment (Woods et al., 2013). The use of D-serine and glycine is
limited by the high doses needed for efficacy, and also nephrotoxicity caused
by D-serine (Williams and Lock, 2004). To circumvent the nephrotoxicity of
D-serine, DAO inhibitors that inhibit the DAO activity leading to increase in
D-serine have been tested as a novel treatment for schizophrenia. The DAO
inhibitor 5-chloro-benzo[d]isoxazol-3-ol (CBIO) administered with D-serine has
been reported to enhance D-serine efficacy in mice (Hashimoto et al., 2009), but
a recent study couldn’t replicate this finding (Sershen et al., 2016). Recently,
sodium benzoate has been tested both in preclinical (Matsuura et al., 2015) and
clinical studies (Lane et al., 2013; Lin et al., 2017) with encouraging results.
However, the affinity of sodium benzoate to DAO is low and the extent to which
the effects were mediated by DAO inhibition remains unclear (Sershen et al.,
2016). To date, no modulators of DAOA has been developed as a novel treatment
for schizophrenia. These unsuccessful attempts in the development of novel
treatment for schizophrenia highlight that the interplay between DAOA, DAO,
D-serine, and NMDA receptors is not yet completely understood. Therefore,
there is a need to elucidate this pathway with the hope that DAO or DAOA
might emerge as therapeutic targets in future.
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4. Aims of the thesis
DAO and DAOA are putative schizophrenia susceptibility genes. These genes are
hypothesised to interact with each other to cause NMDA receptor hypofunction
in schizophrenia. Despite many years of research in the field of schizophrenia,
the exact function of DAOA, its expression in the normal human brain, and
its interaction with DAO still needs to be elucidated (Sacchi et al., 2016). The
overall objectives of this thesis were to understand DAO and DAOA trajectory
expression in the normal human brain, to re-evaluate the association of DAO
and DAOA SNPs with schizophrenia using meta-analysis, to assess whether
DAO and DAOA SNPs predict transition to schizophrenia and endophenotypes
in individuals at clinical risk for psychosis, and to determine the interaction
between DAO and DAOA in human cell lines.
Study I: Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino
Acid Oxidase Activator (DAOA/G72) during development and aging in the
human post-mortem brain
In this study, we used human post-mortem brain samples from 55 subjects across
six brain regions (cerebellum, brainstem, amygdala, thalamus, striatum, and
frontal cortex) with ages ranging from 16 weeks of gestation to 91 years, who
had no history of neuropsychiatric disorder and their brain tissues showed no
neuropathological evidence of any neuropsychiatric disorder. The main aims of
this study were as follows:
(a) To determine DAO and DAOA mRNA and protein expression in the normal
human brain during development and aging to understand the concomitant
expression of DAO and DAOA in different brain regions.
(b) To assess the effect of DAO and DAOA SNPs on DAO and DAOA
expression levels to elucidate the role of these SNPs in the regulation of
DAO and DAOA expression.
(c) To determine DNA methylation levels at DAO and DAOA CpG sites in the
cerebellum and the frontal cortex of control human post-mortem brain in
silico to understand the regulation of DAO and DAOA expression at the
transcription level.
To address these aims, we quantified DAO and DAOA mRNA levels using
quantitative real-time reverse transcription-PCR (qRT-PCR), and DAO
and DAOA protein levels using commercially available DAO and DAOA
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enzyme-linked immunosorbent assay (ELISA) kits. We assessed DAO
(rs3918347, rs4623951) and DAOA (rs778293, rs3916971, rs746187) SNPs using
TaqMan SNP genotyping assay. In silico DNA methylation levels at DAO and
DAOA CpG sites were downloaded from Gene Expression Omnibus (GEO)
datasets.
Study II: A systematic meta-analysis of the association of Neuregulin 1
(NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72
polymorphisms with schizophrenia
The aim of this study was to perform an up to date systematic meta-analysis of
both previously meta-analysed as well as new schizophrenia association studies
to comprehensively evaluate the association of 8 DAO and 12 DAOA SNPs
with schizophrenia. To address this, we conducted systematic literature search
which resulted ultimately in 20 DAO and 23 DAOA case-control schizophrenia
association studies that fulfilled the inclusion criteria. Meta-analyses of
these studies were conducted using the MIX 2.0-Professional software for
meta-analysis in Excel, version 2.0.1.4.
Study III: Prediction analysis for transition to schizophrenia in individuals at
clinical high-risk for psychosis: The relationship of DAO, DAOA and NRG1
variants with negative symptoms and cognitive deficits
In this study, we used whole blood samples from 185 individuals at clinical risk
for psychosis who were followed-up at 6, 12, 24, and 36 months for the transition
to schizophrenia-spectrum disorders. The main aims of this study were as
follows:
(a) To determine DAO and DAOA SNPs and mRNA levels in at-risk
individuals to identify predictive genetic markers in these individuals for
the transition to schizophrenia-spectrum disorders.
(b) To identify endophenotypes in at-risk individuals using psychopathology
constructs according to Research Domain Criteria (RDoC) guidelines.
To address these aims, we quantified DAO and DAOA mRNA levels using
qRT-PCR and assessed DAO (rs3918347, rs4623951) and DAOA (rs778293,
rs3916971, rs746187) SNPs using TaqMan SNP genotyping assay.
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Study IV: Controversial effects of D-amino acid oxidase activator (DAOA)/G72
on D-amino acid oxidase (DAO) activity in human neuronal, astrocyte, and
kidney cell lines: The N-methyl D-aspartate (NMDA) receptor hypofunction
point of view
In this study, we used human neuroblastoma SH-SY5Y cells, human astrocytoma
cells 1321N1 cells, and human embryonic kidney HEK293 cells. The aims of this
study were as follows:
(a) To measure DAO activity in DAO and DAOA co-transfected SH-SY5Y,
1321N1, and HEK293 cells to understand the effect of DAOA on DAO
activity.
(b) To measure NMDA receptor activity in HEK293 cells stably transfected with
NMDA receptor subunits NR1 and NR2A to determine the effect of DAOA
on NMDA receptor activity.
(c) To simulate the DAO and DAOA interactions to evaluate the effect of
DAOA on DAO in silico.
To address these aims, the human cell lines were co-transfected with DAO and
DAOA plasmid constructs, DAO activity was measured based on the release
of hydrogen peroxide and its interaction with an Amplex Red reagent, NMDA
receptor activity was measured using patch-clamp whole-cell recording, and in
silico experiments were performed using Molecular Dynamics simulations.
27

5. Results
5.1 Study I: Expression of D-Amino Acid Oxidase (DAO/DAAO)
and D-Amino Acid Oxidase Activator (DAOA/G72) during
development and aging in the human post-mortem brain
Vinita Jagannath1, Zoya Marinova1, Camelia-Maria Monoranu2, Susanne
Walitza1,3,4, Edna Gru¨nblatt1,3,4∗
1 Molecular and Neurobiochemistry Laboratory, Centre for Child and Adolescent
Psychiatry Research, Department of Child and Adolescent Psychiatry and
Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich,
Zurich, Switzerland
2 Department of Neuropathology, Institute of Pathology, University of
Wu¨rzburg, Wu¨rzburg, Germany
3 Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich,
Switzerland
4 Zurich Center for Integrative Human Physiology, University of Zurich, Zurich,
Switzerland
* Correspondence:
Edna Gru¨nblatt
edna.gruenblatt@kjpd.uzh.ch
Running title: Expression of DAO and DAOA in the human brain
Keywords: DAO/DAAO, DAOA/G72, gene and protein expression, DNA
methylation, human post-mortem brain regions
Published in Frontiers in Neuroanatomy. 2017 Apr 6;11:31.
Author contributions
ZM, C-MM, and EG designed the experiments. VJ performed experiments,
analysed data, and wrote the manuscript. ZM, C-MM, SW, and EG reviewed and
revised the manuscript. All authors have approved the final manuscript.
29
Study I: Abstract
5.1.1 Abstract
In the brain, D-amino acid oxidase (DAO/DAAO) mainly oxidizes D-serine,
a co-agonist of the N-methyl-D-aspartate (NMDA) receptors. Thus, DAO can
regulate the function of NMDA receptors via D-serine breakdown. Furthermore,
DAO activator (DAOA)/G72 has been reported as both DAOA and repressor.
The co-expression of DAO and DAOA genes and proteins in the human brain is
not yet elucidated. The aim of this study was to understand the regional and
age span distribution of DAO and DAOA (mRNA and protein) in a concomitant
manner. We determined DAO and DAOA mRNA and protein expression
across six brain regions in normal human post-mortem brain samples (16 weeks
of gestation to 91 years) using quantitative real-time reverse transcription
polymerase chain reaction and enzyme-linked immunosorbent assay. We
found higher expression of DAO mRNA in the cerebellum, whereas lower
expression of DAO protein in the cerebellum compared to the other brain
regions studied, which suggests post-transcriptional regulation. We detected
DAOA protein but not DAOA mRNA in all brain regions studied, suggesting a
tightly regulated expression. To understand this regulation at the transcriptional
level, we analyzed DNA methylation levels at DAO and DAOA CpG sites in
the cerebellum and frontal cortex of control human post-mortem brain obtained
from Gene Expression Omnibus datasets. Indeed, DAO and DAOA CpG sites
in the cerebellum were significantly more methylated than those in the frontal
cortex. While investigating lifespan effects, we found that DAO mRNA levels
were positively correlated with age <2 years in the cerebellum and amygdala.
We also detected a significant positive correlation (controlled for age) between
DAO and DAOA protein in all of the brain regions studied except for the frontal
cortex. In summary, DAO and DAOA expression in the human brain are both
age and brain region dependent.
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5.1.2 Introduction
Brain development is a continuous process, which extends from the prenatal
period into adulthood (Rapoport et al., 2012). Abnormal neurodevelopmental
processes are implicated in many psychiatric disorders such as schizophrenia,
attention deficit hyperactivity disorder, autism spectrum disorder, and
intellectual disability (Rapoport et al., 2012; Miller et al., 2016). Moreover,
altered gene expression across different brain regions and lifespan has been
reported in psychiatric disorders (Sibille, 2013; Darby et al., 2016). For example,
schizophrenia risk genes are reported to be associated with transcripts that are
either enriched in specific brain regions or unique to the human brain, and some
also show preferential expression in the fetal brain (Kang et al., 2011; Kleinman
et al., 2011). Therefore, it is important to analyze the brain region-specific
expression of risk genes for psychiatric disorders in the normal human brain
across the lifespan to understand the mechanisms underlying pathological
changes in psychiatric disorders.
D-amino acid oxidase (DAO/DAAO; from now on addressed as DAO) is a
flavoenzyme, which oxidizes D-amino acids. Its main substrate in the brain
is D-serine (Pollegioni et al., 2007; Sacchi et al., 2012). D-serine is a co-agonist
of N-methyl-D-aspartate (NMDA) receptors. In addition to glutamate, NMDA
receptors require a co-agonist (glycine or D-serine) binding at the glycine
modulatory site in order to function normally. D-serine is shown to be more
potent in binding to NMDA receptors than glycine (Matsui et al., 1995; Shleper
et al., 2005; Sacchi et al., 2012). Thus, DAO can regulate the function of
NMDA receptors via D-serine breakdown, which may lead to NMDA receptor
hypofunction (Kantrowitz and Javitt, 2010; Labrie and Roder, 2010; Verrall et al.,
2010; Labrie et al., 2012). One of the possible explanations for NMDA receptor
hypofunction theory proposed in schizophrenia is probably an increased
activity of DAO leading to decreased D-serine. D-amino acid oxidase activator
(DAOA)/G72 (from now on addressed as DAOA) binds to DAO, but the effect
of DAOA on DAO is controversial. This is because DAOA is reported to both
increase (Chumakov et al., 2002; Chang et al., 2013) and decrease (Sacchi et al.,
2008, 2011) the activity of DAO. DAOA is localized in mitochondria and reported
to modulate its function (Kvajo et al., 2008; Sacchi et al., 2011; Otte et al., 2014).
Thus, the exact function of DAOA is not yet completely understood.
The human DAO gene located on chromosome 12q24 encodes for a ∼39 kDa
protein (Almond et al., 2006; Sacchi et al., 2008; Verrall et al., 2010) and the
human DAOA gene encodes for a ∼20 kDa protein (Benzel et al., 2008). The
genes DAOA/G30 overlap and are transcribed from opposite strands on
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chromosome 13q33. The polymorphisms of these genes in non-coding regions
have been described to be associated with the pathophysiology of schizophrenia
and bipolar disorder (Detera-Wadleigh and McMahon, 2006; Korostishevsky
et al., 2006; Corvin et al., 2007b; Prata et al., 2008; Mo¨ssner et al., 2010; Labrie
et al., 2012; Gatt et al., 2015; Liu et al., 2016). However, a recent genome-wide
association study (GWAS) conducted by the Psychiatric Genomics Consortium
(PGC) found that out of 108 schizophrenia-associated loci, none were within
DAO and DAOA gene regions (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). There are several lines of evidence showing
regional and cellular expression of DAO mRNA and protein in the human
brain (Kapoor et al., 2006; Verrall et al., 2007; Habl et al., 2009; Ono et al., 2009),
however, none of these studies isolated mRNA and protein concomitantly
from the same brain tissue as we did in this study. On the other hand, the
reports of DAOA mRNA and protein expression in the human brain remain
unconvincing to date. Studies showing DAOA mRNA expression in the human
brain are limited (Chumakov et al., 2002; Korostishevsky et al., 2006). Moreover,
the expression of DAOA mRNA and protein in the human brain has been
questioned (Benzel et al., 2008; GTEx Consortium, 2015). The human protein
atlas detected DAOA protein (also known as pLG72, from now on addressed as
DAOA) in the cerebellum and the cerebral cortex (Uhle´n et al., 2015). Thus, the
regulation of DAO and DAOA expression in the human brain has not yet been
elucidated.
Furthermore, since DNA methylation can lead to both increases and decreases in
gene expression (Wagner et al., 2014), it may play a crucial role in the regulation
of normal brain development (Fan et al., 2001). Hannon et al., (Hannon et al.,
2015) quantified DNA methylation using Illumina 450K array in normal human
post-mortem brain, and reported that DNA methylation levels in cortical
regions differ from the cerebellum. Moreover, epigenetic regulation of gene
expression is very important in the human brain (Gra¨ff et al., 2011; Numata
et al., 2012). However, the extent to which DNA methylation or other epigenetic
modifications affect the expression of genes important for human brain function,
such as DAO/DAOA, is largely unknown.
In the present study, our main aim was to understand concomitant DAO and
DAOA mRNA and protein expression in the normal human post-mortem
brain during development and aging in six brain regions. We also correlated
DAO mRNA and DAO protein as well as DAO protein and DAOA protein to
understand their concomitant expression in different brain regions. Furthermore,
we assessed the potential effect of DAO and DAOA polymorphisms on DAO
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and DAOA expression levels to elucidate their role in the regulation of DAO
and DAOA expression. To understand the hypothesized regulation of DAO
and DAOA expression at the transcription level in an indirect manner, we
determined the DNA methylation levels at CpG sites of DAO and DAOA genes
in the cerebellum and the frontal cortex of control human post-mortem brain
obtained from Gene Expression Omnibus (GEO) datasets.
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5.1.3 Materials and methods
Subjects
Human post-mortem brain samples from six brain regions were studied. These
brain samples were from 55 subjects with age ranging from 16 weeks of gestation
to 91 years, who had no history of psychiatric or neurological illness, and their
post-mortem brain samples showed no neuropathological evidence of any
neuropsychiatric disorder. The brain samples were collected from six brain
regions, namely: the cerebellum (n=47), brainstem (n=49), amygdala (n=47),
striatum (n=52), thalamus (n=52), and frontal cortex (n=54). These brain samples
were procured from the Department of Neuropathology, Institute of Pathology,
University of Wurzburg, Germany (member of the BrainNet Europe-BNEII)
and the London Neurodegenerative Diseases Brain Bank, United Kingdom.
Informed written consent for tissue donation was obtained from the individuals
or the next of kin. The causes of death of the study population are presented
in Supplementary Table S6. This study was approved by the Cantonal Ethic
Commission of Zurich (Ref. Nr. EK: KEK-ZH-Nr. 2013-0177).
DNA, RNA and protein isolation
DNA, RNA, and protein were simultaneously isolated from the same frozen
human post-mortem brain samples using AllPrep DNA/RNA/Protein Mini Kit
(Qiagen, Switzerland). Firstly, frozen brain tissue samples weighing around 27
34 mg were disrupted and homogenized in the buffer provided in the kit using
the TissueLyser II (Qiagen, Switzerland). Secondly, tissue lysates were added
to the AllPrep DNA spin column, and DNA was eluted. Thirdly, RNA was
eluted after adding an ethanol treated sample to a RNeasy spin column. Finally,
proteins in the sample were precipitated and pelleted by centrifugation. Since
the buffer provided in the kit interferes with protein determination and does
not dissolve proteins completely, protein eluates were acetone precipitated, and
precipitated proteins were redissolved in urea buffer (7M urea, 2M thiourea, 2%
CHAPS and trace bromophenol, pH 8).
TaqMan single nucleotide polymorphism (SNP) genotyping
DNA isolated from post-mortem human cerebellum (n=46), striatum (n=2),
thalamus (n=5), and amygdala (n=2) were used for genotyping. DNA
concentrations, A260/A280, and A260/A230 ratios were measured using a
spectrophotometer (NanoVue Plus, GE Healthcare Life Sciences). Real-time
PCR was used to genotype DAO (rs3918347, rs4623951), and DAOA (rs778293,
rs3916971, rs746187) polymorphisms. These SNPs were chosen based on
previously reported association with schizophrenia (Allen et al., 2008). DNA,
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TaqMan R© Genotyping Master Mix (Applied Biosystems, USA), and SNP
Genotyping Assays (rs778293 assay number: C 8704507 10, rs3916971 assay
number: C 27495752 10, rs746187 assay number: C 1925241 10, rs3918347
assay number: C 27937201 10, and rs4623951 assay number: C 32177440 10, all
from Applied Biosystems, USA) were combined in a 384-well plate. Real-time
PCR was performed in a C1000TMCFX384TM Thermal cycler (Bio-Rad) using
TaqMan R© SNP Genotyping Assay PCR standard protocol. Genotypes were
determined by the allelic discrimination program of Bio-Rad CFX ManagerTM
Software version 2.1. The Hardy-Weinberg Equilibrium (HWE) p-value and
allele frequencies were computed using PLINK software (Purcell et al., 2007),
and p<0.05 was considered as statistically significant.
Quantification of DAO and DAOA mRNA levels using quantitative real-time
reverse transcription-polymerase chain reaction (qRT-PCR)
RNA isolated from post-mortem human cerebellum (n=44), brainstem (n=40),
amygdala (n=39), striatum (n=35), thalamus (n=37), and frontal cortex (n=36)
were used for quantitative real-time reverse transcription-polymerase chain
reaction (qRT-PCR). A spectrophotometer (NanoVue Plus, GE) was used to
measure RNA concentrations, A260/A280, and A260/A230 ratios. RNA integrity
was analyzed using Experion automated electrophoresis system (Bio-Rad,
Switzerland) in a subset of samples. RNA (500 ng) was reverse transcribed using
iScriptTM cDNA Synthesis Kit (Bio-Rad, Switzerland) as per manufacturer’s
protocol. In a subset of samples, negative controls were prepared with RNA
without reverse transcriptase enzyme. qRT-PCR was performed using cDNA,
QuantiFast SYBR Green PCR kit (Qiagen, Switzerland), 1 µM forward and
reverse DAO primers (Microsynth, Switzerland), and reference genes [β-actin
(ACTB) (QT01680476), aminolevulinate synthetase (ALAS1) (QT00073122),
ribosomal protein L13a (RPL13A) (QT00089915), alanyl-tRNA synthetase
(AARS) (QT00054747), glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(QT01192646), peptidyl prolyl isomerase A (PPIA) (QT00866137), ribosomal RNA
(R18S) (QT00019936), and X-prolyl aminopeptidase1 (XPNPEP1) (QT00051471);
all from Qiagen, , Switzerland]. These eight reference genes were selected based
on previous reports of their stability in human post-mortem brain (Durrenberger
et al., 2012). The DAO primers used in this study have been described by Verrall
et al., (Verrall et al., 2007) (Forward primer: CGCAGACGTGATTGTCAACT;
Reverse primer: GGATGATGTACGGGGAATTG). DAO mRNA levels were
normalized to the reference genes. PCR efficiencies were calculated using
LinReg PCR program (Ruijter et al., 2009) and mean PCR efficiencies for all
studied amplicons were found to be between 88 and 95%. Normalized DAO
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mRNA levels were quantified by importing qRT-PCR quantification cycle
(Cq) values of the gene of interest and reference genes across brain regions
and lifespan into qBASE plus software (Biogazelle, Belgium) which utilizes
gene-specific amplification efficiencies, and allows normalization with multiple
reference genes. The qBASE plus software automatically selects multiple stably
expressed reference genes in the samples across brain regions and lifespan by
taking into account their stability. The software carries out a normalization
of the gene of interest with multiple reference genes, ultimately producing
calibrated normalized relative quantities (CNRQ) of the gene of interest which
was used to perform statistical analysis (Hellemans et al., 2007). To detect
DAOA mRNA in human post-mortem brain, qRT-PCR was performed using
several different primers for DAOA gene described by Benzel et al., (Benzel
et al., 2008), Cheng et al., (Cheng et al., 2014), and pre-designed primers
[QT00058863 (Qiagen), Hs.PT.58.555086 (IDT), 4331182 (ThermoFisher scientific),
qHsaCEP0024792 (BioRad)]. As a positive control, these primers were also
tested on the cDNA prepared from human neuroblastoma cells (SK-N-SH and
SH-SY5Y) overexpressing DAOA, and these primers detected DAOA mRNA
in these cells, but not in the human post-mortem brain samples (data not
shown). DAOA mRNA was still undetectable in human post-mortem brain after
increasing the cDNA amounts in qRT-PCR. Furthermore, amplification using
QuantiTect Whole Transcriptome Kit (207043, Qiagen) followed by qRT-PCR to
detect DAOA mRNA levels was not successful. In summary, we were unable
to quantify DAOA mRNA levels with any of the aforementioned methods in
human post-mortem brain.
Quantification of DAO and DAOA protein levels using commercially
available enzyme-linked immunosorbent assay (ELISA) kits
Protein isolated and acetone-precipitated from post-mortem human cerebellum
(n=40), brainstem (n=47), amygdala (n=46), striatum (n=48), thalamus (n=48),
and frontal cortex (n=54) were used for enzyme-linked immunosorbent assay
(ELISA). Total protein concentration was quantified using the Bradford assay
(Sigma-Aldrich) (Bradford, 1976). DAO and DAOA protein concentrations
were quantified using a commercially available DAO ELISA kit (SEJ298Hu;
Cloud-Clone Corp.) with a high specificity and a sensitivity of 0.56 ng/mL
and a commercially available DAOA ELISA kit (SEJ297Hu; Cloud-Clone
Corp.) with a high specificity and a sensitivity of 0.061 ng/mL according to
the manufacturers instructions. A standard curve was obtained by plotting
absorbance versus different concentration of protein standards provided with
the kit, and DAO and DAOA protein concentrations were determined from
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the standard curve. Normalized DAO and DAOA protein concentrations
were calculated by dividing DAO and DAOA protein concentrations by the
total protein concentration measured using Bradford assay. The specificity
of DAO and DAOA ELISA kits was proved using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting which is
described in detail in supplementary methods S1.
DNA methylation levels across DAO and DAOA CpG sites in the cerebellum
and frontal cortex
The processed and normalized methylation beta values from two datasets:
Gene Expression Omnibus (GEO) accession number GSE61431 as described in
the study of Pidsley et al.,(Pidsley et al., 2014) and GSE63347 as described by
Horvath et al.,(Horvath et al., 2015) were downloaded from the GEO website
(http://www.ncbi.nlm.nih.gov/geo/). From these datasets, the methylation
beta values for DAO and DAOA CpG sites from the cerebellum and frontal cortex
of controls were extracted. DAO (cg03868278, cg22621535, cg22801690) and
DAOA (cg00809502) CpG sites in the repeat masker region sites were excluded
from the analysis. DAO CpG sites: cg01694331, cg25362648, cg18037826,
cg12592321 lie in the exon 1 and cg26725638 in the exon 2 of DAO gene. DAOA
CpG sites: cg22773522, cg25623522, cg01297020 are in the promoter region,
cg13846327 and cg20888753 in the intron 2, and cg11374446 in the intron 3 region
of the DAOA gene. In the GSE61431 dataset, there were 23 control cerebellum
and frontal cortex samples ranging from ages 25 to 96 years. In the GSE63347
dataset, there were 9 control cerebellum samples in the ages between 38 and 64
years and 17 control frontal cortex samples between ages 32 and 64 years.
Statistical analysis
IBM R© SPSS R© Statistics (version 21) software was used for statistical analysis.
Shapiro-Wilk test with Lilliefors significance correction was used to assess
the normality of the distribution of mRNA, protein expression, and DNA
methylation data. DAO mRNA, DAO and DAOA protein expression, and DNA
methylation data showed both normal and non-normal distribution across
different brain regions. In order to maintain consistency between statistical
evaluations, non-parametric tests were used even for normally distributed data.
Linear regression with brain regions as dummy variables was used after a
logarithmic transformation of the non-normally distributed data to determine
the differences in DAO mRNA, DAO and DAOA protein expression in the brain
regions studied; p<0.05 was taken as statistically significant. The differences in
DAO mRNA, and DAO and DAOA protein levels across different age groups
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were assessed by the Kruskal-Wallis test followed by pair-wise comparisons
with the Mann-Whitney test by adjusting p-value based on the number of
comparisons (Bonferroni correction, p<0.005). As we do not have post-mortem
brain samples from ages 2 to 20 years, we divided the ages for correlation into
two groups, namely less than 2 years and more than 20 years. Then, Spearman’s
rank correlation test was used to assess the correlation between age groups (<2
years and >20 years) and DAO mRNA, DAO and DAOA protein levels; p<0.05
was taken as statistically significant. We correlated DAO mRNA with DAO
protein levels, and DAO protein levels with DAOA protein levels across six brain
regions by controlling for age using partial correlation, p<0.05 was taken as
statistically significant. To analyze the effect of DAO and DAOA SNP genotypes
on DAO mRNA, DAO and DAOA protein expression, analysis of covariance
(ANCOVA) with age as a covariate was used after a logarithmic transformation
of not normally distributed DAO mRNA and DAOA protein expression data
and the inverse transformation of the non-normally distributed DAO protein
expression data; p<0.05 was taken as statistically significant. The differences
in methylation levels between the cerebellum and frontal cortex at each CpG
site was assessed using the Mann-Whitney test by adjusting p-value based on a
number of CpG sites analyzed (Bonferroni correction, p<0.005). The correlation
between age and methylation levels at each CpG site in the cerebellum and
frontal cortex was assessed using Spearman’s rank correlation test, and p<0.05
was considered statistically significant. GraphPad Prism software (version 6.01)
was used to plot the graphs. The post-hoc power analyses for DAO mRNA,
DAO and DAOA protein expression across five age groups were conducted
using G*Power software (Faul et al., 2009), the effect sizes were determined
from means of age groups, and the alpha level was set at 0.05 (Supplementary
Table S7).
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5.1.4 Results
DAO and DAOA expression in different brain regions
The current study aimed to assess brain region specific DAO and DAOA
expression across the lifespan in normal human post-mortem brain using
qRT-PCR and ELISA techniques. The human post-mortem brain samples were
obtained from 55 subjects with no clinical or neuropathological evidence of
neuropsychiatric disorders. The demographic characteristics of the study sample
across five age groups are presented in Supplementary Table S1. In order to
assess any confounding factors inherent in human post-mortem studies, we
addressed factors such as post-mortem interval (PMI) and gender. The length of
PMI did not differ significantly between different age groups as assessed by the
Kruskal-Wallis test. Gender had a significant effect on DAO mRNA (p=0.048)
and protein (p=0.047) expression in the thalamus and frontal cortex respectively
(Mann-Whitney test, p<0.05). DAO mRNA in the thalamus and DAO protein
in the frontal cortex was significantly more expressed in males than in females.
Gender had no significant effect on DAOA protein expression in all brain areas
studied. There was no statistically significant correlation between PMI and DAO
mRNA, DAO and DAOA protein levels in the studied brain regions (Spearman’s
rank correlation, p>0.05).
With the aim of investigating brain region-specific patterns of DAO and DAOA,
we assessed their expression in the normal brain. We found that DAO mRNA
was significantly more expressed in the cerebellum (set to 100%), followed by
the brainstem (17.6%), thalamus (4.8%), striatum (2.5%), amygdala (0.9%), and
the frontal cortex (0.7%) as assessed by linear regression (Figure 1A and 1B).
In contrast to DAO mRNA, DAO protein was significantly less expressed in
the cerebellum than in the remaining brain regions. In the amygdala (set to
100%), DAO protein was significantly more expressed than in the brainstem
(79.2%) (Figure 1C). DAOA protein was significantly more expressed in the
frontal cortex (set to 100%) than in the cerebellum (65.2%), amygdala (80.4%),
and the thalamus (69.6%). In the striatum (set to 100%), DAOA protein was
significantly more expressed than in the amygdala (66.7%) and the cerebellum
(54.1%). DAOA protein was significantly less expressed in the thalamus (57.7%)
than in the brainstem (85.6%) and striatum (set to 100%) (Figure 1D). Thus, DAO
and DAOA exhibit region-specific expression patterns in the human brain.
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Figure 1: DAO mRNA, DAO and DAOA protein levels quantified in six regions of human
post-mortem brain. (A) Normalized DAO mRNA levels across six brain regions. (B) For
clarity, this figure focuses only on amygdala, striatum, thalamus, and frontal cortex results
presented in A. DAO protein levels (µg DAO/mg total protein) (C) and DAOA protein levels
(µg DAOA/mg total protein) (D) in studied brain regions. Values are presented as box and
whisker plots, whiskers represent minimum to maximum values, “+” indicates mean values, and
*p<0.05. Linear regression with brain regions as dummy variables was used after logarithmic
transformation of non-normally distributed data.
Expression of DAO mRNA, DAO and DAOA protein across lifespan in six
brain regions
The expression patterns across lifespan were analyzed using two approaches.
The first approach was by grouping ages into five groups, while the second
approach was by correlating ages with expression levels which provided
information on expression patterns during brain development, maturation,
and degeneration. We assessed DAO and DAOA expression across age groups
in six brain regions to understand critical and sensitive periods during brain
development. As the sample size in each age group was small, we performed
a power analysis which showed reasonable power (>0.76) in the cerebellum,
striatum, and thalamus for DAO mRNA as well as reasonable power (>0.64)
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in the cerebellum, striatum, and frontal cortex for DAO protein, but the power
was too low in the brain regions studied for DAOA protein to conduct statistical
analysis (Supplementary Table S7).
We found statistically significant (p<0.05) differences in DAO mRNA levels
across the five different age groups, as assessed by the Kruskal-Wallis test, in the
cerebellum, brainstem (Figure 2B), amygdala, striatum, and thalamus. However,
differences in DAO mRNA levels were found to be statistically non-significant
in the frontal cortex (Figure 2F). Pair-wise comparisons using the Mann-Whitney
test showed statistically significant differences (p<0.005) in DAO mRNA levels
between age groups 0-2 years and >61 years in the cerebellum (Figure 2A)
and striatum (Figure 2D), between prenatal and >61 years in the amygdala
(Figure 2C), and between prenatal and >61 years, 0-2 years and 36-60 years, 0-2
years and >61 years in the thalamus (Figure 2E).
Figure 2: DAO mRNA levels across five different age groups in six regions of human post-mortem
brain (A-F). Data presented as scatter plots. Kruskal-Wallis test followed by pairwise comparisons
with the Mann-Whitney test (*p<0.005) was performed to assess the differences in DAO mRNA
levels between different age groups across six brain regions.
The differences in DAO protein levels across the five different age groups was
found to be statistically significant (p<0.05), as assessed by the Kruskal-Wallis
test, in the cerebellum (Figure 3A), striatum (Figure 3D), and frontal cortex
(Figure 3F). However, differences in DAO protein levels were found to be
statistically non-significant in the brainstem (Figure 3B), amygdala (Figure 3C),
and thalamus (Figure 3E). Pair-wise comparisons with the Mann-Whitney test
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showed statistically significant differences (p<0.005) in DAO protein levels
for age groups >61 years versus prenatal and 0-2 years in the frontal cortex
(Figure 3F). The differences in DAOA protein levels across the five different
age groups were found to be statistically significant (p<0.05) in the brainstem
as assessed by the Kruskal-Wallis test. There were no statistically significant
differences in DAOA protein levels in the cerebellum, amygdala, striatum,
thalamus, and frontal cortex (Figure 4). The specificity of DAO and DAOA
ELISA kits was demonstrated by Western blot as presented in Supplementary
Figure S2.
Figure 3: DAO protein levels (µg DAO/mg total protein) across different age groups in six regions
of human post-mortem brain (A-F). Data presented as scatter plots. Differences in DAO protein
levels across different age groups was assessed by the Kruskal-Wallis test followed by pairwise
comparisons with the Mann-Whitney test (*p<0.005).
Using the second approach, we correlated age (<2 years and >20 years) with
DAO and DAOA expression across different brain regions to understand the
critical developmental period and brain region in DAO and DAOA expression.
We found a statistically significant positive correlation (p<0.05) as assessed
by Spearman’s rank correlation test, between age less than 2 years and DAO
mRNA levels in the cerebellum and amygdala (Table 1). Furthermore, there was
a significant positive correlation (Spearman’s rank correlation, p<0.01) between
age more than 20 years and DAO protein concentration in the frontal cortex
(Table 1). There was no statistically significant correlation between age and
DAOA protein concentration in the brain regions studied (Table 1).
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Figure 4: DAOA protein expression (µg DAOA/mg total protein) across five different age groups
in six regions of human post-mortem brain (A-F). Values are presented as scatter plots. Differences
in DAOA protein levels across different age groups were assessed with the Kruskal-Wallis test.
Correlation between DAO mRNA, DAO and DAOA protein in different brain
regions
In order to assess whether there is a concomitant expression of DAO mRNA
and its protein, we correlated the two in various brain regions. We did not find
any statistically significant correlation (partial correlation controlled for age)
between DAO mRNA and DAO protein in each of the studied brain regions
(Supplementary Figure S3).
As we concomitantly measured DAO and DAOA proteins in the human brain,
we examined whether these two proteins correlate in each brain region. A
statistically significant positive correlation (partial correlation controlled for age)
was found between DAO and DAOA protein expression in the cerebellum [r(36)
=0.74, p<0.0001; Figure 5A], the brainstem [r(43) =0.84, p<0.0001; Figure 5B], the
amygdala [r(36) =0.88, p<0.0001; Figure 5C], the striatum [r(43) =0.84, p<0.0001;
Figure 5D], and the thalamus [r(44) =0.91, p<0.0001; Figure 5E]. However, there
was no statistically significant correlation between DAO and DAOA protein
concentration in the frontal cortex [r(49) =0.27, p=0.06 Figure 5F].
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Table 1: Correlation between age and DAO mRNA, DAO and DAOA protein expression across
brain regions of human post-mortem brain
Brain
regions
Age in years
Prenatal and 0-2 years 20-91 years
N
Spearman’s rank
correlation
co-efficient
p-value N
Spearman’s rank
correlation
co-efficient
p-value
Normalised
DAO mRNA
levels
Cerebellum 12 0.828 0.001** 32 0.127 0.488
Brainstem 11 0.310 0.354 29 0.117 0.546
Amygdala 13 0.669 0.017* 26 0.261 0.198
Striatum 9 0.008 0.983 26 0.259 0.202
Thalamus 10 0.427 0.218 27 0.254 0.200
Frontal cortex 11 0.352 0.288 25 0.022 0.918
Relative DAO
protein
concentration
(µg DAO/mg
total protein)
Cerebellum 12 -0.495 0.102 27 -0.143 0.478
Brainstem 16 0.092 0.736 31 0.077 0.679
Amygdala 16 -0.122 0.652 30 0.162 0.392
Striatum 18 0.082 0.747 30 0.142 0.455
Thalamus 20 0.285 0.224 28 0.180 0.359
Frontal cortex 21 0.185 0.422 33 0.482 0.004*
Relative DAOA
protein
concentration
(µg DAOA/mg
total protein)
Cerebellum 13 0.120 0.695 27 0.099 0.623
Brainstem 16 0.332 0.210 30 0.324 0.081
Amygdala 13 0.318 0.268 26 0.306 0.121
Striatum 19 0.037 0.879 29 -0.120 0.536
Thalamus 20 0.195 0.411 27 0.021 0.916
Frontal cortex 20 -0.200 0.398 32 0.149 0.417
*p<0.05 (bold font); **p<0.01 (bold font)
DAO and DAOA expression across DAO and DAOA SNP genotypes in
different brain regions
We assessed the potential effect of DAO and DAOA SNPs on DAO and DAOA
expression to understand whether such genetic variations known to be risk
factors in schizophrenia play a role in the regulation of their expression. The
DAO and DAOA SNPs were in Hardy-Weinberg equilibrium (p>0.05), and
the minor allele frequency (MAF) of DAO and DAOA SNPs were similar to
HapMap CEU MAF (Supplementary Table S2). In the thalamus, DAO mRNA
was significantly more expressed in rs3918347 DAO genotype GG (minor
allele G) than in rs3918347 DAO genotypes (GA, AA), and DAO mRNA was
less expressed in rs3918347 DAO genotypes GG+GA than in rs3918347 DAO
genotype AA as assessed by ANCOVA with age as covariate (Supplementary
Table S3). However, for the DAO protein, no statistically significant difference
was detected among rs3918347 and rs4623951 DAO genotypes (Supplementary
Table S4). For DAOA protein expression, there was a significantly higher
expression in rs3916971 DAOA genotype TT (minor allele T) than in rs3916971
DAOA genotypes (CT, CC, CT+CC) in the amygdala, as assessed by ANCOVA
with age as a covariate (Supplementary Table S5). Nonetheless, from our
findings, we cannot conclusively comment on the effect of DAO and DAOA
SNPs on their expression due to their rather small sample size.
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Figure 5: Correlation between DAO (µg DAO/mg total protein) and DAOA protein expression
(µg DAOA/mg total protein) in six regions of the human post-mortem brain (A-F). Data is
presented as scatter plots with linear fit and 95% confidence intervals. Correlation between DAO
and DAOA protein levels in different brain regions were assessed with the partial correlation
test, controlled for age; p<0.05 was taken as statistically significant (N: sample size, r: correlation
co-efficient).
DNA methylation across DAO and DAOA CpG sites in cerebellum and frontal
cortex
From our DAO and DAOA mRNA and protein findings, we hypothesized a
possible regulation of their expression at the transcriptional levels. To elucidate
this, we analyzed in silico DNA methylation across DAO and DAOA CpG sites
in the cerebellum and frontal cortex to indirectly explain the differential DAO
and DAOA expression in the human brain. In GSE61431 and GSE63347 datasets,
gender had no statistically significant effect on DNA methylation levels at DAO
and DAOA CpG sites in the cerebellum and frontal cortex (Mann-Whitney test,
p>0.005). In GSE61431 and GSE63347 datasets, DAO CpG site cg18037826
is significantly more methylated in the cerebellum than in the frontal cortex
as assessed by the Mann-Whitney test, p<0.001 (supplementary Figure S1A).
In the GSE61431 dataset, all studied DAOA CpG sites except cg13846327 are
statistically significantly (p<0.001) more methylated in the cerebellum than in
the frontal cortex (Supplementary Figure S1B). In GSE63347 dataset, DAOA CpG
sites cg22773522, cg20888753, and cg11374446 are significantly more methylated
in the cerebellum than in the frontal cortex (Supplementary Figure S1B). There
was no statistically significant correlation between age and DNA methylation
levels at DAO and DAOA CpG sites in the cerebellum and frontal cortex in both
studied datasets.
45
Study I: Discussion
5.1.5 Discussion
This study investigated the age-span expression of DAO and DAOA mRNA and
protein in six brain regions of normal human post-mortem brain samples. In this
study, we also determined in silico DNA methylation levels at DAO and DAOA
CpG sites in the cerebellum and frontal cortex of control human post-mortem
brain. The results of this study have implications for understanding the
regulation and expression of DAO and DAOA genes in the normal human brain
during development and aging.
In this study, DAO mRNA and protein was detected in all brain regions
studied. DAO mRNA was highly expressed in the cerebellum as compared to
the other brain regions studied. This finding is in line with previous studies
of DAO expression in the human brain (Kapoor et al., 2006; Verrall et al.,
2007; GTEx Consortium, 2015). This is the first study which quantified DAO
protein in human post-mortem brain using the quantitative ELISA method.
Previous studies detected DAO protein in the human brain using methods
such as immunohistochemistry and Western blot (Bendikov et al., 2007; Verrall
et al., 2007; Uhle´n et al., 2015). Immunohistochemical studies measured DAO
immunoreactivity in the human brain and found that DAO protein was robustly
detected both in the cerebellum and cerebral cortex (Verrall et al., 2007; Uhle´n
et al., 2015). Another study detected DAO protein in the frontal cortex and
hippocampus using Western blot (Bendikov et al., 2007). We found that DAO
protein was less expressed in the cerebellum, but DAO mRNA was highly
expressed in the cerebellum as compared to other regions studied, which might
indicate post-transcriptional regulation such as microRNA (miRNA) mediated
regulation. The miRWalk 2.0 database (Dweep and Gretz, 2015) with prediction
algorithms from 4 different databases (miRWalk, miRanda, RNA22, Targetscan)
showed that there are around 327 predicted miRNA target sites in the promoter
region (miRWalk, miRanda, Targetscan), 3 predicted miRNA target sites in the
5’UTR (miRWalk, miRanda, RNA22), 74 predicted miRNA target sites in the
coding DNA sequence (CDS) (miRWalk, miRanda, RNA22, Targetscan), and
9 predicted miRNA target sites in the 3’UTR (miRWalk, miRanda, RNA22,
Targetscan) of the DAO gene. The interaction of these miRNAs with the DAO
gene in the cerebellum might be the reason for more DAO mRNA and less DAO
protein. However, these interactions have to be confirmed experimentally. We
measured DAO protein but not the activity of DAO protein because the buffer
used to isolate proteins deactivated the DAO enzyme. Therefore, in our study,
we are unable to comment on the activity of DAO in different brain regions.
The DAO protein can be either in an active [Flavin adenine dinucleotide (FAD
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bound)] or inactive (FAD unbound) state (Caldinelli et al., 2009; Terry-Lorenzo
et al., 2014). Kapoor et al., (Kapoor et al., 2006) showed that DAO activity was
detected in the human cerebellum but not in the human forebrain. Moreover, a
recent study by Sasabe et al., (Sasabe et al., 2014) showed that DAO activity was
detected in the human hindbrain, midbrain, spinal cord, and only in the white
matter of the forebrain. Therefore, DAO activity in the human forebrain is not
yet very clear.
DAOA is a primate-specific gene which shows a complex alternative splicing
pattern, and encodes a protein characterized by a rapidly changing structure
during evolution (Chumakov et al., 2002). The DAOA gene and protein
expression in the human brain have not yet been fully characterized. We
detected DAOA protein using ELISA in all of the brain regions studied. The
human protein atlas detected DAOA protein in the cerebellum and cerebral
cortex using immunohistochemistry (Uhle´n et al., 2015). Kvajo et al., detected
DAOA protein in the human amygdala using Western blot (Kvajo et al., 2008).
However, Benzel et al., could not detect DAOA protein in the human brain
(cerebellum, amygdala, frontal cortex) using Western blot (Benzel et al., 2008).
Studies showing DAOA mRNA expression in the human brain are limited
(Chumakov et al., 2002; Korostishevsky et al., 2006). We were unable to detect
DAOA mRNA in all the brain regions studied using qRT-PCR, which is in line
with previous studies that used methods such as northern blotting, qRT-PCR,
and RNA sequencing (Benzel et al., 2008; GTEx Consortium, 2015). The reason
for detecting DAOA protein but not DAOA mRNA in the human brain might
be a tightly regulated DAOA expression or extremely localized expression
or post-transcriptional regulation by RNA methylation. A previous study
suggested that undetectable DAOA mRNA in the human brain might be because
of RNA instability motif found in the 5’UTR of DAOA gene (Benzel et al.,
2008). There are around 314 predicted miRNA target sites in the promoter
region (miRWalk, miRanda, Targetscan), 5 predicted miRNA target sites in the
5’UTR (miRWalk, miRanda, RNA22), 317 predicted miRNA target sites in the
coding DNA sequence (CDS) (miRWalk, miRanda, Targetscan), and 70 predicted
miRNA target sites in the 3’UTR (miRWalk, miRanda, RNA22) of the DAOA
gene as described in the miRWalk 2.0 database (Dweep and Gretz, 2015) with
prediction algorithms from 4 different databases (miRWalk, miRanda, RNA22,
Targetscan). The interaction of these miRNAs with the DAOA gene might be the
reason for the variation of DAOA protein expression in different brain regions.
However, the interactions of miRNA with the DAOA gene have to be confirmed
experimentally.
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During brain development, there are critical and sensitive periods during which
the brain is more vulnerable to environmental insults that can potentially lead
to psychiatric disorders (Meredith, 2015). In order to understand pathological
changes that occur in psychiatric disorders, it is important to analyze the
expression of risk genes for psychiatric disorders in the normal brain across
the lifespan. In our study, we found that DAO mRNA levels were positively
correlated with age less than 2 years in the cerebellum and amygdala. Our data
is in agreement with previous studies of whole-genome expression analysis
in the developing brain which reported that prenatal and neonatal periods
are associated with a rapid change of gene expression patterns in the brain as
compared to other age periods (Kang et al., 2011; Naumova et al., 2013). During
brain development and maturation, synaptic plasticity varies significantly across
different brain regions, which might contribute to the brain region-specific
gene expression (Huttenlocher and Dabholkar, 1997; Caruana et al., 2012). In
this study, DAO expression was brain region specific, indicating that DAO is
differentially regulated across hindbrain and forebrain regions. Interestingly, we
found a significant positive correlation between DAO and DAOA protein in all
the brain regions studied except for the frontal cortex. This positive correlation
between DAO and DAOA protein might be because of the variability in density
of particular cell types in different brain regions. A recent in vitro study showed
that there is an interaction between DAO and DAOA proteins (Birolo et al., 2016).
Nonetheless, the effect of DAOA protein on DAO is controversial. Chumakov
and colleagues (Chumakov et al., 2002) reported DAOA to be an activator of
DAO, but Sacchi and colleagues (Sacchi et al., 2008) reported DAOA to be a
repressor of DAO. From our finding, we are still unable to conclude regarding
DAO and DAOA interaction, but we could show their simultaneous expression.
DNA methylation has been widely acknowledged to be crucial for normal
brain development (Fan et al., 2001), and alterations in DNA methylome in
the human brain might contribute to neuropsychiatric disorders (Illingworth
et al., 2015). DNA methylation can lead to both increases and decreases in gene
expression (Wagner et al., 2014). We found in silico that the cerebellum was
significantly more methylated than the frontal cortex in most of the DAO and
DAOA CpG sites which is in line with previous studies (Davies et al., 2012;
Hannon et al., 2015; Illingworth et al., 2015). This finding might explain the
differential expression of DAO mRNA in the cerebellum and frontal cortex.
However, further studies are required to understand the extent to which DNA
methylation or other epigenetic modifications affect the expression of genes
important for human brain function.
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In this study, we attempted to carefully address confounding factors such as
PMI and gender that are inherent in human post-mortem studies. Our study is
the first study which measured concomitantly DAO and DAOA protein levels
in human post-mortem brain using quantitative ELISA method. Nevertheless,
we were only able to measure total DAO protein but not the DAO activity in
different brain regions because of the isolation procedure used. In our study, we
had no post-mortem samples between ages 2 years and 20 years, therefore we are
unable to comment on alterations within this particular developmental phase.
We also do not have schizophrenia brain samples to comment on regulation and
expression of DAO and DAOA mRNA and protein across different brain regions
in schizophrenia. DAO and DAOA are susceptibility genes for schizophrenia
and bipolar disorders. Both disorders are discussed as neurodevelopmental
disorders, and first symptoms often occur before early adulthood, whereas
the definitive onset of the disorder is typically in early adulthood (Cacabelos
and Martı´nez-Bouza, 2011; Rapoport et al., 2012). Therefore, it is important to
investigate the regulation of these genes between 2 years and 20 years in the
normal human brain. Hence, future studies in this age period would be useful to
elucidate this question. Another limitation of the study is that because of limited
sample size, it is not powered appropriately, particularly regarding the effect of
DAO and DAOA polymorphisms on their expression. However, the strength of
this study lies in the fact that we extracted DNA, RNA and total protein from the
same tissue, which allowed us to investigate concomitantly DAO and DAOA
expression in six different brain regions and across a wide range of ages.
In summary, our results showed the regional expression of DAO and DAOA
with age in normal human post-mortem brain samples. We detected DAOA
protein, despite undetectable DAOA mRNA levels in the human post-mortem
brain.
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5.1.6 Supplementary Information
Supplementary Methods
S1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and Western blot
The acetone precipitated proteins from all six brain regions of subject 081/01
(3 months male) were subjected to electrophoresis on 10-20% Tris-HCl Gel
(Bio-Rad) and transferred to PVDF membrane (Bio-Rad). The membrane was
blocked with 5% non-fat milk in 1x phosphate buffered saline (PBS) pH 7.4
(Gibco) with 0.1% Tween-20 (Sigma-Aldrich) for 2 hours at room temperature
and then it was incubated with primary antibody against DAO (1 µg/ml, same
primary antibody that was used in DAO ELISA kit, SEJ298Hu; Cloud-Clone
Corp.) or DAOA (1 µg/ml, same primary antibody that was used in DAOA
ELISA kit, SEJ297Hu; Cloud-Clone Corp.) at 4◦C overnight. The membrane was
washed thrice with PBS-T (1x PBS with 0.1% Tween-20) and then incubated with
anti-rabbit secondary HRP-conjugated antibody (1:5000, ab97051, abcam) for
one hour at room temperature. The protein visualisation was carried out with
20X LumiGLO R© Reagent and 20X Peroxide (Cell Signaling) by exposing the
membrane to X-ray film in cassette for 1 minute.
Supplementary Results
To prove the specificity of DAO and DAOA ELISA kits, we performed SDS-PAGE
and western blot with acetone precipitated samples of subject 081/01 (3 month
old male) from six brain regions. We found that DAO and DAOA proteins were
expressed in all six brain regions at the expected sizes of 40 kDa (Supplementary
Figure S2A) and 20 kDa (Supplementary Figure S2B) respectively. This finding
proves the specificity of the primary antibody used in DAO and DAOA ELISA
kits.
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Supplementary Figures
Supplementary Figure S1: Percentage of DNA methylation across DAO (A) and DAOA (B) CpG
sites in cerebellum and frontal cortex of human brain reported in GEO datasets GSE61431 and
GSE63347. Values are presented as box and whisker plots, whiskers represent minimum to
maximum values, “+” indicates mean values. Differences in DNA methylation levels between
cerebellum and frontal cortex at each CpG site was assessed by the Mann-Whitney test (*p<0.005,
**p<0.001).
Supplementary Figure S2: Expression of DAO (A) and DAOA (B) proteins across six brain
regions of subject 081/01. DAO and DAOA proteins are detected in all studied brain regions
at the expected sizes of 40 kDa (A) and 20 kDa (B), respectively.
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Supplementary Figure S3: Correlation between DAO mRNA and DAO protein expression (µg
DAO/mg total protein) in six regions of the human post-mortem brain (A-F). Data is presented
as scatter plots with linear fit and 95% confidence intervals. Correlation between DAO mRNA
and DAO protein levels in different brain regions were assessed with the partial correlation test,
controlled for age; p<0.05 was taken as statistically significant (N: sample size, r: correlation
co-efficient).
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Supplementary Tables
Supplementary Table S1: Demographic data of the study population by age groups
Age groups N
Gender
Age (mean±SD) PMI (mean±SD)Male
N (%)
Female
N (%)
Prenatal 11 4 (36%) 7 (64%) 21.3±6.9 g.w 36.9±19.9 hours
0-2 years 11 6 (55%) 5 (45%) 0.62±0.60 years 25.5±7.7 hours
20-35 years 4 3 (75%) 1 (25%) 30.5±5.8 years 27.3±20.8 hours
36-60 years 12 6 (50%) 6 (50%) 49.8±6.1 years 26.3±12.1 hours
>61 years 17 11 (65%) 6 (35%) 73.6±8.6 years 25.9±10.2 hours
PMI: post-mortem interval; SD: standard deviation; g.w: gestational weeks
Supplementary Table S2: Genotype distribution and minor allele frequencies of DAO and DAOA
SNPs
Gene SNP ID
Genotype distribution Minor
allele MAF
HapMap
CEU MAFGenotype N H-Wp-value
DAO
rs3918347
GG 3
1 G 0.25 0.274GA 22
AA 31
rs4623951
CC 6
0.096 C 0.411 0.412CT 34
TT 16
DAOA
rs3916971
TT 13
1 T 0.482 0.394CT 28
CC 15
rs778293
GG 10
0.791 G 0.438 0.389AG 29
AA 17
rs746187
CC 6
0.52 C 0.295 0.375CT 21
TT 29
H-W: Hardy-Weinberg; MAF: minor allele frequency; SNP: single nucleotide polymorphism
53
Study I: Supplementary Information
Supplementary Table S3: Differences in DAO mRNA levels among rs3918347 and rs4623951
DAO SNP genotypes across six brain regions of human post-mortem brain
DAO
SNP
ID
Brain
regions
Normalised DAO mRNA levels
Genotypes
(N)
Mean±
SEM
p-
valuea
Dom
model
Mean±
SEM
p-
valuea
Rec
model
Mean±
SEM
p-
valuea
rs
39
18
34
7
Cb
GG (2) 34.7±18.6
0.378 GG+GA 37.1±4.84 0.276
GG 34.7±18.6
0.272GA (19) 37.4±5.20 GA+AA 39.6±4.16AA (23) 41.4±6.40 AA 41.4±6.40
BS
GG (2) 7.11±1.67
0.366 GG+GA 6.06±0.93 0.17
GG 7.11±1.67
0.506GA (16) 5.93±1.03 GA+AA 6.90±0.88AA (22) 7.62±1.33 AA 7.62±1.33
Amg
GG (2) 0.39±0.23
0.88 GG+GA 0.25±0.06 0.638
GG 0.39±0.23
0.739GA (14) 0.23±0.06 GA+AA 0.33±0.08AA (23) 0.40±0.11 AA 0.40±0.11
Str
GG (2) 2.63±0.48
0.728 GG+GA 1.02±0.26 0.636
GG 2.63±0.48
0.61GA (16) 0.82±0.24 GA+AA 0.89±0.17AA (17) 0.95±0.23 AA 0.95±0.23
TH
GG (2) 3.44±0.62
0.049* GG+GA 1.32±0.30 0.017*
GG 3.44±0.62
0.97GA (14) 1.02±0.25 GA+AA 1.82±0.33AA (21) 2.36±0.49 AA 2.36±0.49
FC
GG (2) 0.06±0.03
0.313 GG+GA 0.14±0.08 0.126
GG 0.06±0.03
0.537GA (13) 0.16±0.09 GA+AA 0.27±0.11AA (21) 0.35±0.17 AA 0.35±0.17
rs
46
23
95
1
Cb
CC (6) 55.4±20.7
0.623 CC+CT 36.3±4.71 0.578
CC 55.4±20.7
0.527CT (28) 32.2±3.5 CT+TT 36.9±3.35TT (10) 49.9±6.76 TT 49.9±6.76
BS
CC (4) 8.15±2.44
0.902 CC+CT 6.63±0.93 0.98
CC 8.15±2.44
0.659CT (25) 6.39±1.02 CT+TT 6.78±0.90TT (11) 7.66±1.87 TT 7.66±1.87
Amg
CC (5) 0.36±0.17
0.96 CC+CT 0.36±0.09 0.776
CC 0.36±0.17
0.969CT (24) 0.36±0.11 CT+TT 0.33±0.08TT (10) 0.28±0.07 TT 0.28±0.07
Str
CC (5) 1.26±0.62
0.839 CC+CT
0.88±0.20
0.561
CC 1.26±0.62
0.766CT (20) 0.79±0.21 CT+TT 0.94±0.18TT (10) 1.26±0.32 TT 1.26±0.32
TH
CC (5) 2.51±0.95
0.662 CC+CT 1.98±0.39 0.403
CC 2.51±0.95
0.556CT (20) 1.84±0.44 CT+TT 1.82±0.34TT (12) 1.78±0.55 TT 1.78±0.55
FC
CC (6) 0.23±0.13
0.771 CC+CT 0.33±0.14 0.553
CC 0.23±0.13
0.572CT (21) 0.35±0.17 CT+TT 0.27±0.12TT (9) 0.07±0.02 TT 0.07±0.02
a p-value by ANCOVA with age as a covariate; *p<0.05 (bold font); SEM: standard error of the mean; Dom model:
dominant model; Rec model: recessive model; Cb: cerebellum; BS: brainstem; Amg: amygdala; Str: striatum; TH:
thalamus; FC: frontal cortex
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Supplementary Table S4: Differences in DAO protein levels among rs3918347 and rs4623951
DAO SNP genotypes across six brain regions of human post-mortem brain
DAO
SNP
ID
Brain
regions
Relative DAO protein concentration (µg DAO/mg total protein)
Genotypes
(N)
Mean±
SEM
p-
valuea
Dom
model
Mean±
SEM
p-
valuea
Rec
model
Mean±
SEM
p-
valuea
rs
39
18
34
7
0.612 Cb
GG (2) 0.18±0.01 GG+GA 0.19±0.01 0.585
GG 0.18±0.01
0.353GA (18) 0.19±0.01 GA+AA 0.19±0.01AA (19) 0.19±0.01 AA 0.19±0.01
BS
GG (2) 0.22±0.01
0.428 GG+GA 0.34±0.06 0.563
GG 0.22±0.01
0.205GA (20) 0.35±0.07 GA+AA 0.38±0.05AA (25) 0.41±0.08 AA 0.41±0.08
Amg
GG (3) 0.34±0.04
0.624 GG+GA 0.44±0.06 0.546
GG 0.34±0.04
0.363GA (18) 0.45±0.07 GA+AA 0.49±0.06AA (25) 0.51±0.09 AA 0.51±0.09
Str
GG (3) 0.30±0.07
0.637 GG+GA 0.49±0.07 0.507
GG 0.30±0.07
0.631GA (20) 0.51±0.08 GA+AA 0.54±0.07AA (25) 0.56±0.10 AA 0.56±0.10
TH
GG (3) 0.41±0.02
0.911 GG+GA 0.37±0.07 0.68
GG 0.41±0.02
0.804GA (20) 0.36±0.08 GA+AA 0.39±0.05AA (25) 0.41±0.06 AA 0.41±0.06
FC
GG (3) 0.37±0.11
0.545 GG+GA 0.38±0.04 0.713
GG 0.37±0.11
0.27GA (22) 0.38±0.04 GA+AA 0.38±0.02AA (29) 0.37±0.03 AA 0.37±0.03
rs
46
23
95
1
Cb
CC (6) 0.21±0.02
0.632 CC+CT 0.19±0.01 0.392
CC 0.21±0.02
0.499CT (24) 0.19±0.01 CT+TT 0.19±0.01TT (9) 0.19±0.01 TT 0.19±0.01
BS
CC (6) 0.31±0.07
0.707 CC+CT 0.35±0.05 0.697
CC 0.31±0.07
0.547CT (28) 0.36±0.06 CT+TT 0.39±0.06TT (13) 0.45±0.14 TT 0.45±0.14
Amg
CC (5) 0.34±0.07
0.498 CC+CT 0.47±0.07 0.795
CC 0.34±0.07
0.289CT (29) 0.49±0.08 CT+TT 0.49±0.06TT (12) 0.49±0.09 TT 0.49±0.09
Str
CC (5) 0.49±0.16
0.723 CC+CT 0.51±0.07 0.954
CC 0.49±0.16
0.442CT (31) 0.51±0.08 CT+TT 0.53±0.07TT (12) 0.58±0.15 TT 0.58±0.15
TH
CC (6) 0.45±0.08
0.957 CC+CT 0.38±0.05 0.776
CC 0.45±0.08
0.87CT (28) 0.37±0.06 CT+TT 0.38±0.05TT (14) 0.40±0.10 TT 0.40±0.10
FC
CC (6) 0.36±0.06
0.892 CC+CT 0.35±0.02 0.895
CC 0.36±0.06
0.679CT (33) 0.35±0.03 CT+TT 0.38±0.03TT (15) 0.44±0.06 TT 0.44±0.06
a p-value by ANCOVA with age as a covariate; *p<0.05 (bold font); SEM: standard error of the mean; Dom model:
dominant model; Rec model: recessive model; Cb: cerebellum; BS: brainstem; Amg: amygdala; Str: striatum; TH:
thalamus; FC: frontal cortex
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Supplementary Table S5: Differences in DAOA protein levels among rs3916971, rs778293 and
rs746187 DAOA SNP genotypes across six brain regions of human post-mortem brain
DAOA
SNP
ID
Brain
regions
Relative DAOA protein concentration (µg DAOA/mg total protein)
Genotypes
(N)
Mean±
SEM
p-
valuea
Dom
model
Mean±
SEM
p-
valuea
Rec
model
Mean±
SEM
p-
valuea
rs
39
16
97
1
Cb
TT (6) 0.02±0.002
0.776 TT+CT 0.02±0.002
0.791 TT 0.02±0.002
0.475CT (21) 0.02±0.003 CT+CC 0.02±0.002CC (13) 0.02±0.002 CC 0.02±0.002
BS
TT (9) 0.05±0.018
0.623 TT+CT 0.03±0.006 0.893
TT 0.05±0.018
0.383CT (23) 0.03±0.003 CT+CC 0.03±0.003CC (14) 0.03±0.007 CC 0.03±0.007
Amg
TT (7) 0.05±0.021
0.017* TT+CT 0.03±0.007 0.719
TT 0.05±0.021
0.012*CT (18) 0.02±0.002 CT+CC 0.02±0.002CC (14) 0.02±0.003 CC 0.02±0.003
Str
TT (10) 0.03±0.009
0.922 TT+CT 0.04±0.005 0.935
TT 0.03±0.009
0.686CT (26) 0.04±0.006 CT+CC 0.04±0.005CC (12) 0.04±0.009 CC 0.04±0.009
TH
TT (10) 0.02±0.004
0.657 TT+CT 0.02±0.003 0.848
TT 0.02±0.004
0.432CT (23) 0.03±0.005 CT+CC 0.02±0.003CC (14) 0.02±0.001 CC 0.02±0.001
FC
TT (13) 0.03±0.005
0.603 TT+CT 0.03±0.002 0.339
TT 0.03±0.005
0.528CT (26) 0.03±0.003 CT+CC 0.03±0.003CC (13) 0.04±0.006 CC 0.04±0.006
rs
77
82
93
Cb
GG (5) 0.02±0.002
0.415 GG+AG 0.02±0.002 0.221
GG 0.02±0.002
0.937AG (21) 0.02±0.003 AG+AA 0.02±0.002AA (14) 0.02±0.002 AA 0.02±0.002
BS
GG (7) 0.05±0.019
0.241 GG+AG 0.03±0.006 0.123
GG 0.05±0.019
0.237AG (23) 0.03±0.005 AG+AA 0.03±0.004AA (16) 0.03±0.007 AA 0.03±0.007
Amg
GG (6) 0.04±0.017
0.300 GG+AG 0.03±0.007 0.143
GG 0.04±0.017
0.332AG (20) 0.03±0.007 AG+AA 0.02±0.004AA (13) 0.02±0.001 AA 0.02±0.001
Str
GG (8) 0.04±0.009
0.538 GG+AG 0.04±0.005 0.637
GG 0.04±0.009
0.400AG (26) 0.04±0.006 AG+AA 0.04±0.005AA (14) 0.04±0.008 AA 0.04±0.008
TH
GG (9) 0.02±0.004
0.549 GG+AG 0.02±0.003 0.39
GG 0.02±0.004
0.756AG (22) 0.02±0.004 AG+AA 0.02±0.003AA (16) 0.02±0.004 AA 0.02±0.004
FC
GG (10) 0.03±0.007
0.689 GG+AG 0.03±0.003 0.67
GG 0.03±0.007
0.556AG (27) 0.03±0.003 AG+AA 0.03±0.002AA (15) 0.03±0.004 AA 0.03±0.004
rs
74
61
87
Cb
CC (4) 0.03±0.011
0.149 CC+CT 0.02±0.003 0.648
CC 0.03±0.011
0.051CT (15) 0.02±0.002 CT+TT 0.02±0.001TT (21) 0.02±0.001 TT 0.02±0.001
BS
CC (5) 0.04±0.011
0.679 CC+CT 0.03±0.006 0.764
CC 0.04±0.011
0.376CT (18) 0.03±0.006 CT+TT 0.03±0.005TT (23) 0.03±0.007 TT 0.03±0.007
Amg
CC (3) 0.01±0.003
0.193 CC+CT 0.03±0.006 0.34
CC 0.01±0.003
0.256CT (14) 0.03±0.008 CT+TT 0.03±0.005TT (22) 0.02±0.006 TT 0.02±0.006
Str
CC (6) 0.05±0.017
0.631 CC+CT 0.04±0.007 0.354
CC 0.05±0.017
0.546CT (18) 0.04±0.007 CT+TT 0.04±0.004TT (24) 0.03±0.005 TT 0.03±0.005
TH
CC (5) 0.04±0.012
0.164 CC+CT 0.03±0.004 0.366
CC 0.04±0.012
0.058CT (18) 0.02±0.005 CT+TT 0.02±0.002TT (24) 0.02±0.002 TT 0.02±0.002
FC
CC (6) 0.03±0.004
0.572 CC+CT 0.03±0.003 0.388
CC 0.03±0.004
0.788CT (21) 0.03±0.004 CT+TT 0.03±0.003TT (25) 0.03±0.004 TT 0.03±0.004
a p-value by ANCOVA with age as a covariate; *p<0.05 (bold font); SEM: standard error of the mean; Dom model:
dominant model; Rec model: recessive model; Cb: cerebellum; BS: brainstem; Amg: amygdala; Str: striatum; TH:
thalamus; FC: frontal cortex
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Supplementary Table S6: Detailed demographic characteristics of the study population
Sl
No. Gender Age PMI (hours) Cause of death Brain bank
1 Female 59 yr 24 Pneumonia, cardiac failure Wurzburg
2 Male 66 yr 19 Cardiovascular failure Wurzburg
3 Male 65 yr 25 Respiratory insufficiency Wurzburg
4 Female 0.42 yr 24 Cardiac arrest Wurzburg
5 Female 84 yr 32 Cardiovascular failure, shock Wurzburg
6 Male 35 yr 58 Sudden cardiac death Wurzburg
7 Male 49 yr 14 Haemorrhagic shock, spleen rupture Wurzburg
8 Female 60 yr 9 Toxic multi-organ failure Wurzburg
9 Male 73 yr 24 Cardiovascular failure, sepsis Wurzburg
10 Female 45 yr 41 Sudden cardiac death Wurzburg
11 Female 41 g.w 7 Aspiration of amniotic fluid, respiratory insufficiency Wurzburg
12 Female 64 yr 32 Cardiovascular failure, septic shock Wurzburg
13 Male 0.25 yr 24 Cardiovascular failure Wurzburg
14 Female 38 yr 20 Aneurism rupture Wurzburg
15 Male 63 yr 24 Bleeding oesophageal varices Wurzburg
16 Female 91 yr 12 Circulatory failure Wurzburg
17 Male 66 yr 23 Acute cardiovascular failure Wurzburg
18 Female 73 yr 24 Acute myocardial infarction Wurzburg
19 Female 76 yr 20 Cardiovascular failure Wurzburg
20 Female 51 yr 12.5 Multi-organ failure Wurzburg
21 Male 84 yr 48 Acute myocardial infarction Wurzburg
22 Female 33 yr 18 Multi-organ failure Wurzburg
23 Male 0.42 yr 48 Respiratory insufficiency Wurzburg
24 Male 85 yr 20.5 Cardiac arrest Wurzburg
25 Female 0.125 yr 24 Acute cardiovascular failure Wurzburg
26 Male 22 yr 21 Cardiovascular failure, sepsis Wurzburg
27 Female 73 yr 24 Multi-organ failure Wurzburg
28 Male 46 yr 19 Cardiovascular failure Wurzburg
29 Male 80 yr 23 Cardiac failure Wurzburg
30 Male 51 yr 42 Cardiovascular failure Wurzburg
31 Male 54 yr 27 Respiratory insufficiency Wurzburg
32 Male 52 yr 44 Myocardial infarction Wurzburg
33 Male 64 yr 50 Respiratory insufficiency Wurzburg
34 Male 32 yr 12 Cardiac failure Wurzburg
35 Male 0.75 yr 24 Cardiovascular failure, septic shock Wurzburg
36 Male 74 yr 12 Circulatory failure Wurzburg
37 Male 71 yr 27 Pulmonary embolism Wurzburg
38 Female 46 yr 27 Cardiac failure Wurzburg
39 Male 47 yr 36 Cardiac failure after acute myocardial infarction Wurzburg
40 Female 0.25 yr 17 Accidental asphyxia London
41 Male 0.375 yr 24 Coronary heart disease London
42 Male 1.83 yr 24 Coronary heart disease London
43 Female 1.75 yr 24 Coronary heart disease London
44 Female 0.29 yr 24 Coronary heart disease London
45 Male 0.33 yr 24 Coronary heart disease London
46 Female 20 g.w 36 Spontaneous abortion London
47 Male 17 g.w 62 Spontaneous abortion London
48 Male 18 g.w 24 Spontaneous abortion London
49 Female 18 g.w 14 Unknown London
50 Female 20 g.w 65 Prostaglandin induction/polydactyly London
51 Male 19 g.w 65 Unknown London
52 Female 22 g.w 32 Spontaneous abortion London
53 Female 23 g.w 42 Unknown London
54 Male 20 g.w 32 Spontaneous miscarriage London
55 Female 16 g.w 27 Unknown London
PMI: post-mortem interval; yr: years; g.w: gestational weeks
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Supplementary Table S7: Power analysis for DAO mRNA, DAO and DAOA protein expression
across age groups
Brain regions Age groups DAO mRNA DAO protein DAOA proteinEffect size Power Effect size Power Effect size Power
Cerebellum
Prenatal
0.53 0.77 0.55 0.73 0.35 0.34
0-2 yr
20-35 yr
36-60 yr
>61 yr
Brainstem
Prenatal
0.42 0.49 0.3 0.3 0.41 0.54
0-2 yr
20-35 yr
36-60 yr
>61 yr
Amygdala
Prenatal
0.31 0.26 0.3 0.3 0.31 0.26
0-2 yr
20-35 yr
36-60 yr
>61 yr
Striatum
Prenatal
0.57 0.78 0.45 0.65 0.35 0.43
0-2 yr
20-35 yr
36-60 yr
>61 yr
Thalamus
Prenatal
0.62 0.82 0.28 0.28 0.36 0.43
0-2 yr
20-35 yr
36-60 yr
>61 yr
Frontal cortex
Prenatal
0.19 0.12 0.56 0.9 0.24 0.22
0-2 yr
20-35 yr
36-60 yr
>61 yr
yr: years
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5.2.1 Abstract
The glutamate hypothesis of schizophrenia is related to the proposed
dysregulation of D-amino acid oxidase (DAO), DAO activator (DAOA)/G72,
and Neuregulin 1 (NRG1) genes. Genetic studies have shown significant
associations between DAO, DAOA, NRG1 single nucleotide polymorphisms
(SNPs) and schizophrenia. The systematic literature search yielded 6, 5, and
18 new studies for DAO, DAOA, and NRG1 published after 2011 and not
included in the previous SchizophreniaGene (SZGene) meta-analysis. We
conducted meta-analyses of 20, 23, and 48 case-control studies, respectively, to
comprehensively evaluate the association of 8 DAO, 12 DAOA, and 14 NRG1
SNPs with schizophrenia. The updated meta-analyses resulted in the following
findings: the C-allele of DAO rs4623951 was associated with schizophrenia across
all pooled studies [Odds ratio (OR)=0.88, 95% confidence interval (CI)=0.79-0.98,
p=0.02, N=3,143)], however, no new reports could be included. The G-allele of
DAOA rs778293 was associated with schizophrenia in Asian patients (OR=1.17,
95% CI=1.08-1.27, p=0.00008, N=6,117), and the T-allele of DAOA rs3916971 was
associated with schizophrenia across all studies (OR=0.84, 95% CI=0.73-0.96,
p=0.01, N=1,765). Again, for both SNPs, no new eligible studies were available.
After adding new reports, the T-allele of NRG1 SNP8NRG241930 (rs62510682)
across all studies (OR=0.95, 95% CI=0.91-0.997, p=0.04, N=22,898) and in
Caucasian samples (OR=0.95, 95% CI=0.90-0.99, p=0.03, N=16,014), and the
C-allele of NRG1 rs10503929 across all studies (OR=0.89, 95% CI=0.81-0.97,
p=0.01, N=6,844) and in Caucasian samples (OR=0.89, 95% CI=0.81-0.98, p=0.01,
N=6,414) were protective against schizophrenia. Our systematic meta-analysis is
the most updated one for the association of DAO, DAOA, and NRG1 SNPs with
schizophrenia.
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5.2.2 Introduction
Schizophrenia is a complex heritable disorder characterised by positive
symptoms such as delusions, hallucinations, and thought disorder; negative
symptoms such as flattening of emotional responses, avolition, apathy, and
social withdrawal (American Psychiatric Association, 2013), and cognitive
deficits such as impairments in attention, memory, and executive functions
(Elvevag and Goldberg, 2000; Fioravanti et al., 2012). Schizophrenia has an
estimated heritability of around 60-80% (Pepper and Cardno, 2014). Several
pathophysiological hypotheses focusing on dysregulation of neurotransmitter
pathways such as dopamine, glutamate, serotonin, and gamma-aminobutyric
acid (GABA) have been put forward to explain the pathophysiology of
schizophrenia (Eggers, 2013; Brisch et al., 2014; Carlsson et al., 2001; Nakazawa
et al., 2012; Veerman et al., 2014). The glutamate hypothesis of schizophrenia
is based on a proposed hypofunction of the N-methyl-D-aspartate (NMDA)
receptors (Veerman et al., 2014; Hu et al., 2015). One possible explanation
for NMDA hypofunction in schizophrenia is increased activity of the enzyme
D-amino acid oxidase (DAO) modulated by the D-amino acid oxidase activator
(DAOA/G72) leading to decreased D-serine, a co-agonist of the NMDA receptor
(Sacchi et al., 2016). Post-mortem studies have shown that there is increased
DAO activity in brains of schizophrenia patients compared to the brains of
controls (Burnet et al., 2008; Madeira et al., 2008). The effect of DAOA on DAO
is controversial, as DAOA has been shown to both increase (Chumakov et al.,
2002; Chang et al., 2013) and decrease (Sacchi et al., 2008, 2011) DAO activity.
DAOA was also reported to modulate mitochondrial function, thereby playing
a role in the pathophysiology of schizophrenia (Kvajo et al., 2008; Otte et al.,
2014). Another important gene in the glutamate hypothesis of schizophrenia is
Neuregulin 1 (NRG1), which is a pleiotropic growth factor involved in normal
developmental processes, synaptic plasticity, and neurotransmission (Harrison
and Law, 2006). NRG1 exerts its action through binding to its receptor tyrosine
kinases, ErbB3 and ErbB4. Altered NRG1/ErbB4 signalling has been described
to result in NMDA receptor hypofunction (Li et al., 2007; Mei and Nave, 2014).
These studies highlight the potential pathogenic link between dysregulation of
DAO, DAOA, and NRG1 genes leading to the NMDA receptor hypofunction,
which form the basis for the glutamate hypothesis of schizophrenia.
Chumakov and colleagues demonstrated the association of DAO and
DAOA/G72 single nucleotide polymorphisms (SNPs) with schizophrenia for
the first time (Chumakov et al., 2002). An association of NRG1 SNPs with
schizophrenia was first reported by Stefansson and colleagues (Stefansson
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et al., 2002). Subsequently, the SchizophreniaGene (SZGene) meta-analysis (last
updated on 23 December 2011) showed a significant association of 24 genetic
variants in 16 different genes with schizophrenia (Allen et al., 2008). In that
meta-analysis, SNPs of DAOA (rs778293, rs3916971) and NRG1 (rs10503929)
were significantly associated with schizophrenia (Allen et al., 2008). In contrast
to these findings, a more recent genome-wide association study (GWAS)
conducted by the Psychiatric Genomics Consortium (PGC) found that out of 108
schizophrenia associated loci, none were within NRG1, DAO, and DAOA gene
regions (Schizophrenia Working Group of the Psychiatric Genomics Consortium,
2014). Although there are ambiguous reports on the association of DAO, DAOA,
and NRG1 SNPs with schizophrenia, these genes still remain candidate genes for
schizophrenia because of their role in the glutamatergic signalling that has been
associated with schizophrenia in multiple lines of research (Catts et al., 2016;
Kantrowitz and Javitt, 2010; Balu and Coyle, 2015; Heresco-Levy et al., 2015;
Ledonne et al., 2015). Since the last SZGene meta-analysis update 6 years ago,
more than a dozen case-control association studies for DAO, DAOA, and NRG1
genes have been published. Thus, we performed an updated systematic review
and meta-analysis of both previously meta-analysed and new studies published
since 2011 in order to comprehensively evaluate the association of DAO, DAOA,
and NRG1 SNPs with schizophrenia.
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5.2.3 Materials and methods
Search strategy and study selection
A systematic literature search was conducted to include studies that examined
associations of DAO, DAOA, and NRG1 polymorphisms with schizophrenia.
We searched PubMed and Web of Science databases for articles published
until March 21, 2017. DAO literature was searched using the keywords: (DAO
OR DAAO) AND schizophrenia; DAOA literature was searched using the
keywords: (DAOA OR G72) AND schizophrenia, and NRG1 literature was
searched using the keywords: (NRG1 OR Neuregulin-1 OR Neuregulin 1
OR Neuregulin1) AND schizophrenia. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Liberati
et al., 2009) was used to report the search flow for this meta-analysis. Studies
included in our meta-analysis had to fulfil the following criteria: (i) detailed
description of the sample size, ancestry of participants, and diagnostic criteria
for schizophrenia, (ii) case-control studies examining the association between
DAO, DAOA, NRG1 polymorphisms and schizophrenia, (iii) containing data on
allele/genotype frequencies in case and control groups and/or odds ratio (OR)
and 95% confidence interval (CI) for the OR, (iv) samples not duplicative of
other studies, and (v) at least 3 studies reporting results for each SNP to conduct
a meta-analysis. In addition to performing a meta-analysis of all studies pooled
together, we conducted a subgroup analysis by dividing the studies into those
including patients with Caucasian or Asian ancestry to examine the effects of
ethnic heterogeneity. If articles only reported allele/genotype frequencies, OR
and 95% CI was calculated from allele frequencies using an online OR calculator
(https://www.medcalc.org/calc/odds ratio.php).
Data synthesis and statistical analysis
The meta-analysis was conducted using the MIX 2.0-Professional software for
meta-analysis in Excel, version 2.0.1.4 (http://www.meta-analysis-made-easy.com/)
(Bax et al., 2006). The OR of each study was converted to the natural logarithm
of OR (Ln (OR)), and 95% CI to standard error (SE) using MIX 2.0 software.
The Ln (OR), SE, and sample size (N) were used in the software to perform
heterogeneity statistics, heterogeneity funnel plots, and synthesis forest plots.
The heterogeneity between studies was assessed by Cochran’s chi-square-based
Q statistic and the inconsistency index (I2), with p<0.05 being considered
statistically significant. If there was significant (p<0.05) heterogeneity
between studies, we used the random-effects model, otherwise we used the
fixed-effects model. The random-effects model considers both between-study
and within-study variation, whereas the fixed-effects model considers only
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within-study variation (Borenstein et al., 2010). The heterogeneity funnel plots
for each included DAO, DAOA, and NRG1 SNPs were plotted to visualise the
heterogeneity between studies. Synthesis forest plots showing N, OR, 95% CI of
each included studies of DAO, DAOA, and NRG1 SNPs were created to visualise
the association of polymorphisms with schizophrenia in an allelic model, p<0.05
being considered statistically significant without Bonferroni correction, and
p<0.0015 being considered statistically significant with Bonferroni correction.
Potential publication bias was assessed using Begg’s test (Begg and Mazumdar,
1994) and Egger’s regression test (Egger et al., 1997), with p<0.05 considered
statistically significant. The a-priori and post hoc power analyses for DAO
(Supplementary Table S11), DAOA (Supplementary Table S12), and NRG1
(Supplementary Table S13) meta-analysis were conducted using G*Power
software (Faul et al., 2009), the proportions of cases and controls carrying minor
allele were calculated from all studies, z-test was used to measure the difference
between these two proportions, and the alpha level was set at 0.05, and for
a-priori power analyses, the power was set at 0.8.
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5.2.4 Results
DAO meta-analysis
The literature search for studies reporting on the association of DAO SNPs
with schizophrenia identified 201 non-duplicated articles (Supplementary
Figure S1). Out of 201 articles, 170 articles were excluded at the title/abstract
level. Altogether, 31 articles were read fully, and 11 articles were excluded
because of missing allele/genotype frequencies and/or OR and 95% CI or other
reasons (Supplementary Table S1). Finally, 20 studies were included in the
meta-analysis (Supplementary Table S2), 6 of which were new studies (Papagni
et al., 2011; Mechelli et al., 2012; Sacchetti et al., 2013; Kartalci and Acar, 2016;
Liu et al., 2016; Chu et al., 2017), that had not been included in the SZGene
meta-analysis. There were at least 3 studies reporting results for 8 DAO SNPs:
rs4623951, rs2111902, rs3918346, rs3918347, rs3741775, rs3825251, rs2070586,
and rs2070587. The meta-analyses summary of all 8 DAO SNPs is provided
in Table 1. We found a significant association between DAO SNP rs4623951
and schizophrenia across all studies, and the minor C-allele was protective
against schizophrenia (OR=0.88, 95% CI=0.79-0.98, p=0.02, N=3,143) (Figure 1A).
However, no significant association was found between any other DAO
SNPs (rs2111902, rs3918346, rs3918347, rs3741775, rs3825251, rs2070586, and
rs2070587) and schizophrenia across all studies, or in the Caucasian and Asian
subsamples (Supplementary Figure S2). The majority of the analyses showed
significant between-study heterogeneity (p<0.05; Supplementary Figure S3),
resulting in the use of random-effects models in these instances. No publication
bias was observed (p>0.05) in any of the DAO meta-analyses as assessed by
Begg’s test and Egger’s regression test (Supplementary Table S3).
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Figure 1: Forest plots of the association between DAO rs4623951, NRG1 SNP8NRG241930
(rs62510682), and NRG1 rs10503929 polymorphisms, and schizophrenia in the allele model.
(A) Forest plot of all studies showing association between DAO rs4623951 polymorphism and
schizophrenia; *p=0.02 (significant without Bonferroni correction). In all studies, C-allele of
DAO rs4623951 was found to be a protective allele for schizophrenia. (B) Forest plot of all
studies showing association between NRG1 SNP8NRG241930 polymorphism and schizophrenia;
*p=0.04 (significant without Bonferroni correction). (C) Forest plot of only Caucasian studies
showing association between NRG1 SNP8NRG241930 polymorphism and schizophrenia; *p=0.03
(significant without Bonferroni correction). In all studies and Caucasian studies, T-allele of
NRG1 SNP8NRG241930 was found to be a protective allele for schizophrenia. (D) Forest
plot of only Asian studies showing association between NRG1 SNP8NRG241930 polymorphism
and schizophrenia; p=0.82. (E) Forest plot of all studies showing association between NRG1
rs10503929 polymorphism and schizophrenia; *p=0.01 (significant without Bonferroni correction).
(F) Forest plot of only Caucasian studies showing association between NRG1 rs10503929
polymorphism and schizophrenia; *p=0.01 (significant without Bonferroni correction). In all
and only Caucasian studies, C-allele of NRG1 rs10503929 was found to be a protective allele for
schizophrenia. In the forest plot, square represents OR of the study, size of the square represents
the weight given to each study, whiskers represent 95% CI, and diamond represents the OR and
95% CI of all studies. The new studies published after SZgene meta-analysis are marked as #.
Abbreviations: OR: Odds ratio; CI: confidence interval for the OR; DAO: D-amino acid oxidase;
NRG1: Neuregulin 1; Minor allele vs. Major allele.
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Study II: Results
DAOA meta-analysis
The literature search studies reporting on the association of DAOA SNPs
with schizophrenia identified 267 non-duplicated articles (Supplementary
Figure S4). Out of 267 articles, 203 articles were excluded at the title/abstract
level. Altogether, 64 articles were read fully, and 41 articles were excluded
because of missing information on allele/genotype frequencies and/or OR
and 95% CI or other reasons (Supplementary Table S4). Finally, 23 articles
were included in the meta-analysis (Supplementary Table S5), 5 of which were
new studies (Mechelli et al., 2012; Sacchetti et al., 2013; Kartalci and Acar,
2016; Chu et al., 2017; Chen et al., 2013), that had not been included in the
SZGene meta-analysis. There were at least 3 studies reporting results for 12
DAOA SNPs: rs3916965 (M12), rs3916966 (M13), rs3916967 (M14), rs2391191
(M15), rs947267 (M18), rs778294 (M19), rs3916970 (M20), rs3916971 (M21),
rs778293 (M22), rs3918342 (M23), rs1421292 (M24), and rs9558562. The summary
of all 12 DAOA SNPs meta-analyses is provided in Table 2. There was a
significant association between DAOA rs778293 (M22) and schizophrenia, and
the G-allele was a risk allele for schizophrenia in Asian populations (OR=1.17,
95% CI=1.08-1.27, p=0.00008, N=6,117) (Figure 2C), but not across all studies
(Figure 2A) or in Caucasian samples (Figure 2B). We also found a significant
association between DAOA rs3916971 (M21) and schizophrenia, in which the
T-allele was protective across all studies (OR=0.84, 95% CI=0.73-0.96, p=0.01,
N=1,765) (Figure 2D), but not in Caucasian populations (Figure 2E). However,
there was no significant association between DAOA SNPs (rs3916965 (M12),
rs3916966 (M13), rs3916967 (M14), rs2391191 (M15), rs947267 (M18), rs778294
(M19), rs3916970 (M20), rs3918342 (M23), rs1421292 (M24), and rs9558562) and
schizophrenia (Supplementary Figure S5). The majority of the analyses showed
significant between-study heterogeneity (p<0.05; Supplementary Figure S6),
resulting in the use of random-effects models in these instances. No publication
bias was observed (p>0.05) in any of the DAOA meta-analyses as assessed by
Begg’s test and Egger’s regression test (Supplementary Table S6).
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Figure 2: Forest plots of the association between DAOA rs778293 (M22) and rs3916971 (M21)
polymorphisms, and schizophrenia in the allele model. (A) Forest plot of all studies showing
association between DAOA rs778293 (M22) polymorphism and schizophrenia; p=0.35. (B)
Forest plot of only Caucasian studies showing association between DAOA rs778293 (M22)
polymorphism and schizophrenia; p=0.80. (C) Forest plot of only Asian studies showing
association between DAOA rs778293 (M22) polymorphism and schizophrenia; *p=0.00008
(significant with Bonferroni correction). In Asian studies, G-allele of DAOA rs778293 (M22) was
found to be a risk allele for schizophrenia. (D) Forest plot of all studies showing association
between DAOA rs3916971 (M21) polymorphism and schizophrenia; *p=0.01 (significant without
Bonferroni correction). In all studies, T-allele of DAOA rs3916971 (M21) was found to be a
protective allele for schizophrenia. (E) Forest plot of only Caucasian studies showing association
between DAOA rs3916971 (M21) polymorphism and schizophrenia; p=0.09. In the forest plot,
square represents OR of the study, size of the square represents the weight given to each study,
whiskers represent 95% CI, and diamond represents the OR and 95% CI of all studies. The new
studies published after SZgene meta-analysis are marked as #. Abbreviations: OR: odds ratio; CI:
confidence interval for the OR; DAOA: D-amino acid oxidase activator; Minor allele vs. Major
allele.
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Study II: Results
NRG1 meta-analysis
The literature search studies reporting on the association of NRG1 SNPs
with schizophrenia identified 853 non-duplicated articles (Supplementary
Figure S7). Out of 853 articles, 753 articles were excluded at the title/abstract
level. Altogether, 100 articles were read fully, and 52 articles were excluded
because of missing information on allele/genotype frequencies and/or
OR and 95% CI or other reasons (Supplementary Table S7). Finally, 48
articles were included in the meta-analysis (Supplementary Table S8), 18
of which were new studies (Supplementary Table S8, serial no. 31-48) that
had not been included in the SZGene meta-analysis. We identified at least
3 studies reporting results for 14 NRG1 SNPs: rs10503929, SNP8NRG241930
(rs62510682), rs6994992, SNP8NRG221132 (rs73235619), rs776401, rs35753505,
rs6988339, SNP8NRG433E1006 (rs113317778), rs3924999, rs2954041, rs4733376,
rs2439272, rs2466058, and rs7014762. The summary of all these 14 NRG1
SNPs meta-analyses is described in Table 3. We found a significant association
between NRG1 SNP8NRG241930 (rs62510682) and schizophrenia, and the
minor T-allele was protective across all studies (OR=0.95, 95% CI=0.91-0.997,
p=0.04, N=22,898) (Figure 1B) as well as in Caucasian populations (OR=0.95,
95% CI=0.90-0.99, p=0.03, N=16,014) (Figure 1C), but not in Asian populations
(Figure 1D). There was also a significant association between NRG1 SNP
rs10503929 and schizophrenia, and the minor C-allele was protective against
schizophrenia across all studies (OR=0.89, 95% CI=0.81-0.97, p=0.01, N=6,844)
(Figure 1E) and Caucasian samples (OR=0.89, 95% CI=0.81-0.98, p=0.01,
N=6,414) (Figure 1F). There was no significant association between NRG1 SNPs
(rs6994992, SNP8NRG221132 (rs73235619), rs776401, rs35753505, rs6988339,
SNP8NRG433E1006 (rs113317778), rs3924999, rs2954041, rs4733376, rs2439272,
rs2466058, and rs7014762) and schizophrenia across all studies, and in Caucasian
and Asian subsamples (Supplementary Figure S8). The majority of the analyses
showed significant between-study heterogeneity (p<0.05; Supplementary
Figure S9), resulting in the use of random-effects models in these instances. No
publication bias was observed (p>0.05) in any of the NRG1 meta-analyses as
assessed by Begg’s test and Egger’s regression test (Supplementary Table S9).
We compared our DAO, DAOA, and NRG1 meta-analyses data with the
published PGC GWAS data (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). We found that only NRG1 SNP8NRG241930
(rs62510682) was significantly associated with schizophrenia (minor T-allele
was protective) in both PGC GWAS (OR=0.97, p=0.03) and our meta-analysis
(OR=0.95, p=0.04; Supplementary Table S10).
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We downloaded linkage disequilibrium (LD) plots of DAO, DAOA, and NRG1
SNPs across all, European, and Asian populations from LDlink, a web-based
application from the National Cancer Institute of National Institutes of Health
(NIH) (Machiela and Chanock, 2015). We found DAO SNPs, rs2070586 and
rs2070587 in European population, and rs3918346 and rs3918346 in Asian
population were in strong LD with a R2 threshold of 0.8 (Supplementary
Figure S10). We also found DAOA SNPs, rs3916965 and rs3916967, rs3916965 and
rs2391191, rs3916967 and rs2391191 in all, the European, and Asian population,
rs3916965 and rs3916966, rs3916966 and rs3916967, and rs1421292 and rs3918342
in the European and Asian population to be in strong LD with a R2 threshold of
0.8 (Supplementary Figure S11). There were no NRG1 SNPs in strong LD with a
R2 threshold of 0.8 (Supplementary Figure S12).
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5.2.5 Discussion
In our comprehensive meta-analysis focussing on DAO, DAOA, and NRG1 SNPs
implicated in the glutamate hypothesis of schizophrenia, we found significant
associations between schizophrenia and DAO (rs4623951, protective across
all studies), DAOA (rs778293, schizophrenia risk in Asian samples; rs3916971,
protective across all studies), NRG1 (rs10503929, protective across all studies and
in Caucasian samples; and SNP8NRG241930 (rs62510682), schizophrenia risk
across all studies and in Caucasian samples) gene variations. A meta-analysis
using only case-control data showed that of the 75 statistically significant
genes, DAOA, DAO, and NRG1 were fourth, eighth, and sixteenth in the list,
respectively (Sun et al., 2008).
The C-allele of DAO rs4623951 was protective against schizophrenia across
all studies. However, in this particular SNP, we could not include any new
association studies to increase the sample size due to the unavailability
of required information, which led to the same report as in the SZGene
meta-analysis (Allen et al., 2008) and an earlier meta-analysis (Shi et al., 2008).
Since the sample size for this particular SNP (N=3,143) is rather small to medium
compared to other analysed DAO SNPs, there is a clear need for more association
studies to enlarge the sample size to rule out a possible type I error and conclude
on its association with schizophrenia. DAO rs4623951 SNP is located in the
5’-UTR of the DAO gene and has been associated with sensorimotor gating,
working memory, and personality patterns in healthy males (Roussos et al.,
2011). However, the mechanism underlying the association of DAO rs4623951
with schizophrenia remains unclear.
In our meta-analysis, we were also only able to include the same number of
studies for DAOA rs778293 and rs3916971 as in the SZGene meta-analysis
(Allen et al., 2008) due to the unavailability of information in newer studies.
As already reported by the SZGene meta-analysis (Allen et al., 2008), the
G-allele of DAOA rs778293 in Asian samples was a risk allele for schizophrenia,
whereas the T-allele of DAOA rs3916971 across all studies was protective
against schizophrenia. Compared to the other meta-analysed DAOA SNPs,
the sample sizes for DAOA rs778293 and rs3916971 were medium (N=6,117)
and small (N=1,765), respectively. Thus, there is a need for more association
studies regarding these two DAOA SNPs before being able to more conclusively
comment on their association with schizophrenia. DAOA rs778293 and rs3916971
are located in the intergenic region and 5’-UTR of the DAOA gene respectively
(Grigoroiu-Serbanescu et al., 2010), but the biological mechanism of these SNPs
has not yet been identified. A recent meta-analysis failed to find a significant
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association between DAOA (rs2391191, rs947267, and rs3918342) SNPs and
schizophrenia (Tan et al., 2014), which is also in accordance with our findings,
despite adding two more recent studies (Kartalci and Acar, 2016; Chu et al.,
2017) in our current analysis (Supplementary Figure S6D, S6E, S6H).
The C-allele of NRG1 rs10503929 was protective against schizophrenia across
studies and in Caucasian samples, which is in accordance with the SZGene
meta-analysis (Allen et al., 2008). In the current meta-analysis, we were able to
add one more study (Terzic´ et al., 2015) increasing the power of the meta-analysis
by 4%. Our finding is also in line with another recent meta-analysis (Mostaid
et al., 2017), which included one more study than our meta-analysis and found
a significant association of NRG1 rs10503929 with schizophrenia. Furthermore,
we found the T-allele of NRG1 SNP8NRG241930 (rs62510682) across all studies
and in Caucasian samples to be protective against schizophrenia which is in line
with a recent meta-analysis that included both case-control and family studies
(Mostaid et al., 2017), as well as PGC GWAS (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014). Contrary to our current study and
the Mostaid et al study, NRG1 SNP8NRG241930 (rs62510682) SNP was not found
to be significantly associated with schizophrenia in the SZGene meta-analysis
(Allen et al., 2008). In the current meta-analysis, we included five more studies
(Shariati et al., 2011; Papiol et al., 2011; Weickert et al., 2012; Gutie´rrez-Ferna´ndez
et al., 2014; Yoshimi et al., 2016) which increased the power of our meta-analysis
by 10%. We found only NRG1 SNP8NRG241930 (rs62510682) SNP to be
associated with schizophrenia in both PGC GWAS and our meta-analysis, but
not other SNPs studied. This might be because of different inclusion criteria,
multiple testing, and heterogeneous samples (e.g., ethnicity and diagnostic
criteria) used in PGC GWAS compared to our meta-analysis. A meta-analysis
published in 2013 (Loh et al., 2013) showed no association between NRG1
(rs3924999 and rs2954041) SNPs and schizophrenia. And even in our current
meta-analysis, which includes an additional 7 studies (Re´thelyi et al., 2010;
Kang et al., 2012; Kim et al., 2012; Dı´ez et al., 2014; Ma et al., 2014; Terzic´ et al.,
2015; He et al., 2016), we continue to find no significant association between
NRG1 (rs3924999 and rs2954041) SNPs and schizophrenia (Supplementary
Figure S8H-I). In contrast to our findings, the T-allele of NRG1 rs2954041 was
found to be a risk for schizophrenia in a recent meta-analysis (Mostaid et al.,
2017), which might be due to the inclusion of a family study (Yang et al., 2003)
and a case-control study (Naz et al., 2011) that we had excluded. Contrary to
Mostaid et al (Mostaid et al., 2017), we excluded Naz et al. (Naz et al., 2011)
from our meta-analysis because of a broad and unreliable 95% CI, but included
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another study Ma et al. (Ma et al., 2014). NRG1 rs10503929, rs2954041 and
SNP8NRG241930 (rs62510682) SNPs are situated in the exon 11, intron 5, and
5’-UTR of the NRG1 gene respectively (Mostaid et al., 2017). Nevertheless, the
functional role of these NRG1 SNPs in the development of schizophrenia is not
well understood.
Although we found significant associations of several DAO, DAOA, and NRG1
SNPs with schizophrenia, we are unable to comment on the putative effect of
these SNPs on DAO, DAOA, and NRG1 expression, which might ultimately
explain the glutamate hypothesis of schizophrenia based on the NMDA receptor
hypofunction. Future studies should concentrate on associations of DAO,
DAOA, and NRG1 SNPs with Research Domain Criteria (RDoC) constructs such
as positive valence, negative valence, and cognitive systems (Insel et al., 2010;
Cuthbert and Insel, 2013) in schizophrenia patients. This approach might help to
better understand the role of these SNPs in the development of schizophrenia
symptomatology.
Results of this meta-analysis need to be interpreted within its limitations.
Although this is the largest and most comprehensive meta-analysis of the
association of DAO, DAOA, and NRG1 SNPs with schizophrenia to date, the
number of studies as well as the sample size for most SNPs were still modest,
making results vulnerable to type I or type II error. The overall power of this
meta-analysis was not very high, which lead to some false positive/negative
results. Thus, the results of this meta-analysis must be interpreted with caution.
There were insufficient studies in ethnic groups other than Caucasian and
Asian, and the ethnically stratified subgroup analyses were based on even
smaller samples. Although we corrected for multiple comparisons, we still
focussed on non-corrected p-values, having performed multiple meta-analyses
for all available SNPs in the three-targeted genes, rendering results of even
significant meta-analyses exploratory. Furthermore, not all studies used research
interviews for diagnostic ascertainment, likely introducing imprecision. The
results were mostly heterogeneous across studies, which we addressed by using
random-effects models (Borenstein et al., 2010). Finally, similar to previous
meta-analyses (Tan et al., 2014; Mostaid et al., 2017), we did not include
PGC SCZ or other GWAS results in our meta-analysis which included only
studies that met the inclusion criteria. This was because of the limitation
in the available meta-analytic methods. Currently, to our knowledge there
are no meta-analytic methods available to combine GWAS data with usual
case-control association studies after weighting the different approaches in a
correct manner. Future methodological advances may make such integration of
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data possible. Nevertheless, despite these limitations, our systematic review and
meta-analysis is the most recent one, having included studies published until
March 21, 2017 that assessed the association of DAO, DAOA, and NRG1 SNPs
with schizophrenia, thus adding 6 (for DAO SNPs), 5 (for DAOA SNPs), and
18 (for NRG1 SNPs) more studies to those previously included in the SZGene
meta-analysis (Allen et al., 2008).
In summary, this updated meta-analysis focussing on DAO, DAOA, and NRG1
SNPs implicated in the glutamate hypothesis of schizophrenia identified 1
schizophrenia risk allele [DAOA (rs778293, in Asian samples)] as well as 4
protective alleles [DAO (rs4623951, across all studies), DAOA (rs3916971, across
all studies) and NRG1 (rs10503929, across all studies and in Caucasian samples,
and SNP8NRG241930 (rs62510682), across all studies and in Caucasian samples).
Nevertheless, these findings should still be considered with caution since sample
sizes were mostly modest and most results showed significant heterogeneity
between studies. Therefore, additional, well conducted and large case-control
studies of DAO, DAOA, and NRG1 SNPs in schizophrenia patients are needed,
ideally, linking genetic data to clinical and endophenotypic and biological
information related to disease mechanisms and putative gene effects, before
the role of DAO, DAOA, and NRG1 SNPs in the development and phenotypic
expression of schizophrenia can be clarified further.
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5.2.6 Supplementary Information
Supplementary Table S1: Excluded studies in the DAO meta-analyses and reasons for exclusion
Serial No. References Reasons
1 (Fallin et al., 2005) Family study
2 (Liu et al., 2006) Family study
3 (Goldberg et al., 2006) Family study
4 (Chung et al., 2007) No healthy controls
5 (Stefanis et al., 2007) Allele and/or genotype frequencies and/or odds ratio not available
6 (Corvin et al., 2007a) Allele and/or genotype frequencies and/or odds ratio not available
7 (Wirgenes et al., 2009) No healthy controls
8 (Roussos et al., 2011) No schizophrenia cases
9 (Yang et al., 2013) Same population as Liu (Liu et al., 2004)
10 (Sprooten et al., 2015) DAO SNPs not studied
11 (Luykx et al., 2015) DAO SNPs not studied
Supplementary Table S2: Characteristics of included studies in the DAO meta-analyses
Serial No. References Cases/Controls (N) Ancestry(Caucasian/Asian/Others)
1 (Chumakov et al., 2002) 213/241 Caucasian
2 (Liu et al., 2004) 547/536 Asian
3 (Schumacher et al., 2004) 299/300 Caucasian
4 (Yamada et al., 2005) 50/52 Asian570/570 Asian
5 (Shinkai et al., 2007) 168/168 Caucasian
6 (Wood et al., 2007) 311/291 Caucasian
7 (Corvin et al., 2007b) 373/812 Caucasian
8 (Vilella et al., 2008) 589/615 Caucasian
9 (Jo¨nsson et al., 2009) 837/1473 Caucasian
10 (Ohnuma et al., 2009) 340/340 Asian
11 (Bass et al., 2009) 431/443 Caucasian
12 (Suliman et al., 2010) 531/755 Caucasian
13 (Ohnuma et al., 2010) 1656/1842 Asian
14 (Kim et al., 2010) 448/337 Asian
15 (Papagni et al., 2011) 40/48 Caucasian
16 (Mechelli et al., 2012) 40/47 Caucasian
17 (Sacchetti et al., 2013) 391/488 Caucasian
18 (Liu et al., 2016) 912/600 Asian
19 (Kartalci and Acar, 2016) 96/100 Others (Turkish)
20 (Chu et al., 2017) 248/267 Asian
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Supplementary Table S3: Tests for publication bias in the DAO meta-analyses
DAO SNP ID Minorallele
Number of
studies
Tests for publication bias
Begg’s test Egger’s regression test
z-value p-value Standard error 95% CI t-value p-value
rs4623951 C 4 1.02 0.31 0.53 -1.28-3.27 1.87 0.20
rs2111902 G 14 0.88 0.38 1.25 -1.36-4.10 1.09 0.30
rs3918346 T 12 0.69 0.49 1.64 -2.35-4.94 0.79 0.45
rs3741775 G 14 0.33 0.74 1.49 -2.67-3.81 0.38 0.71
rs3918347 G 5 1.71 0.09 1.10 -0.85-6.17 2.41 0.09
rs3825251 G 7 0.3 0.76 1.17 -2.35-3.66 0.56 0.60
rs2070586 A 6 1.13 0.26 3.49 -7.25-12.14 0.70 0.52
rs2070587 G 6 0 1.00 3.64 -9.32-10.90 0.22 0.84
*p<0.05 (bold font)
Supplementary Table S4: Excluded studies in the DAOA meta-analyses and reasons for exclusion
Serial No. References Reasons
1 (Addington et al., 2007) No healthy controls
2 (Hall et al., 2004) Family study
3 (Fallin et al., 2005) Family study
4 (Mulle et al., 2005) Family study
5 (Zou et al., 2005) Family study
6 (Goldberg et al., 2006) Family study
7 (Hong et al., 2006) Family study
8 (Korostishevsky et al., 2006) Family study
9 (Liu et al., 2006) Family study
10 (Mattai et al., 2006) Family study
11 (Yue et al., 2006) Same population as Yue (Yue et al., 2007)
12 (Chung et al., 2007) No healthy controls
13 (Donohoe et al., 2007) 95% confidence interval for the odds ratio not available
14 (Nicodemus et al., 2007) Allele and/or genotype frequencies and/or odds ratio not available
15 (Stefanis et al., 2007) No schizophrenia cases
16 (Hall et al., 2008) No schizophrenia cases
17 (Opgen-Rhein et al., 2008) Allele and/or genotype frequencies and/or odds ratio not available
18 (Soronen et al., 2008) Family study
19 (Kotaka et al., 2009) No schizophrenia cases
20 (Ma et al., 2009) Family study
21 (Maziade et al., 2009) DAOA SNPs not studied
22 (Shi et al., 2009) Allele and/or genotype frequencies and/or odds ratio not available
23 (Carrera et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
24 (Hartz et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
25 (Huang et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
26 (Jansen et al., 2010) No schizophrenia cases
27 (Mo¨ssner et al., 2010) No schizophrenia cases
28 (Pae et al., 2010) No healthy controls
29 (Li et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
30 (Chiesa et al., 2011) Allele and/or genotype frequencies and/or odds ratio not available
31 (Mu¨ller et al., 2011) Family study
32 (Nixon et al., 2011) No schizophrenia cases
33 (Schultz et al., 2011) Allele and/or genotype frequencies and/or odds ratio not available
34 (Graw et al., 2012) DAOA SNPs not studied
35 (Prata et al., 2012) No schizophrenia cases
36 (Bousman et al., 2013) No schizophrenia cases
37 (Chiesa et al., 2013) Allele and/or genotype frequencies and/or odds ratio not available
38 (Pauli et al., 2013) No schizophrenia cases
39 (Andreou et al., 2015) No schizophrenia cases
40 (Nickl-Jockschat et al., 2015) No schizophrenia cases
41 (Soler et al., 2016) Family study
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Supplementary Table S5: Characteristics of included studies in the DAOA meta-analyses
Serial No. References Cases/Controls (N) Ancestry(Caucasian/Asian/Others)
1 (Chumakov et al., 2002) 213/241 Caucasian183/183 Caucasian
2 (Korostishevsky et al., 2006) 60/130 Caucasian
3 (Schumacher et al., 2004) 299/300 Caucasian
4 (Wang et al., 2004) 537/538 Asian
5 (Ma et al., 2006) 588/588 Asian183/182 Caucasian
6 (Williams et al., 2006) 709/1416 Caucasian
7 (Bakker et al., 2007) 308/467 Caucasian
8 (Corvin et al., 2007b) 373/812 Caucasian
9 (Shin et al., 2007) 388/367 Asian
10 (Shinkai et al., 2007) 168/168 Caucasian
11 (Wood et al., 2007) 311/291 Caucasian
12 (Yue et al., 2007) 359/359 Asian
13 (Sanders et al. 2008) 1678/2002 Caucasian
14 (Vilella et al., 2008) 589/615 Caucasian
15 (Bass et al., 2009) 431/443 Caucasian
16 (Jo¨nsson et al., 2009) 837/1473 Caucasian
17 (Ohi et al., 2009) 1774/2092 Asian
18 (Re´thelyi et al., 2010) 284/238 Caucasian
19 (Mechelli et al., 2012) 40/47 Caucasian
20 (Chen et al., 2013) 454/480 Asian
21 (Sacchetti et al., 2013) 391/488 Caucasian
22 (Kartalci and Acar, 2016) 96/100 Others (Turkish)
23 (Chu et al., 2017) 248/267 Asian
Supplementary Table S6: Tests for publication bias in the DAOA meta-analyses
DAOA SNP ID Minorallele
Number of
studies
Tests for publication bias
Begg’s test Egger’s regression test
z-value p-value Standard error 95% CI t-value p-value
rs3916965 (M12) A 16 -0.14 0.89 0.96 -1.9-2.2 0.16 0.88
rs3916966 (M13) C 6 0 1.00 0.79 -2.19-2.17 -0.02 0.98
rs3916967 (M14) G 14 0 1.00 0.74 -1.22-2.02 0.54 0.60
rs2391191 (M15) A 22 -0.56 0.57 0.90 -2.39-1.34 -0.59 0.56
rs947267 (M18) C 11 0.31 0.76 1.81 -1.85-6.35 1.24 0.25
rs778294 (M19) T 14 -0.44 0.66 0.7 -1.8-1.27 -0.38 0.71
rs3916970 (M20) A 5 -0.73 0.46 0.33 -1.51-0.57 -1.45 0.24
rs3916971 (M21) T 4 -0.34 0.73 1.56 -6.61-6.83 0.07 0.95
rs778293 (M22) G 13 -0.79 0.43 1.17 -3.47-1.69 -0.76 0.46
rs3918342 (M23) T 19 0.21 0.83 1.05 -2.49-1.93 -0.27 0.79
rs1421292 (M24) A 5 -0.24 0.81 1.31 -4.28-4.03 -0.095 0.93
rs9558562 G 3 0 1.00 1.20 -15.96-14.6 -0.57 0.67
*p<0.05 (bold font)
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Supplementary Table S7: Excluded studies in the NRG1 meta-analyses and reasons for exclusion
Serial No. References Reasons
1 (Yang et al., 2003) Family study
2 (Hall et al., 2004) Family study
3 (Tang et al., 2004) Allele and/or genotype frequencies and/or odds ratio not available
4 (Thiselton et al., 2004) Family study
5 (Costas et al., 2005) No schizophrenia cases
6 (Duan et al., 2005) Family study
7 (Lin et al., 2005) No schizophrenia cases
8 (Liu et al., 2005) Family study
9 (Gardner et al., 2006) No schizophrenia cases
10 (Hall et al., 2006) No schizophrenia cases
11 (Law et al., 2006) Allele and/or genotype frequencies and/or odds ratio not available
12 (Norton et al., 2006) Allele and/or genotype frequencies and/or odds ratio not available
13 (Walss-Bass et al., 2006b) Allele and/or genotype frequencies and/or odds ratio not available
14 (Walss-Bass et al., 2006a) Family study
15 (Addington et al., 2007) No schizophrenia cases
16 (Mathew et al., 2007) Allele and/or genotype frequencies and/or odds ratio not available
17 (Rosa et al., 2007) Family study
18 (Thomson et al., 2007) Allele and/or genotype frequencies and/or odds ratio not available
19 (Turunen et al., 2007) Family study
20 (Georgieva et al., 2008) Family study
21 (Gruber et al., 2008) Family study
22 (Mechelli et al., 2008) Allele and/or genotype frequencies and/or odds ratio not available
23 (Winterer et al., 2008) No schizophrenia cases
24 (Dutt et al., 2009) Allele and/or genotype frequencies and/or odds ratio not available
25 (Keri et al., 2009) No schizophrenia cases
26 (Ke´ri et al., 2009) Family study
27 (Kircher et al., 2009) Allele and/or genotype frequencies and/or odds ratio not available
28 (Mata et al., 2009) Allele and/or genotype frequencies and/or odds ratio not available
29 (Okochi et al., 2009) No schizophrenia cases
30 (van Schijndel et al., 2009) Allele and/or genotype frequencies and/or odds ratio not available
31 (Mata et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
32 (Parlapani et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
33 (Shibuya et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
34 (Walker et al., 2010) Allele and/or genotype frequencies and/or odds ratio not available
35 (Garcia-Barcelo´ et al., 2011) Allele and/or genotype frequencies and/or odds ratio not available
36 (Greenwood et al., 2011) Family study
37 (Naz et al., 2011) 95% confidence interval for the odds ratio is very broad
38 (Cannon et al., 2012) No schizophrenia cases
39 (Greenwood et al., 2012) 95% confidence interval for the odds ratio not given
40 (Tosato et al., 2012) Allele and/or genotype frequencies and/or odds ratio not available
41 (Walshe et al., 2012) No schizophrenia cases
42 (Yokley et al., 2012) Family study
43 (Bousman et al., 2013) No schizophrenia cases
44 (Loh et al., 2013) Allele and/or genotype frequencies and/or odds ratio not available
45 (Yang et al., 2013) Allele and/or genotype frequencies and/or odds ratio not available
46 (Grimm et al., 2014) Family study
47 (Nawaz et al., 2014) Allele and/or genotype frequencies and/or odds ratio not available
48 (Tosato et al., 2014) No healthy controls
49 (Cho et al., 2015) Allele and/or genotype frequencies and/or odds ratio not available
50 (Sua´rez-Pinilla et al., 2015) No schizophrenia cases
51 (Greenwood et al., 2016) Family study
52 (Jajodia et al., 2016) Same population as Jajodia (Jajodia et al., 2015)
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Supplementary Table S8: Characteristics of included studies in the NRG1 meta-analyses
Serial No. References Case/Control (N) Ancestry(Caucasian/Asian/Others)
1 (Stefansson et al., 2002) 478/394 Caucasian
2 (Stefansson et al., 2003) 609/618 Caucasian
3 (Williams et al., 2003) 573/618 Caucasian
4 (Bakker et al., 2004) 260/585 Caucasian
5 (Corvin et al., 2004) 243/222 Caucasian
6 (Hong et al., 2004) 228/269 Asian
7 (Iwata et al., 2004) 607/515 Asian
8 (Kampman et al., 2004) 94/395 Caucasian
9 (Li et al., 2004) 298/336 Asian
10 (Zhao et al., 2004) 369/299 Asian
11 (Petryshen et al., 2005) 321/242 Caucasian
12 (Fukui et al., 2006) 349/424 Asian
13 (Ingason et al., 2006) 325/353 Caucasian
14 (Kim et al., 2006) 242/242 Asian
15 (Lachman et al., 2006) 177/164 Caucasian141/142 Asian
16 (Benzel et al., 2007) 396/1342 Caucasian
17 (Ha¨nninen et al., 2007) 113/393 Caucasian
18 (Bramon et al., 2008) 60/34 Caucasian
19 (Crowley et al., 2008) 738/733 Others (Mixed)
20 (Hong et al., 2008) 244/186 Asian
21 (Ikeda et al., 2008) 1126/1022 Asian
22 (Sanders et al., 2008) 1870/2002 Caucasian
23 (Shiota et al., 2008) 416/520 Asian
24 (Vilella et al., 2008) 589/617 Caucasian
25 (Alaerts et al., 2009) 486/514 Caucasian
26 (Jo¨nsson et al., 2009) 837/1473 Caucasian
27 (Nicodemus et al., 2009) 296/365 Others (Mixed)
28 (Wang et al., 2009) 31/36 Asian
29 (Re´thelyi et al., 2010) 280/230 Caucasian
30 (Squassina et al., 2010) 171/349 Caucasian
31 (Shariati et al., 2011) 95/95 Caucasian
32 (Moon et al., 2011) 273/479 Others (Costa Rican)
33 (Papiol et al., 2011) 1071/1056 Caucasian
34 (Crisafulli et al., 2012) 221/170 Asian
35 (Kang et al., 2012) 287/120 Asian
36 (Kim et al., 2012) 435/390 Asian
37 (Yang, 2012) 221/359 Asian
38 (Weickert et al., 2012) 37/37 Caucasian
39 (Kukshal et al., 2013) 1007/1019 Asian
40 (Dı´ez et al., 2014) 31/23 Caucasian
41 (Ma et al., 2014) 976/1043 Asian
42 (Thirunavukkarasu et al., 2014) 38/37 Asian
43 (Gutie´rrez-Ferna´ndez et al., 2014) 215/650 Caucasian
44 (Jajodia et al., 2015) 436/401 Asian351/385 Asian
45 (Terzic´ et al., 2015) 138/94 Caucasian
46 (He et al., 2016) 248/236 Asian
47 (Wen et al., 2016) 1248/1248 Asian
48 (Yoshimi et al., 2016) 59/60 Asian
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Supplementary Table S9: Tests for publication bias in the NRG1 meta-analyses
NRG1 SNP ID Minorallele
Number of
studies
Tests for publication bias
Begg’s test Egger’s regression test
z-value p-value Standard error 95% CI t-value p-value
SNP8NRG241930
(rs62510682) T 22 -0.28 0.78 0.57 -1.52-0.85 -0.58 0.57
rs10503929 C 4 -0.34 0.73 0.11 -0.49-0.44 -0.23 0.84
rs6994992 T 25 0.07 0.94 0.73 -1.55-1.48 -0.05 0.96
rs35753505 C 29 -0.69 0.49 0.56 -1.67-0.62 -0.94 0.36
rs6988339 G 6 0.75 0.45 1.93 -4.75-5.96 0.31 0.77
SNP8NRG221132
(rs73235619) A 8 -0.62 0.54 0.84 -3.32-0.79 -1.51 0.18
rs3924999 A 13 -1.53 0.13 0.61 -2.11-0.58 -1.25 0.24
SNP8NRG433E1006
(rs113317778) A 6 1.13 0.26 1.36 -3.2-4.33 0.42 0.70
rs2954041 T 6 0 1.00 0.87 -2.05-2.8 0.43 0.69
rs776401 C 4 -0.34 0.73 3.08 -15.3-11.19 -0.67 0.57
rs2439272 A 5 -0.73 0.46 2.35 -9.87-5.07 -1.02 0.38
rs2466058 T 4 0.34 0.73 3.11 -12.2-14.59 0.38 0.74
rs4733376 G 5 0.24 0.81 2.16 -4.72-9.06 1 0.39
rs7014762 A 3 1.04 0.30 2.30 -26.9-31.44 0.99 0.50
*p<0.05 (bold font)
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Supplementary Table S10: Comparison of our meta-analysis of DAO, DAOA, and NRG1 SNPs
with Psychiatric Genomics Consortium (PGC) 2014 genome-wide association study (GWAS) data
Gene SNP ID PGC GWAS Our meta-analysisReference allele
for ORa OR SE p-value
Minor
allele OR p-value
D-amino acid
oxidase (DAO)
rs4623951 T 0.98708 0.0116 0.2628 C 0.88 0.02*
rs2111902 T 0.96696 0.0123 0.006262* G 1.02 0.74
rs3918346 T 1.02922 0.013 0.02661* T 1.00 0.97
rs3741775 T 1.02665 0.0114 0.02091* G 1.01 0.93
rs3918347 A 0.97609 0.0123 0.04916* G 1.11 0.18
rs3825251 A 0.98728 0.0151 0.3961 G 1.02 0.5
rs2070586 A 1.0321 0.0149 0.03354* A 1.04 0.65
rs2070587 T 0.96841 0.0141 0.02247* G 1.00 0.99
D-amino acid
oxidase activator
(DAOA)
rs3916965 (M12) A 0.9997 0.0113 0.9801 A 0.98 0.67
rs3916966 (M13) A 1.0024 0.0112 0.8301 C 0.95 0.17
rs3916967 (M14) A 1.0011 0.0112 0.9191 G 0.999 0.96
rs2391191 (M15) A 0.9992 0.0112 0.9452 A 1.02 0.65
rs947267 (M18) A 0.99154 0.011 0.4398 C 1.04 0.51
rs778294 (M19) T 1.0008 0.0119 0.945 T 0.97 0.3
rs3916970 (M20) A 1.00552 0.0117 0.6362 A 1.06 0.14
rs3916971 (M21) T 0.99551 0.011 0.6779 T 0.84 0.01*
rs778293 (M22) A 1.00582 0.0111 0.5972 G 1.04 0.35
rs3918342 (M23) T 1.0007 0.0108 0.9464 T 1.00 0.95
rs1421292 (M24) A 1.0024 0.0109 0.8248 A 0.95 0.30
rs9558562 A 2.42202 1.047 0.3981 G 0.93 0.47
Neuregulin1
(NRG1)
SNP8NRG241930
(rs62510682) T 0.97424 0.0118 0.02719* T 0.95 0.04*
rs10503929 T 1.01959 0.014 0.1641 C 0.89 0.01*
rs6994992 T 1.01005 0.0115 0.385 T 1.02 0.56
rs35753505 T 0.99293 0.0113 0.5285 C 1.04 0.14
rs6988339 A 1.0027 0.0111 0.8079 G 0.995 0.93
SNP8NRG221132
(rs73235619) A 0.98748 0.0185 0.4959 A 0.98 0.62
rs3924999 A 1.01542 0.0112 0.1726 A 0.98 0.34
SNP8NRG433E1006
(rs113317778) A 1.0023 0.0212 0.912 A 0.98 0.87
rs2954041 T 1.01329 0.0449 0.7694 T 1.05 0.34
rs776401 T 1.0031 0.0112 0.7852 C 0.97 0.69
rs2439272 A 1.002 0.0114 0.8635 A 0.82 0.06
rs2466058 T 1.04175 0.0205 0.0458* T 1.08 0.47
rs4733376 A 0.96069 0.0175 0.02182* G 1.04 0.57
rs7014762 A 1.01867 0.0129 0.1523 A 1.04 0.47
*p<0.05 (bold font); #p<0.0015 (italics) (significant with Bonferroni correction); a Reference allele is not necessarily a
minor allele, OR: Odds ratio; SE: standard error of ln(OR))
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Supplementary Figure S1: PRISMA Flow diagram for literature search of DAO SNP data
published till March 21, 2017. Search terms were (DAO OR DAAO) AND SCHIZOPHRENIA.
OR: odds ratio; CI: confidence interval.
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Supplementary Figure S2: Forest plots of the association between DAO polymorphisms and
schizophrenia in the allele model. Forest plots of all studies, only Caucasian and only Asian
samples showing association between DAO rs2111902 (A), rs3918346 (B), rs3918347 (C), rs3741775
(D), rs3825251 (E), rs2070586 (F), and rs2070587 (G) polymorphisms and schizophrenia; *p<0.05
(significant). There was no significant association found between above mentioned DAO
polymorphisms and schizophrenia.
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Supplementary Figure S3: Heterogeneity funnel plots of DAO rs2111902 (A), rs3918346 (B),
rs3741775 (C), rs3918347 (D), rs4623951 (E), rs3825251 (F), rs2070586 (G), and rs2070587 (H)
polymorphisms in all, only Caucasian and only Asian studies. The heterogeneity between studies
was assessed by inconsistency index (I2), and was considered statistically significant if p<0.05 (*).
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Supplementary Figure S4: PRISMA Flow diagram for literature search of DAOA SNP data
published till March 21, 2017. Search terms were (DAOA OR G72) AND SCHIZOPHRENIA.
OR: odds ratio; CI: confidence interval.
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Supplementary Figure S5: Forest plots of the association between DAOA polymorphisms
and schizophrenia in the allele model. Forest plots of all studies, only Caucasian and only
Asian samples showing association between DAOA rs3916965 (A), rs3916967 (B), rs3916966
(C), rs2391191 (D), rs947267 (E), rs1421292 (F), rs778294 (G), rs3918342 (H), rs3916970 (I), and
rs9558562 (J) polymorphisms and schizophrenia; *p<0.05 (significant). There was no significant
association found between above mentioned DAOA polymorphisms and schizophrenia.
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Supplementary Figure S6: Heterogeneity funnel plots of DAOA rs3916965 (A), rs3916967 (B),
rs2391191 (C), rs947267 (D), rs778294 (E), rs3916970 (F), rs3916971 (G), rs3916966 (H), rs778293
(I), rs3918342 (J), rs1421292 (K), and rs9558562 (L) polymorphisms in all studies, only Caucasian
and only Asian samples. The heterogeneity between studies was assessed by inconsistency index
(I2), and was considered statistically significant if p<0.05 (*).
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Supplementary Figure S7: PRISMA Flow diagram for literature search of NRG1 SNP data
published till March 21, 2017. Search terms were (NRG1 OR Neuregulin-1 OR Neuregulin 1 OR
Neuregulin1) AND SCHIZOPHRENIA. OR: odds ratio; CI: confidence interval.
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Supplementary Figure S8: Forest plots of the association between NRG1 polymorphisms
and schizophrenia in the allele model. Forest plots of all, only Caucasian and only Asian
studies showing association between NRG1 rs2954041 (A), rs6994992 (B), SNP8NRG221132
(rs73235619) (C), rs776401 (D), rs35753505 (E), rs6988339 (F), SNP8NRG433E1006 (rs113317778)
(G), rs3924999 (H), rs4733376 (I), rs7014762 (J), rs2439272 (K), and rs2466058 (L) polymorphisms
and schizophrenia; *p<0.05 (significant). There was no significant association found between
above mentioned NRG1 polymorphisms and schizophrenia.
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Supplementary Figure S9: Heterogeneity funnel plots of NRG1 SNP8NRG241930 (rs62510682)
(A), rs6994992 (B), rs35753505 (C), rs6988339 (D), SNP8NRG221132 (rs73235619) (E),
SNP8NRG433E1006 (rs113317778) (F), rs3924999 (G), rs2954041 (H), rs776401 (I), rs2439272 (J),
rs2466058 (K), rs4733376 (L), rs7014762 (M), and rs10503929 (N) polymorphisms in all studies,
only Caucasian and only Asian samples. The heterogeneity between studies was assessed by
inconsistency index (I2), and was considered statistically significant if p<0.05 (*).
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Supplementary Figure S10: Linkage disequilibrium (LD) plots of DAO SNPs from LDlink
databases. Linkage disequilibrium plots with D’ and R2 values across all (A), European (B), and
Asian (C) populations. D’ and R2 values are mentioned inside the squares of the LD plots.
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Supplementary Figure S11: Linkage disequilibrium (LD) plots of DAOA SNPs from LDlink
databases. Linkage disequilibrium plots with D’ and R2 values across all (A), European (B), and
Asian (C) populations. D’ and R2 values are mentioned inside the squares of the LD plots; NA:
Not calculated.
110
Study II: Supplementary Information
Supplementary Figure S12: Linkage disequilibrium (LD) plots of NRG1 SNPs from LDlink
databases. Linkage disequilibrium plots with D’ and R2 values across all (A), European (B), and
Asian (C) populations. D’ and R2 values are mentioned inside the squares of the LD plots.
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5.3.1 Abstract
Schizophrenia is characterized by positive and negative symptoms and cognitive
dysfunction. The glutamate hypothesis of schizophrenia has been hypothesized
to explain the negative symptoms and cognitive deficits better than the dopamine
hypothesis alone. Therefore, we aimed to evaluate whether glutamatergic
variants such as D-amino acid oxidase (DAO), DAO activator (DAOA)/G72,
and Neuregulin 1 (NRG1) single nucleotide polymorphisms (SNPs) and their
mRNA levels predicted (i) transition to schizophrenia-spectrum disorders, and
(ii) Research Domain Criteria (RDoC) domains, mainly negative valence and
cognitive systems. In a 3-year prospective study cohort of 185 individuals (age:
13-35 years) at high risk (HR) and ultra-high risk (UHR) for psychosis, we
assessed DAO (rs3918347, rs4623951), DAOA (rs778293, rs3916971, rs746187),
and NRG1 (rs10503929) SNPs and their mRNA expression. Furthermore, we
investigated their association with RDoC domains, mainly negative valence (e.g.,
anxiety, hopelessness) and cognitive (e.g., perception disturbances, disorganized
symptoms) systems. NRG1 rs10503929 CC+CT versus TT genotype carriers
experienced significantly more disorganized symptoms. DAOA rs746187 CC
versus CT+TT genotype, DAOA rs3916971 TT versus TC+CC genotype, and
DAO rs3918347 GA+AA versus GG genotype carriers experienced nominally
more hopelessness, visual perception disturbances, and auditory perception
disturbances, respectively. The schizophrenia risk G-allele of DAO rs3918347
nominally increased risk for those UHR individuals with attenuated positive
symptoms syndrome. No association between DAO, DAOA, NRG1 SNPs
and conversion to schizophrenia-spectrum disorders was observed. Our
findings suggest that DAO, DAOA and NRG1 polymorphisms might influence
both RDoC negative valence and cognitive systems, but not transition to
schizophrenia-spectrum disorders.
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5.3.2 Introduction
Schizophrenia is a chronic and debilitating disorder, preceded by a broad range
of symptoms. The emergence of psychotic features in schizophrenia is typically
between the late teens and mid-30s (McGrath et al., 2008). Early recognition of
individuals at-risk for psychosis and the provision of early intervention is likely
to be associated with improved outcomes (Stafford et al., 2013). Individuals
at clinical risk for psychosis are identified by two complementary approaches:
the high risk (HR) and the ultra-high risk (UHR) criteria. The HR concept is
based on basic symptoms and comprises of two partially overlapping risk
constellations, the cognitive-perceptive basic symptoms (COPER) and the
cognitive disturbances (COGDIS) (Schultze-Lutter et al., 2015, 2012). The UHR
criteria comprises of attenuated positive symptoms syndrome (APSS), brief
limited intermittent psychotic symptoms (BLIPS), and a combination of a risk
factor for psychosis and a recent functional decline (McGlashan et al., 2010). A
meta-analysis of 27 studies showed that 18%, 21%, 27% and 32% of individuals
at-risk for psychosis (HR+UHR) transitioned to psychotic disorders at 6, 12,
24 and 36 months of follow-up, respectively (Fusar-Poli et al., 2012). This
meta-analysis also showed that the mean transition risk was 49%, 28%, and 22%
using the HR approach, UHR approach, and when combining both HR and UHR
approaches, respectively (Fusar-Poli et al., 2012). One study reported that about
one-third of individuals at UHR for psychosis transitioned to psychosis (Gee
and Cannon, 2011). Our recent study, using a multivariable prediction model,
demonstrated that as expected, UHR criteria predicted conversion to psychosis
but combining HR and UHR criteria in this help-seeking at risk population did
not improve the predictive accuracy of UHR alone (Hengartner et al., 2017). It is
therefore important to optimise the identification of individuals at HR/UHR for
psychosis by minimising the false positive rate and improving the true positive
prediction rate of conversion to psychosis.
The estimated heritability in schizophrenia is around 60-80% (Pepper and
Cardno, 2014). Studies have demonstrated an association between schizophrenia
and D-amino acid oxidase (DAO), DAO activator (DAOA)/G72, and Neuregulin
1 (NRG1) single nucleotide polymorphisms (SNPs) (Allen et al., 2008; Jagannath
et al., 2017a). DAOA and NRG1 polymorphisms were shown to predict
the transition to schizophrenia in individuals at HR/UHR for psychosis
(Bousman et al., 2013; Keri et al., 2009; Mo¨ssner et al., 2010). Genetic studies in
schizophrenia have shown association of neurocognitive endophenotypes with
several glutamatergic gene polymorphisms including NRG1 (Greenwood et al.,
2011, 2012; Stevenson et al., 2016). These studies suggest that genetic variations
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and neurocognitive endophenotypes may help to improve the prediction
accuracy of clinical symptoms and HR/UHR criteria for transition in an at-risk
population.
The glutamate hypothesis of schizophrenia originated from the observation
that N-methyl-D-aspartate (NMDA) receptor blockers like ketamine, induced
schizophrenia-like symptoms. As antipsychotics (dopamine D2 receptor
antagonists) have little effect on negative symptoms and cognitive deficits,
the glutamatergic system is an attractive therapeutic target (Javitt, 1999).
Meta-analyses have reported that addition of NMDA receptor agonist D-serine
and glycine transporter type 1 inhibitor sarcosine as an adjunct to antipsychotics
reduce total and negative symptoms (Singh and Singh, 2011; Tiihonen and
Wahlbeck, 2006). Based on these observations, the glutamate hypothesis
is thought to describe the pathophysiology underlying negative symptoms
and cognitive deficits better than the dopamine hypothesis (Merritt et al.,
2013; Veerman et al., 2014; Frohlich and Van Horn, 2014). NMDA receptor
hypofunction might lead to decreased dopamine activity in the mesocortical
pathway, which may manifest as negative symptoms and cognitive dysfunction
in schizophrenia (Stahl et al., 2007). The NMDA receptor hypofunction theory
proposed in schizophrenia might be partly explained by increased DAO activity
modulated by DAOA leading to decreased D-serine, a co-agonist of NMDA
receptors (Sacchi et al., 2016). The function of NRG1 is mediated by binding
to receptor tyrosine kinases called ErbB (ErbB3 and ErbB4), and an altered
NRG1/ErbB4 signaling is thought to result in NMDA receptor hypofunction
(Li et al., 2007; Mei and Nave, 2014). These studies highlight the potential
pathogenic link between NMDA receptor hypofunction and dysregulation of
DAO, DAOA, and NRG1 genes.
The National Institute of Mental Health started the Research Domain Criteria
(RDoC) initiative to guide and organize research in psychiatric disorders
beyond the typical diagnostic classification approach (Insel et al., 2010). This
initiative provides a non-disease-based structured conceptual framework to
understand the dimensional range of human behavior from normal to abnormal
by integrating multiple levels of information (from genomics to self-reports).
The RDoC represents a paradigm shift from Diagnostic and Statistical Manual
of Mental Disorders (DSM)/International Classification of Diseases (ICD)
to dimensional approaches with an aim to integrate basic research and
psychopathology (Cuthbert, 2014).
In this study, we aimed (1) to identify predictive glutamatergic genetic
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polymorphisms in at-risk individuals for transition to schizophrenia-spectrum
disorders, (2) to identify endophenotypes potentially linked to the glutamatergic
system in at-risk individuals using RDoC constructs, and (3) to evaluate
differences in DAO, DAOA, and NRG1 mRNA levels across clinical and RDoC
domains.
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5.3.3 Materials and methods
Study population
Participants were recruited by the “Early Recognition and Intervention Program
for Psychosis and Bipolar Disorder” project as part of the Zurich Program for
Sustainable Development of Mental Health Services (ZInEP; www.zinep.ch)
in the Canton of Zurich, Switzerland. The detailed study design, inclusion,
and exclusion criteria were described in our previous studies (Metzler et al.,
2014; Theodoridou et al., 2014). A total of 185 individuals aged 13-35 years
at HR/UHR for psychosis were assessed at baseline and were subsequently
followed-up at 6, 12, 24, and 36 months for the transition to schizophrenia.
At 36 months follow-up, 50% of individuals (n=93) dropped out of the study.
The dropouts were due to refusal to participate in the study in most of the
cases and due to non-response after contacting in few cases. However, we
are unable to give exact numbers of individuals who refused to participate or
who did not respond due to missing information in several study participants.
Individuals at HR for psychosis were assessed using the Schizophrenia
Proneness Instrument-Child and Youth version (SPI-CY) (age < 18 years)
(Schultze-Lutter and Koch, 2009; Fux et al., 2013) or Schizophrenia Proneness
Instrument-Adult version (SPI-A) (age ≥ 18 years) (Schultze-Lutter et al., 2007),
and were included when they had one cognitive-perceptive (COPER) basic
symptom or at least two cognitive disturbances (COGDIS). Individuals at UHR
for psychosis were assessed using the Structured Interview for Prodromal
Syndromes (SIPS) (McGlashan et al., 2001; Miller et al., 2003) and were included
when they met criteria for the attenuated positive symptoms syndrome (APSS)
or the brief limited intermittent psychotic symptom (BLIPS) or the state-trait
criteria (>30% reduction in global assessment of functioning in the past year plus
either schizotypal personality disorder or a first degree relative with psychosis).
The transition to schizophrenia was defined according to ICD-10 criteria (World
Health Organization, 1992). The severity of positive and negative symptoms
was assessed using the Positive and Negative Syndrome Scale (PANSS) (Kay
et al., 1987), severity of depressive symptoms was assessed with the Calgary
Depression Rating scale for Schizophrenia (CDSS) (Addington et al., 1992), and
anxiety symptoms with the Beck Anxiety Inventory (BAI) (Beck et al., 1988).
The demographic and diagnostic characteristics of the study population are
shown in Supplementary Table S1. This study was approved by the Cantonal
Ethic Commission of Zurich (Ref. Nr. EK: E-63/2009) and complies with the
Declaration of Helsinki. Informed written consent was obtained from adult
participants and legal guardians of minors, and written assent was obtained
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from minors.
Phenotypic domains
The participants were grouped into clinical phenotypes (cases versus
controls) namely, converters to schizophrenia-spectrum disorders (n=27), i.e.,
schizophrenia, schizophreniform disorder, and acute psychotic disorder, versus
non-converters (n=65) at 36 months follow-up [dropouts (n=93)], and APSS
(n=98) group versus all other help-seeking individuals (BLIPS, state-trait criteria,
COGDIS, COPER) (n=87) at baseline. The transition to schizophrenia was
defined according to ICD-10 criteria (World Health Organization, 1992).
First, we grouped our cohort as per the factor structure of the PANSS,
concentrating on negative symptoms and general psychopathology (Kay et al.,
1987). As we did not find any significant differences in negative symptoms
(sum score of negative (N1-N7) PANSS subscale) and general psychopathology
(sum score of general psychopathology (G1-G16) PANSS subscale) across DAO,
DAOA, and NRG1 SNPs, we then decided to use an exploratory approach by
focussing on subgroups of psychopathology constructs defined according to
the RDoC domains. The RDoC framework consists of five domains namely,
negative valence systems, positive valence systems, cognitive systems, systems
for social process, and arousal/regulatory systems (Cuthbert and Insel, 2013).
In this study, we decided to concentrate on two RDoC domains: negative
valence systems and cognitive systems, due to the potential role of DAO, DAOA
and NRG1 polymorphisms in the glutamate hypothesis of schizophrenia, as
it appears to explain the pathogenesis of negative and cognitive symptoms
better than the dopamine hypothesis (Hu et al., 2015; Veerman et al., 2014)
and unavailability of relevant neuropsychological scales in our study to create
the positive valence domain. Negative valence systems focus on responses to
aversive situations, such as fear, anxiety and loss. Cognitive systems concentrate
on various cognitive processes, such as perception, language, memory, and
cognitive control. Within negative valence systems, we focused on the constructs
of threat (acute and sustained) and loss. The negative valence system construct
of threat was assessed by the total score of BAI with higher BAI scores pointing
to increased severity of anxiety (Beck et al., 1988). The negative valence system
construct loss was assessed by the response to the CDSS item 2 “hopelessness”
which can be scored as either 0 (absent), 1 (mild), 2 (moderate), or 3 (severe)
(Addington et al., 1992). Within cognitive systems, we chose the constructs of
perception (visual and auditory) and cognitive control. The cognitive system
construct visual perception was assessed by summing the following four SPI-A
(and equivalent SPI-CY) items O4 (other visual perception disturbances), F1
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(hypersensitivity to light), F2 (photopsia), and F3 (micropsia/macropsia), with
higher scores pointing to more frequent disturbances in visual perception. The
cognitive system construct of auditory perception was assessed by summing
the following three SPI-A (and equivalent SPI-CY) items O5 (other acoustic
perception disturbances), F4 (hypersensitivity to sounds/noise), and F5
(changed intensity/quality of acoustic stimuli), with higher scores pointing
to more frequent disturbances in auditory perception. The cognitive system
construct of cognitive control was obtained by summing the following four SIPS
disorganization items D1, D2, D3, and D4 (McGlashan et al., 2001; Miller et al.,
2003), with higher scores indicating more severe disturbance in disorganised
symptoms.
The above-mentioned scales used to tap into RDoC domains were assessed at
baseline and last-available follow-up until 36 months. As there was a dropout
rate of 50% at 36 months, if there were no data available at 36 months, we took
the scores from the last follow-up that the individual attended (i.e., 6 or 12 or 24
months).
TaqMan single nucleotide polymorphism (SNP) genotyping
The study population was genotyped for DAO (rs3918347, rs4623951), DAOA
(rs778293, rs3916971, rs746187), and NRG1 (rs10503929) SNPs. These SNPs were
selected based on previously reported significant association with schizophrenia
(Allen et al., 2008; Mechelli et al., 2012). In our recent meta-analysis, we
found a significant association of DAO rs4623951 [odds ratio (OR)=0.88;
minor allele: C), DAOA rs778293 (OR=1.17; minor allele: G), DAOA rs3916971
(OR=0.84; minor allele: T), and NRG1 rs10503929 (OR=0.89; minor allele: C)
with schizophrenia (Jagannath et al., 2017a). In this study, the carriers of the
risk allele of DAO, DAOA, and NRG1 SNPs were anticipated to have worse
psychopathology scores in RDoC negative valence and cognitive system
constructs. DNA was isolated from whole blood Ethylenediaminetetraacetic
acid (EDTA) tubes collected from the study population using QIAamp DNA
Blood Maxi Kit (Qiagen) as per manufacturer’s protocol. A spectrophotometer
(NanoVue Plus, GE) was used to measure DNA concentrations, A260/A280, and
A260/A230 ratios. The study population was genotyped for DAO (rs3918347
assay number: C 27937201 10, rs4623951 assay number: C 32177440 10, both
from Applied Biosystems, USA), DAOA (rs778293 assay number: C 8704507 10,
rs3916971 assay number: C 27495752 10, rs746187 assay number: C 1925241 10,
all from Applied Biosystems, USA), and NRG1 (rs10503929, assay number:
C 2870393 10, Applied Biosystems, USA) SNPs (Jagannath et al., 2017b). DNA
(10 ng/µl), TaqMan R© Genotyping Master Mix (Applied Biosystems, USA),
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and above-mentioned DAO, DAOA, NRG1 SNP Genotyping Assays (Applied
Biosystems, USA) were combined in a 384-well plate. Real-time PCR was
performed in a C1000TMCFX384TM Thermal cycler (Bio-Rad) using TaqMan R©
SNP Genotyping Assay PCR standard protocol. The allelic discrimination
program of Bio-Rad CFX ManagerTM Software version 2.1 was used to determine
genotypes (Jagannath et al., 2017b). Samples were run in duplicates to ensure
correct results. In case of ambiguity in duplicates, genotyping was repeated
in a separate run to ensure correct results. No-template controls (NTC) were
included in every run to exclude impurities.
Quantification of NRG1, DAO, and DAOA mRNA levels using quantitative
real-time reverse transcription-polymerase chain reaction (qRT-PCR)
RNA was isolated from whole blood collected from the study population
using PAXgene Blood RNA Kit (Qiagen) according to manufacturer’s
protocol. A spectrophotometer (NanoVue Plus, GE) was used to measure
RNA concentrations, A260/A280, and A260/A230 ratios. RNA integrity was
analysed using Experion automated electrophoresis system (Bio-Rad) in a subset
of samples to ensure RNA Integrity Number (RIN)/RNA quality Indicator
(RQI) > 7. RNA (500 ng) was reverse transcribed using iScriptTM cDNA
Synthesis Kit (Bio-Rad) as per manufacturer’s protocol. In a subset of samples,
negative controls were prepared with RNA using iScriptTM cDNA Synthesis
Kit (Bio-Rad) without reverse transcriptase enzyme as per manufacturer’s
protocol. qRT-PCR was performed using cDNA, QuantiFast SYBR Green
PCR kit (Qiagen), 1 µM NRG1 primer (QT00061964, Qiagen), and reference
genes (β-actin (ACTB) (QT01680476), aminolevulinate synthetase (ALAS1)
(QT00073122), ribosomal protein L13a (RPL13A) (QT00089915), alanyl-tRNA
synthetase (AARS) (QT00054747), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (QT01192646), peptidyl prolyl isomerase A (PPIA) (QT00866137), and
X-prolyl aminopeptidase1 (XPNPEP1) (QT00051471); all from Qiagen). NRG1
mRNA levels were normalised to the references genes (Jagannath et al., 2017b).
PCR efficiencies were calculated using LinReg PCR program (Ruijter et al., 2009)
and mean PCR efficiencies for all studied amplicons were found to be between
91% and 93%. Normalised NRG1 mRNA levels were quantified using qBASE
plus software (Biogazelle) which utilises gene-specific amplification efficiencies,
and allows normalisation with multiple reference genes (Hellemans et al., 2007).
We performed qRT-PCR to detect DAO mRNA using DAO primers described
by Verrall et al.,(Verrall et al., 2007) and pre-designed primers (qHsaCID0011122
and qHsaCEP0058247 (Bio-Rad), Hs.PT.58.3248433 and Hs.PT.58.45768871
(IDT)). We performed qRT-PCR to detect DAOA mRNA using primers for DAOA
121
Study III: Materials and methods
gene described by Benzel et al., (Benzel et al., 2008), Cheng et al., (Cheng et al.,
2014), and pre-designed primers (QT00058863 (Qiagen), Hs.PT.58.555086 (IDT),
4331182 (ThermoFisher scientific), qHsaCEP0024792 (Bio-Rad)). QuantiTect
Whole Transcriptome Kit (207043, Qiagen) followed by qRT-PCR was also used
to detect DAO and DAOA mRNA levels (Jagannath et al., 2017b). However,
we were unable to quantify DAO and DAOA mRNA with the aforementioned
methods in the whole blood as either no signal was observed or genomic DNA
was amplified concomitantly.
Statistical analysis
The results from SNP genotyping was analysed using PLINK software (Purcell
et al., 2007). The minor allele frequency and deviation from Hardy-Weinberg
Equilibrium (HWE) was computed using PLINK software, and p<0.05 was
considered as statistically significant. The DAO (rs3918347), DAOA (rs3916971,
rs778293, rs746187), and NRG1 (rs10503929) SNPs were in Hardy-Weinberg
equilibrium (p>0.05), and the minor allele frequency (MAF) of DAO, DAOA, and
NRG1 SNPs were similar to HapMap CEU MAF (Supplementary Table S5). The
DAO rs4623951 SNP deviated from the Hardy-Weinberg equilibrium (p<0.05)
(Supplementary Table S4). The differences in allele and genotype frequencies
across clinical phenotypes (cases versus controls) were assessed using Chi-square
test, p<0.05 was taken as statistically significant. The OR, 95% CI, and p-value
for SNP models (allelic, dominant and recessive) across clinical phenotypes
were calculated from allele/genotype frequencies using an online OR calculator
(https://www.medcalc.org/calc/odds ratio.php), and p-value was adjusted
based on the number of analysed SNPs (Bonferroni correction, p<0.008). The
post hoc power analyses for association of DAO, DAOA, and NRG1 SNPs
with converters to schizophrenia-spectrum disorders versus non-converters
(Supplementary Table S5) and APSS versus all other help-seeking group were
conducted using Fisher’s exact test of independence in G*Power software (Faul
et al., 2009), the calculated OR was used, and the alpha level was set at 0.05.
IBM R© SPSS R© Statistics (version 21) software was used for statistical analysis.
Shapiro-Wilk test with Lilliefors significance correction was used to assess the
normality of the distribution of NRG1 gene expression and clinical scales (BAI,
CDSS, SPI-A/SPI-CY, SIPS, PANSS). NRG1 gene expression and clinical scales
showed both normal and non-normal distribution. We used non-parametric tests
even for normally distributed data in order to maintain consistency between
statistical evaluations. The differences in RDoC domains (negative valence
and cognitive systems) across models (genotypic, dominant, recessive) were
assessed using Mann-Whitney test (for 2 groups) or Kruskal-Wallis test (for >2
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groups), p-values were adjusted based on the number of constructs analysed
(Bonferroni correction, p<0.008). The differences in NRG1 mRNA levels across
clinical phenotypes were assessed using Mann-Whitney test and p<0.05 was
set as statistically significant. The post hoc power analyses for RDoC negative
valence and cognitive systems across DAO, DAOA, and NRG1 SNPs were
conducted using analysis of variance (ANOVA) test for 3 groups or t-test for 2
groups in G*Power software (Faul et al., 2009), the effect sizes were determined
from means of neuropsychological scales used in RDoC negative valence and
cognitive systems, and the alpha level was set at 0.05 (Supplementary Table S7).
The differences in NRG1 mRNA levels across NRG1 rs10503929 SNP genotypes
was assessed using Kruskal-Wallis test and across dominant (CC+CT, TT) and
recessive models (CC, CT+TT) were assessed using Mann-Whitney test, with
p<0.05 being set as statistically significant. The correlation between NRG1 gene
expression and RDoC domains (negative valence and cognitive systems) was
assessed using Spearman’s rank correlation test and p<0.05 was considered
statistically significant.
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5.3.4 Results
The DAO (rs3918347), DAOA (rs3916971, rs778293, rs746187), and NRG1
(rs10503929) SNPs were in Hardy-Weinberg equilibrium (p>0.05), and the
minor allele frequency (MAF) of DAO, DAOA, and NRG1 SNPs were similar to
HapMap CEU MAF (Supplementary Table S2).
DAO, DAOA, and NRG1 polymorphisms across clinical phenotypes
There were no significant associations between DAO, DAOA, and NRG1
SNPs with converters to schizophrenia-spectrum disorders compared to
non-converters at 36 months follow-up (power range: 0.05-0.31; Supplementary
Table S3). However, there was a nominal association (p>0.008) of DAO rs3918347
with APSS compared to all other help-seeking group at baseline, and the G-allele
had a tendency to be a risk allele for APSS (OR=1.84, 95% CI=1.13-3.01, p=0.01),
with a power of 0.76 (Supplementary Table S4). There were no significant
association between the of rest of the DAO, DAOA, NRG1 SNPs and APSS
(power range: 0.05-0.89; Supplementary Table S4).
DAO, DAOA, and NRG1 polymorphisms across RDoC domains
DAOA rs746187 recessive (CC) genotype carriers experienced nominally more
hopelessness (higher item 2 score, CDSS) than CT+TT genotype carriers at the
last available follow-up time point (LA) until 36 months (p=0.04) analysed by
Mann-Whitney test (RDoC negative valence system: loss; Figure 1; power=0.62;
effect size=0.55; Supplementary Table S8). DAOA rs3916971 recessive (TT)
genotype carriers experienced nominally more disturbances in visual perception
(higher sum of O4+F1+F2+F3, SPI-A) than TC+CC genotype carriers at LA
until 36 months (p=0.009) analysed by Mann-Whitney test (RDoC cognitive
system: visual perception; Figure 2; power=0.28; effect size=0.34; Supplementary
Table S8). Individuals with DAOA rs3916971 TC+CC versus TT genotype
improved and had fewer visual perceptual disturbances at LA until 36 months
compared to baseline, but at LA until 36 months versus baseline, they continued
to have less visual perceptual disturbances than individuals with TT genotype
(Figure 2C). There were no significant differences in negative valence (threat;
Supplementary Table S5; power range: 0.05-0.72, Supplementary Table S8),
auditory perception disturbances (Supplementary Table S6; power range:
0.05-0.56, Supplementary Table S8), and cognitive control (Supplementary
Table S7; power range: 0.05-0.31, Supplementary Table S8) in individuals with
DAOA SNP genotypes (rs3916971, rs778293, rs746187).
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Figure 1: Differences in RDoC negative valence system loss across DAOA rs746187 genotypes.
Differences in Calgary Depression Scale for Schizophrenia (CDSS) item 2: hopelessness scale
across DAOA rs746187 genotypes in genotype (A), dominant (B), and recessive (C) model at
baseline and last available follow-up time point until 36 months. Data is presented as mean±SEM;
*p<0.008 (significant with Bonferroni correction); #0.008<p<0.05 (significant without Bonferroni
correction).
Figure 2: Differences in RDoC cognitive system visual perception across DAOA rs3916971
genotypes. Differences in Schizophrenia Proneness Instrument-Adult version (SPI-A)
O4+F1+F2+F3 sum score across DAOA rs3916971 genotypes in genotype (A), dominant (B), and
recessive (C) model at baseline and last available follow-up time point until 36 months. Data
is presented as mean±SEM; *p<0.008 (significant with Bonferroni correction); #0.008<p<0.05
(significant without Bonferroni correction).
DAO rs3918347 GA+AA genotype carriers experienced nominally (p=0.04)
more disturbances in auditory perception (higher sum of O5+F4+F5, SPI-A)
than GG genotype carriers at baseline analysed by Mann-Whitney test (RDoC
cognitive system: auditory perception; Figure 3; power=0.41; effect size=0.44;
Supplementary Table S8). Individuals with DAO rs3918347 GA+AA versus GG
genotype improved and had lesser auditory perceptual disturbances at LA until
36 months compared to baseline, but at LA until 36 months versus baseline, they
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continued to experience more auditory perceptual disturbances than individuals
with CC genotype (Figure 3C). We did not find significant differences in negative
valence systems (anxiousness and hopelessness; Supplementary Table S5; power
range: 0.05-0.92, Supplementary Table S8), visual perception disturbances
(Supplementary Table S6; power range: 0.05-0.57, Supplementary Table S8),
and cognitive control (Supplementary Table S7; power range: 0.05-0.22,
Supplementary Table S8) in individuals with DAO (rs3918347, rs4623951) SNP
genotypes.
NRG1 rs10503929 CC+CT genotype carriers had significantly (p=0.001) more
disorganised symptoms (higher sum of the D1-D4 score, SIPS) than TT genotype
carriers at baseline analysed by Mann-Whitney test (RDoC cognitive system:
cognitive control; Figure 4; power=0.99; effect size=0.59; Supplementary
Table S8). There were no significant differences in negative valence systems
(anxiousness and hopelessness; Supplementary Table S5; power range: 0.07-0.51,
Supplementary Table S8), and visual and auditory perception disturbances
(Supplementary Table S6; power range: 0.05-0.36, Supplementary Table S8) in
individuals with NRG1 (rs10503929) SNP genotypes.
To analyse the effect of age on RDoC domains across DAO, DAOA, and NRG1
SNPs, we performed an analysis of covariance (ANCOVA) with age as a
covariate after transformation of not normally distributed BAI, SPI-A, and SIPS
data, as described previously (Templeton, 2011). We did not find a significant
effect of age on differences in RDoC domains across DAO, DAOA, and NRG1
SNPs (data not shown).
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Figure 3: Differences in RDoC cognitive system auditory perception across DAO rs3918347
genotypes. Differences in Schizophrenia Proneness Instrument-Adult version (SPI-A) O5+F4+F5
sum score across DAO rs3918347 genotypes in genotype (A), dominant (B), and recessive (C)
model at baseline and last available follow-up time point until 36 months. Data is presented
as mean±SEM; *p<0.008 (significant with Bonferroni correction); #0.008<p<0.05 (significant
without Bonferroni correction).
127
Study III: Results
Figure 4: Differences in RDoC cognitive system cognitive control across NRG1 rs10503929
genotypes. Differences in Structured Interview for Prodromal Syndromes (SIPS) sum score of
D1-D4 across NRG1 rs10503929 genotypes in genotype (A), dominant (B), and recessive (C)
model at baseline and last available follow-up time point until 36 months. Data is presented
as mean±SEM; *p<0.008 (significant with Bonferroni correction); #0.008<p<0.05 (significant
without Bonferroni correction).
NRG1, DAO and DAOA mRNA expression across RDoC and clinical domains
There was a significant positive correlation between increased NRG1 mRNA
levels and higher scores on the RDoC negative valence system loss at LA until
36 months (Supplementary Table S9). Apart from this, there were no significant
correlations between NRG1 mRNA levels and RDoC domains at baseline and
at LA until 36 months (Supplementary Table S9). There were no statistically
significant differences in NRG1 mRNA levels across clinical phenotypes
(Supplementary Table S10). We did not find significant differences in NRG1
mRNA levels across NRG1 rs10503929 SNP genotypes, dominant, and recessive
models analysed by Mann-Whitney and Kruskal-Wallis test (Supplementary
Table S11). We were unable to quantify DAO and DAOA mRNA levels in the
whole blood of at-risk population.
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5.3.5 Discussion
In this 3-year follow-up study of 185 at-risk individuals, NRG1 rs10503929
CC+CT versus TT genotype carriers experienced significantly more disorganized
symptoms, DAOA rs746187 CC versus CT+TT genotype, DAOA rs3916971
TT versus TC+CC genotype, and DAO rs3918347 GA+AA versus GG
genotype carriers experienced nominally more hopelessness, visual perception
disturbances, and auditory perception disturbances, respectively. Moreover,
we found no significant association between DAO, DAOA, NRG1 SNPs and
conversion to schizophrenia-spectrum disorders, however, we did find a
nominally increased risk for APSS with the G-allele of DAO rs3918347 carriers.
The DAO, DAOA, and NRG1 SNPs did not predict conversion to
schizophrenia-spectrum disorders at 36 months follow-up. This lack of
association may be due to a low conversion rate of 14.6%, a high drop-out rate of
50% at 36 months follow-up, and that the comparison group of non-converters
was not a healthy control group but rather a heterogeneous group of HR
and UHR individuals. In this heterogeneous at-risk population, individuals
are likely to be on different developmental trajectories of/towards various
neuropsychiatric disorders, which might have further complicated the genetic
prediction of transition to schizophrenia in our study. Furthermore, our
conversion group not only contained patients with schizophrenia, but also
patients with other schizophrenia-spectrum disorders. Thus, recruiting a more
homogeneous at-risk population would have been more appropriate (Cornblatt
and Carrio´n, 2016; Cornblatt et al., 2015). In contrast to previous meta-analyses
showing conversion rates of 29-32% at 36 months follow-up (Fusar-Poli et al.,
2012; Schultze-Lutter et al., 2015), our study had a low conversion rate of 14.6%.
A study of 82 UHR individuals showed that 100% of the DAOA rs1341402 CC
genotype carriers (n=4) compared to 50% of the DAOA rs778294 AA genotype
carriers (n=10; A-allele protective against schizophrenia) progressed to psychosis
within 24 months (Mo¨ssner et al., 2010). However, a recent study with 225 UHR
individuals did not replicate these findings (Bousman et al., 2013). Furthermore,
another study of 67 UHR individuals showed that 100% of TT genotype carriers
(n=25) of NRG1 rs62510682 developed psychosis within 12-months (Keri et al.,
2009), but this finding was not replicated in the aforementioned study with 225
UHR individuals (Bousman et al., 2013). About 46% of the NRG1 rs4281084
AA genotype UHR carriers (n=13), and 44% of the T-allele UHR carriers
(n=45) transitioned to psychosis within a 15 year follow-up period (Bousman
et al., 2013). Thus, there is ambiguity regarding the association of DAOA and
NRG1 polymorphisms with the transition to psychosis. We did not assess the
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aforementioned DAOA and NRG1 SNPs in this study as we only focussed on the
SNPs associated with schizophrenia (Allen et al., 2008; Mechelli et al., 2012).
Our finding that NRG1 rs10503929 TT genotype carriers had significantly
less disorganised symptoms than the dominant (CC+CT) genotype carriers
at baseline (RDoC cognitive control) is consistent with previous finding of a
significant association of NRG1 rs10503929 with cognitive domains (abstraction
and mental flexibility, attention and verbal memory) in schizophrenia patients,
in which the C-allele (protective against schizophrenia) was associated with
decreased cognitive performance (Yokley et al., 2012). We found that NRG1
rs10503929 (CT+TT) versus CC genotype carriers had nominally more auditory
perception disturbances. To our knowledge, there are no previous studies
on associations between the NRG1 rs10503929 (exon 8/9/10) and perceptual
disturbances. However, a study in adolescents demonstrated that NRG1
rs3924999 (exon 2) was associated with perceptual disturbances (Lin et al., 2005).
The nominal associations between DAOA rs746187 and the RDoC negative
valence system: loss, and that between DAOA rs3916971 and the RDoC cognitive
system: visual perception, points to the possible role of DAOA variations in
modulating endophenotypes underlying psychosis risk. A recent study found
a nominal association of DAOA rs3916971 with a psychotic disorder (Andreou
et al., 2015). Another study conducted in healthy male controls found that DAOA
rs3916971 schizophrenia risk C-allele carriers had worse visual-spatial skills
(Leach et al., 2013; Crespi and Leach, 2016). In our study, DAO rs3918347 GA+AA
genotype carriers experienced nominally more auditory perception disturbances
than GG genotype carriers at baseline (RDoC cognitive system). Another study
found a negative association of DAO rs3918346 with neurocognitive functioning
in schizophrenia patients (Goldberg et al., 2006). Therefore, the association of
DAO and DAOA SNPs with hopelessness and perception disturbances of our
study needs further confirmation.
We further found that NRG1 mRNA levels increased with higher CDSS
hopelessness scores. Previous post-mortem studies have shown increased
NRG1 mRNA levels in the hippocampus (Law et al., 2006) and prefrontal cortex
(Chong et al., 2008; Hashimoto et al., 2004) of schizophrenia patients compared
to healthy controls. Moreover, studies have shown dysfunctions in these regions
might lead to hopelessness (Johnston et al., 2015; Mayberg et al., 1999; Warden
et al., 2012).
We examined associations of DAO, DAOA, and NRG1 SNPs with risk profiles in
individuals at-risk for psychosis. For the sake of higher homogeneity, we also
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focussed on the APSS subsample, a classification which the DSM-5 working
group included under “conditions for further study” (American Psychiatric
Association, 2013). We found that the schizophrenia risk G-allele of DAO
rs3918347 had a tendency to be a risk allele for APSS compared to the remaining
help-seeking group. This result has to be interpreted cautiously because the
help-seeking group is not a healthy control group, but a mixed group of BLIPS,
state-trait risk criterion, and HR.
We did not find any significant differences in NRG1 mRNA levels between
converters to schizophrenia-spectrum disorders versus non-converters, and
APSS versus all other help-seeking non-converters, which might be due to
small subsample size leading to modest power (supplementary tables S3 and
S4) and heterogeneous subgroups. Our results are in contrast to a study, which
showed that NRG1 (type I and II isoforms) mRNA expression was significantly
lower in blood of UHR individuals who transitioned to psychosis (n=31)
compared to non-converters (n=66) and controls (n=50) (Kiss et al., 2012). The
discrepancy in the results of our study and the aforementioned study might
also be due to the differences in isolation method, number of reference genes,
stability of the reference genes, and normalisation method used to normalise
NRG1 mRNA levels to reference genes. A study conducted on immortalised
lymphocytes showed that there was no difference in NRG1 mRNA levels
between schizophrenia patients and healthy controls (Yamamori et al., 2011).
We were unable to detect DAO and DAOA mRNA using qRT-PCR in the whole
blood of individuals at-risk for psychosis, which is in line with a study which
used RNA sequencing to detect DAO and DAOA mRNA in healthy participants
(GTEx Consortium, 2015). As qRT-PCR can detect low copy number genes
(Morrison et al., 1998), undetectable DAO and DAOA mRNA levels might
suggest either very low expression below the detection limit of qRT-PCR or
extremely localised expression (Jagannath et al., 2017b). The reasons for very low
or no expression of DAO and DAOA mRNA in blood might be highly methylated
(75-90%) Illumina CpG sites of DAO and DAOA genes in healthy individuals
(Hannon et al., 2015). Another reason for this low or no expression might be the
expression of these genes specifically in the brain (Korostishevsky et al., 2006;
Verrall et al., 2007) because of their role in glutamatergic neurotransmission via
NMDA receptors (Sacchi et al., 2016).
In our study, DAO rs4623951 genotype data showed that the study population
deviated from the Hardy-Weinberg Equilibrium (HWE). Since we controlled
for genotyping errors, this deviation from HWE might be due to the observed
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excess of CT heterozygotes (54%). This excess heterozygosity might be caused
by “selection favouring heterozygotes, outbreeding, and negative assortative
mating” (Ziegler et al., 2010). As deviation from the HWE creates bias in
the associations reported (Salanti et al., 2005), the association results of DAO
rs4623951 SNP should be interpreted with caution. As this study did not have all
the instruments suggested by RDoC for negative valence and cognitive systems,
we used an exploratory approach, using the instruments available in this study
to create the respective constructs. Thus, future studies are needed to confirm
our RDoC findings.
Our study has several limitations, which must be acknowledged. Although
a total of 185 individuals at-risk for psychosis were recruited, sample sizes
within genotypes across clinical and RDoC domains were small and the power
of the study was modest. In this study, only a small percentage (14.6%) of
at-risk individuals converted to schizophrenia at 36 months follow-up, 50%
of individuals dropped out of the study before 36 months, and there was no
healthy control group. The conversion status of the dropouts is unknown, and
thus it is not possible to reliably determine the conversion rate. The group of
all other help seeking individuals was at heterogeneous risk (BLIPS, state-trait
criteria, COPER, COGDIS). The sample size at 36-months follow-up for different
psychopathology scales was small because of the high dropout rate. To
circumvent this problem, we used the last psychopathology assessment available
from each individual. Therefore, the results of LA until 36 months should be
interpreted with caution, as they are not based on a homogeneous 36-month
follow-up score. We studied only few genes (3 genes) and a relatively small
number of their polymorphisms (6 SNPs) which might be the reason for not
finding markers for predicting conversion to schizophrenia spectrum disorders.
However, these genes and their polymorphisms are still of interest due to their
importance in glutamatergic neurotransmission. This study also has strengths,
which needs to be highlighted. We recruited individuals from a broad age range
(13-35 years) and used age-specific scales (e.g., SPI-A/SPI-CY). Most of the
published literature in at-risk population has focussed on clinical phenotypes.
The present study used both clinical phenotypes and RDoC domains, especially
negative valence and cognitive systems, due to the role of the studied genes in
the glutamate hypothesis of schizophrenia.
In summary, although DAO, DAOA, and NRG1 SNPs did not emerge as
predictive markers for conversion to schizophrenia-spectrum disorders, future
association studies with larger cohorts and longer follow-ups are needed to
confirm the role of these genes in transition to schizophrenia-spectrum disorders
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in the at-risk population. We also identified an association between the studied
glutamatergic variants and RDoC negative valence and cognitive systems,
which indirectly implicates the role of these genetic variants in the glutamate
hypothesis of schizophrenia. Future studies using RDoC domains might help
to determine specific endophenotypes within at-risk populations. This might
provide clinically useful, genetically informed risk prediction for dimensional
and categorical outcomes among populations who maybe at-risk for developing
psychosis.
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5.3.6 Supplementary Information
Supplementary tables
Supplementary Table S1: Demographics and diagnostic characteristics of the study population
Categorical variables Baseline (n=185)N %
Female 75 40.5
Male 110 59.5
Converters 27 14.6
Non-converters 65 35.1
APSS 98 53
All other help-seeking
(n=87)
COPER 28 15.1
COGDIS 7 3.8
HR (COPER+COGDIS) 43 23.2
BLIPS 4 2.2
State-trait criteria 5 2.7
Continuous variables Baseline (n=185)
Last available follow-up data
until 36 months (n=151)
N Range Mean±SEM N Range Mean±SEM
Age in years 185 13-35 20.51±0.42 151 13-35 20.04±0.23
Threat (sum of BAI scale) 169 0-57 19.6±0.88 139 0-84 12.29±1.07
CDSS: item 2 185 0-3 1.06±0.07 151 0-3 0.67±0.07
Visual perception
(SPI-A O4+F1+F2+F3) 111 1-15 3.39±0.32 98 1-15 2.29±0.27
Auditory perception
(SPI-A O5+F4+F5) 173 0-16 3.77±0.29 135 0-15 2.17±0.23
Cognitive control
(SIPS: sum of D1-D4) 185 0-15 4.46±0.22 150 0-10 2.40±0.20
APSS: attenuated positive symptoms syndrome; COPER: cognitive-perceptive basic symptoms; COGDIS: cognitive
disturbances; BLIPS: brief limited intermittent psychotic symptoms; HR: high risk criteria; BAI: Beck Anxiety Inventory;
CDSS: Calgary Depression Rating scale for Schizophrenia; SPI-A: Schizophrenia Proneness Instrument-Adult version (≥
18 years); SPI-CY: Schizophrenia Proneness Instrument-Child and Youth version (< 18 years); SIPS: Structured Interview
for Prodromal Symptoms; SEM: standard error of the mean
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Supplementary Table S2: Hardy-Weinberg equilibrium and minor allele frequencies of DAO,
DAOA and NRG1 SNPs in the study population
Gene SNP ID Genotype N H-Wp-value
Minor
allele MAF
HapMap/ NCBI
CEU MAF
D-amino acid
oxidase (DAO)
rs3918347
GG 24
0.09 G 0.3189 0.274GA 70
AA 91
rs4623951
CC 18
0.04* C 0.3676 0.412CT 100
TT 67
D-amino acid
oxidase activator
(DAOA)
rs3916971
TT 42
0.14 T 0.4462 0.394TC 82
CC 62
rs778293
GG 43
0.18 G 0.4541 0.389GA 82
AA 60
rs746187
CC 26
0.87 C 0.3703 0.375CT 85
TT 74
Neuregulin 1
(NRG1) rs10503929
CC 7
0.82 C 0.207 0.225CT 63
TT 116
H-W: Hardy-Weinberg; MAF: minor allele frequency; SNP: single nucleotide polymorphism; *p<0.05 (bold font)
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Supplementary Table S3: Association of DAO, DAOA and NRG1 SNPs with converters to
schizophrenia-spectrum disorders (n=27) versus non-converters (n=65) at 36 months follow-up
and power analysis
Gene SNPID
Minor
allele Model
Genotype/
allele
Phenotype
OR 95% CI p-value Power
bConverters
(N)
Non-
converters
(N)
D
-a
m
in
o
ac
id
ox
id
as
e
(D
A
O
) r
s3
91
83
47
G
Genotypic
GG 2 6
- - 0.27a -GA 10 18
AA 8 35
Allelic G 14 30 1.58 0.73-3.41 0.25 0.29A 26 88
Dominant GG+GA 12 24 2.19 0.78-6.15 0.14 0.31AA 8 35
Recessive GG 2 6 0.98 0.18-5.30 0.98 0.05GA+AA 18 53
rs
46
23
95
1
C
Genotypic
CC 3 7
- - 0.62a -CT 9 34
TT 8 18
Allelic C 15 48 0.88 0.41-1.83 0.72 0.06T 25 70
Dominant CC+CT 12 41 0.66 0.23-1.89 0.44 0.13TT 8 18
Recessive CC 3 7 1.31 0.30-5.64 0.72 0.08CT+TT 17 52
D
-a
m
in
o
ac
id
ox
id
as
e
ac
ti
va
to
r
(D
A
O
A
)
rs
39
16
97
1
T
Genotypic
TT 6 11
- - 0.20a -TC 5 28
CC 9 20
Allelic T 17 50 1.01 0.49-2.08 0.99 0.05C 23 68
Dominant TT+TC 11 39 0.63 0.22-1.76 0.38 0.14CC 9 20
Recessive TT 6 11 1.87 0.59-5.96 0.29 0.22TC+CC 14 48
rs
77
82
93
G
Genotypic
GG 3 14
- - 0.68a -GA 9 22
AA 8 22
Allelic G 15 50 0.79 0.38-1.66 0.54 0.09A 25 66
Dominant GG+GA 12 36 0.92 0.32-2.59 0.87 0.05AA 8 22
Recessive GG 3 14 0.55 0.14-2.18 0.40 0.20GA+AA 17 44
rs
74
61
87
C
Genotypic
CC 3 12
- - 0.69a -CT 11 26
TT 6 21
Allelic C 17 50 1.01 0.49-2.08 0.99 0.05T 23 68
Dominant CC+CT 14 38 1.29 0.43-3.85 0.65 0.08TT 6 21
Recessive CC 3 12 0.69 0.17-2.75 0.60 0.11CT+TT 17 47
N
eu
re
gu
lin
1
(N
R
G
1)
rs
10
50
39
29
C
Genotypic
CC 0 1
- - 0.74a -CT 6 21
TT 14 37
Allelic C 6 23 0.73 0.27-1.94 0.53 0.14T 34 95
Dominant CC+CT 6 22 0.72 0.24-2.15 0.56 0.10TT 14 37
Recessive CC 0 1 0.95 0.04-24.3 0.98 0.05CT+TT 20 58
*p<0.008 (bold font); #p<0.05 (italics) (significant without Bonferroni correction); a Chi-square p-value; b power (1-β)
calculated using the Fisher’s exact test for two independent proportions; OR: Odds ratio; CI: confidence interval for the
OR
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Supplementary Table S4: Association of DAO, DAOA and NRG1 SNPs with APSS (n=98)
compared to all other help-seeking group (n=87) at baseline and power analysis
Gene SNPID
Minor
allele Model
Genotype/
allele
Phenotype
OR 95% CI p-value Power
bAPSS
(N)
Help-
seeking (N)
D
-a
m
in
o
ac
id
ox
id
as
e
(D
A
O
) r
s3
91
83
47
G
Genotypic
GG 11 5
- - 0.053a -GA 37 26
AA 33 45
Allelic G 59 36 1.84 1.13-3.01 0.01# 0.76A 103 116
Dominant GG+GA 48 31 2.11 1.12-3.99 0.02# 0.63AA 33 45
Recessive GG 11 5 2.23 0.74-6.75 0.16 0.69GA+AA 70 71
rs
46
23
95
1
C
Genotypic
CC 7 7
- - 0.99a -CT 43 40
TT 31 29
Allelic C 57 54 0.99 0.62-1.57 0.95 0.05T 105 98
Dominant CC+CT 50 47 1.00 0.52-1.90 0.99 0.05TT 31 29
Recessive CC 7 7 0.93 0.31-2.80 0.90 0.06CT+TT 74 69
D
-a
m
in
o
ac
id
ox
id
as
e
ac
ti
va
to
r
(D
A
O
A
)
rs
39
16
97
1
T
Genotypic
TT 17 19
- - 0.79a -TC 33 32
CC 31 26
Allelic T 67 70 0.85 0.54-1.32 0.46 0.11C 95 84
Dominant TT+TC 50 51 0.82 0.43-1.58 0.56 0.09CC 31 26
Recessive TT 17 19 0.82 0.39-1.71 0.58 0.09TC+CC 64 58
rs
77
82
93
G
Genotypic
GG 17 17
- - 0.88a -GA 34 35
AA 29 25
Allelic G 68 69 0.91 0.58-1.42 0.68 0.07A 92 85
Dominant GG+GA 51 52 0.85 0.44-1.64 0.62 0.09AA 29 25
Recessive GG 17 17 0.95 0.45-2.04 0.90 0.05GA+AA 63 60
rs
74
61
87
C
Genotypic
CC 10 14
- - 0.57a -CT 39 34
TT 32 28
Allelic C 59 62 0.83 0.53-1.31 0.43 0.13T 103 90
Dominant CC+CT 49 48 0.89 0.47-1.70 0.73 0.07TT 32 28
Recessive CC 10 14 0.62 0.26-1.50 0.29 0.33CT+TT 71 62
N
eu
re
gu
lin
1
(N
R
G
1)
rs
10
50
39
29
C
Genotypic
CC 3 1
- - 0.19a -CT 33 23
TT 45 53
Allelic C 39 25 1.64 0.93-2.86 0.08 0.60T 123 129
Dominant CC+CT 36 24 1.77 0.92-3.39 0.09 0.42TT 45 53
Recessive CC 3 1 2.92 0.30-28.7 0.36 0.89CT+TT 78 76
*p<0.008 (bold font); #p<0.05 (italics) (significant without Bonferroni correction); a Chi-square p-value; b power (1-β)
calculated using the Fisher’s exact test for two independent proportions; OR: Odds ratio; CI: confidence interval for the
OR
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Supplementary Table S5: Differences in RDoC domain negative valence systems: threat (acute
and sustained) and loss across DAO, DAOA and NRG1 SNPs
Gene SNPID M
od
el
G
en
ot
yp
es Negative valence systems
Threat (sum of BAI scale) Loss (CDSS: item 2)
Baseline LA Baseline LA
N Mean±SEM
p-
valuea N
Mean
SEM p-valuea N
Mean±
SEM
p-
valuea N
Mean±
SEM
p-
valuea
D
-a
m
in
o
ac
id
ox
id
as
e
(D
A
O
)
rs
39
18
34
7 G
GG 16 16.3±1.8
0.48
12 15.8±6.9
0.84
18 1.1±0.2
0.47
14 0.64±0.3
0.73GA 57 19.4±1.5 46 11.8±1.5 59 0.97±0.1 48 0.69±0.1
AA 67 20.7±1.5 62 11.8±1.5 78 1.1±0.1 67 0.64±0.1
D GG+GA 73 18.71.2 0.42 58 12.7±1.8 0.71 77 0.99±0.1 0.34 62 0.68±0.1 0.62AA 67 20.7±1.5 62 11.8±1.5 78 1.1±0.1 67 0.64±0.1
R GG 16 16.3±1.8 0.26 12 15.8±6.9 0.77 18 1.1±0.2 0.72 14 0.64±0.3 0.69GA+AA 124 20.1±1.1 108 11.8±1.1 137 1.1±0.1 115 0.66±0.1
rs
46
23
95
1 G
CC 13 24.0±3.6
0.23
15 13.5±3.4
0.5
15 1.1±0.1
0.45
15 0.67±0.2
0.95CT 76 20.2±1.3 64 13.6±1.9 81 1.2±0.1 69 0.65±0.1
TT 51 17.7±1.5 41 9.5±1.3 59 0.92±0.1 45 0.67±0.1
D CC+CT 89 20.8±1.3 0.16 79 13.6±1.6 0.24 96 1.2±0.1 0.21 84 0.65±0.1 0.77TT 51 17.7±1.5 41 9.5±1.3 59 0.92±0.1 45 0.67±0.1
R CC 13 24.0±3.6 0.19 15 13.5±3.4 0.74 15 1.1±0.1 0.62 15 0.67±0.2 0.97CT+TT 127 19.2±1.0 105 12.0±1.3 140 1.1±0.1 114 0.66±0.1
D
-a
m
in
o
ac
id
ox
id
as
e
ac
ti
va
to
r
(D
A
O
A
)
rs
39
16
97
1 G
TT 31 20.5±2.0
0.68
24 17.3±4.0
0.47
36 1.1±0.2
0.63
31 0.61±0.2
0.65TC 62 20.0±1.4 50 11.4±1.6 67 0.97±0.1 52 0.60±0.1
CC 47 18.7±1.8 46 10.4±1.3 52 1.2±0.1 46 0.76±0.1
D TT+TC 93 20.2±1.1 0.38 74 13.3±1.7 0.69 103 1.0±0.1 0.40 83 0.60±0.1 0.37CC 47 18.7±1.8 46 10.4±1.3 52 1.2±0.1 46 0.76±0.1
R TT 31 20.5±2.0 0.78 24 17.3±4.0 0.22 36 1.1±0.2 0.93 31 0.61±0.2 0.87TC+CC 109 19.4±1.1 96 10.9±1.0 119 1.1±0.1 98 0.67±0.1
rs
77
82
93
G
GG 32 20.9±2.2
0.82
24 18.1±3.9
0.21
35 1.1±0.2
0.35
28 0.89±0.2
0.28GA 60 19.1±1.3 49 10.4±1.5 68 0.94±0.1 53 0.51±0.1
AA 48 19.6±1.8 47 11.0±1.5 52 1.2±0.1 48 0.69±0.1
D GG+GA 92 19.7±1.2 0.86 73 13.0±1.7 0.66 103 0.99±0.1 0.25 81 0.64±0.1 0.6AA 48 19.6±1.8 47 11.0±1.5 52 1.2±0.1 48 0.69±0.1
R GG 32 20.9±2.2 0.54 24 18.1±3.9 0.08 35 1.1±0.2 0.71 28 0.89±0.2 0.24GA+AA 108 20.9±2.2 96 10.7±1.1 120 1.1±0.1 101 0.59±0.1
rs
74
61
87
G
CC 21 19.9±3.2
0.11
20 10.7±2.2
0.38
24 1.4±0.2
0.04#
21 1.05±0.2
0.11CT 64 21.3±1.3 56 13.6±1.9 72 0.88±0.1 61 0.54±0.1
TT 55 17.7±1.5 44 11.2±1.9 59 1.2±0.1 47 0.64±0.1
D CC+CT 85 20.9±1.3 0.07 76 12.8±1.5 0.22 96 1.0±0.1 0.40 82 0.67±0.1 0.91TT 55 17.7±1.5 44 11.2±1.9 59 1.2±0.1 47 0.64±0.1
R CC 21 19.9±3.2 0.68 20 10.7±2.2 0.86 24 1.4±0.2 0.052 21 1.05±0.2 0.04#CT+TT 119 19.6±1.0 100 12.5±1.3 131 1.0±0.1 108 0.58±0.1
N
eu
re
gu
lin
1
(N
R
G
1)
rs
10
50
39
29 G
CC 5 14.0±5.6
0.47
4 16.5±7.3
0.53
5 0.6±0.4
0.37
5 0.80±0.6
0.82CT 46 20.9±1.8 42 13.4±1.9 51 1.2±0.1 44 0.55±0.1
TT 89 19.3±1.2 74 11.3±1.5 99 1.0±0.1 80 0.71±0.1
D CC+CT 51 20.2±1.7 0.81 46 13.7±1.8 0.31 56 1.1±0.1 0.65 49 0.57±0.1 0.54TT 89 19.3±1.2 74 11.3±1.5 99 1.0±0.1 80 0.71±0.1
R CC 5 14.0±5.6 0.27 4 16.5±7.3 0.49 5 0.6±0.4 0.23 5 0.80±0.6 0.99CT+TT 135 19.9±1.0 116 12.1±1.2 150 1.1±0.1 124 0.65±0.1
a p-value by Kruskal-Wallis test for genotypic model and Mann-Whitney test for dominant and recessive models;
*p<0.008 (bold font); # 0.008<p<0.05 (italics) (significant without Bonferroni correction); G: genotypic model; D:
dominant model; R: recessive model; LA: last-available follow-up data until 36 months; BAI: Beck Anxiety Inventory;
CDSS: Calgary Depression Rating scale for Schizophrenia; SEM: standard error of the mean
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Supplementary Table S6: Differences in RDoC domain cognitive systems: visual and auditory
perception across DAO, DAOA and NRG1 SNPs
Gene SNPID M
od
el
G
en
ot
yp
es
Cognitive systems
Visual perception
(SPI-A O4+F1+F2+F3)
Auditory perception
(SPI-A O5+F4+F5)
Baseline LA Baseline LA
N Mean±SEM
p-
valuea N
Mean±
SEM
p-
valuea N
Mean±
SEM
p-
valuea N
Mean±
SEM
p-
valuea
D
-a
m
in
o
ac
id
ox
id
as
e
(D
A
O
)
rs
39
18
34
7 G
GG 9 3.1±1.4
0.4
8 1.1±0.1
0.31
18 2.3±0.7
0.13
14 1.8±0.7
0.34GA 37 3.6±0.5 34 2.4±0.4 52 3.8±0.5 42 2.0±0.4
AA 45 3.5±0.6 43 2.3±0.5 72 4.1±0.5 60 2.5±0.4
D GG+GA 46 3.5±0.5 0.57 42 2.1±0.3 0.54 70 3.4±0.4 0.33 56 1.9±0.3 0.27AA 45 3.5±0.6 43 2.3±0.5 72 4.1±0.5 60 2.5±0.4
R GG 9 3.1±1.4 0.32 8 1.1±0.1 0.26 18 2.3±0.7 0.04# 14 1.8±0.7 0.19GA+AA 82 3.6±0.4 77 2.4±0.3 124 4.0±0.4 102 2.3±0.3
rs
46
23
95
1 G
CC 8 5.3±1.3
0.15
9 4.1±1.7
0.30
13 5.2±1.1
0.15
13 3.0±0.9
0.20CT 50 3.4±0.5 49 2.2±0.4 76 3.6±0.4 65 2.3±0.3
TT 33 3.3±0.6 27 1.7±0.3 53 3.7±0.6 38 1.8±0.4
D CC+CT 58 3.7±0.5 0.44 58 2.5±0.4 0.48 89 3.8±0.4 0.18 78 2.4±0.3 0.13TT 33 3.3±0.6 27 1.7±0.3 53 3.7±0.6 38 1.8±0.4
R CC 8 5.3±1.3 0.053 9 4.1±1.7 0.13 13 5.2±1.1 0.09 13 3.0±0.9 0.19CT+TT 83 3.4±0.4 76 2.0±0.3 129 3.6±0.3 103 2.1±0.3
D
-a
m
in
o
ac
id
ox
id
as
e
ac
ti
va
to
r
(D
A
O
A
)
rs
39
16
97
1 G
TT 26 4.1±0.8
0.09
22 2.9±0.6
0.02#
32 3.6±0.5
0.36
26 1.8±0.4
0.96TC 35 2.2±0.3 32 1.9±0.5 61 4.2±0.6 46 2.5±0.5
CC 30 4.6±0.8 31 2.1±0.5 49 3.3±0.6 44 2.1±0.3
D TT+TC 61 3.0±0.4 0.17 54 2.3±0.4 0.73 93 4.0±0.4 0.15 72 2.3±0.4 0.77CC 30 4.6±0.8 31 2.1±0.5 49 3.3±0.6 44 2.1±0.3
R TT 26 4.1±0.8 0.36 22 2.9±0.6 0.009# 32 3.6±0.5 0.55 26 1.8±0.4 0.95TC+CC 65 3.3±0.4 63 2.0±0.4 110 3.8±0.4 90 2.3±0.3
rs
77
82
93
G
GG 25 3.9±0.8
0.21
17 1.9±0.4
0.18
32 3.3±0.6
0.93
22 2.1±0.5
0.77GA 39 2.9±0.5 35 2.8±0.6 61 3.7±0.5 47 2.0±0.4
AA 27 4.0±0.7 33 1.8±0.4 49 4.1±0.6 47 2.5±0.5
D GG+GA 64 3.3±0.4 0.17 52 2.5±0.4 0.07 93 3.6±0.4 0.75 69 2.0±0.3 0.54AA 27 4.0±0.7 33 1.8±0.4 49 4.1±0.6 47 2.5±0.5
R GG 25 3.9±0.8 0.62 17 1.9±0.4 0.49 32 3.3±0.6 0.76 22 2.1±0.5 0.91GA+AA 66 3.4±0.4 68 2.3±0.4 110 3.9±0.4 94 2.2±0.3
rs
74
61
87
G
CC 15 2.1±0.6
0.15
15 2.3±0.9
0.95
22 4.2±1.0
0.37
20 3.4±1.0
0.26CT 38 3.6±0.6 36 2.0±0.3 67 3.3±0.4 52 2.0±0.3
TT 38 4.0±0.6 34 2.4±0.6 53 4.2±0.6 44 2.0±0.3
D CC+CT 53 3.2±0.5 0.27 51 2.1±0.4 0.74 89 3.5±0.4 0.32 72 2.3±0.4 0.89TT 38 4.0±0.6 34 2.4±0.6 53 4.2±0.6 44 2.0±0.3
R CC 15 2.1±0.6 0.06 15 2.3±0.9 0.87 22 4.2±1.0 0.55 20 3.4±1.0 0.12CT+TT 76 3.8±0.4 70 2.2±0.3 120 3.7±0.4 96 2.0±0.2
N
eu
re
gu
lin
1
(N
R
G
1)
rs
10
50
39
29 G
CC 2 2.5±1.5
0.64
2 1.0±0.0
0.20
5 1.0±0.5
0.17
4 0.8±0.3
0.30CT 28 3.8±0.6 28 2.3±0.4 44 3.8±0.5 41 2.5±0.4
TT 61 3.4±0.5 55 2.3±0.4 93 3.9±0.4 71 2.1±0.3
D CC+CT 30 3.7±0.6 0.4 30 2.2±0.4 0.16 49 3.5±0.5 0.80 45 2.4±0.4 0.69TT 61 3.4±0.5 55 2.3±0.4 93 3.9±0.4 71 2.1±0.3
R CC 2 2.5±1.5 0.81 2 1.0±0.0 0.40 5 1.0±0.5 0.06 4 0.8±0.3 0.17CT+TT 89 3.6±0.4 83 2.3±0.3 137 3.9±0.3 112 2.3±0.3
a p-value by Kruskal-Wallis test for genotypic model and Mann-Whitney test for dominant and recessive models;
*p<0.008 (bold font); # 0.008<p<0.05 (italics) (significant without Bonferroni correction); G: genotypic model; D:
dominant model; R: recessive model; LA: last-available follow-up data until 36 months; BAI: Beck Anxiety Inventory;
CDSS: Calgary Depression Rating scale for Schizophrenia; SEM: standard error of the mean
139
Study III: Supplementary Information
Supplementary Table S7: Differences in RDoC domain cognitive system: cognitive control across
DAO, DAOA and NRG1 SNPs
Gene SNP ID Model Genotypes
Cognitive systems
Cognitive control (SIPS: sum of D1-D4)
Baseline LA
N Mean±SEM
p-
valuea N
Mean±
SEM
p-
valuea
D-amino acid
oxidase (DAO)
rs3918347
G
GG 18 4.8±0.9
0.59
14 2.2±0.5
0.95GA 58 4.5±0.4 49 2.4±0.4
AA 79 4.1±0.3 65 2.2±0.3
D GG+GA 76 4.6±0.4 0.32 63 2.3±0.3 0.75AA 79 4.1±0.3 65 2.2±0.3
R GG 18 4.8±0.9 0.90 14 2.2±0.5 0.85GA+AA 137 4.3±0.2 114 2.3±0.2
rs4623951
G
CC 15 3.9±0.9
0.65
15 1.9±0.6
0.52CT 81 4.4±0.3 69 2.6±0.3
TT 59 4.4±0.4 44 2.0±0.3
D CC+CT 96 4.3±0.3 0.56 84 2.4±0.3 0.73TT 59 4.4±0.4 44 2.0±0.3
R CC 15 3.9±0.9 0.40 15 1.9±0.6 0.34CT+TT 140 4.4±0.3 113 2.3±0.2
D-amino acid
oxidase activator
(DAOA)
rs3916971
G
TT 36 3.7±0.5
0.43
29 2.6±0.5
0.70TC 67 4.6±0.4 53 2.1±0.3
CC 52 4.4±0.4 46 2.4±0.4
D TT+TC 103 4.3±0.3 0.67 82 2.2±0.3 0.91CC 52 4.4±0.4 46 2.4±0.4
R TT 36 3.7±0.5 0.19 29 2.6±0.5 0.41TC+CC 119 4.5±0.3 99 2.2±0.2
rs778293
G
GG 35 3.8±0.5
0.49
28 2.7±0.5
0.32GA 68 4.7±0.4 52 2.4±0.4
AA 52 4.2±0.4 48 1.9±0.3
D GG+GA 103 4.4±0.3 0.90 80 2.5±0.3 0.19AA 52 4.2±0.4 48 1.9±0.3
R GG 35 3.8±0.5 0.25 28 2.7±0.5 0.22GA+AA 120 4.5±0.3 100 2.2±0.2
rs746187
G
CC 24 3.4±0.6
0.22
21 3.0±0.6
0.61CT 73 4.6±0.4 59 2.1±0.3
TT 58 4.3±0.4 48 2.2±0.4
D CC+CT 97 4.3±0.3 0.60 80 2.4±0.3 0.45TT 58 4.3±0.4 48 2.2±0.4
R CC 24 3.4±0.6 0.08 21 3.0±0.6 0.38CT+TT 131 4.5±0.3 107 2.2±0.2
Neuregulin 1
(NRG1) rs10503929
G
CC 5 5.4±2.1
0.003*
5 2.6±1.0
0.33CT 50 5.5±0.5 44 2.5±0.3
TT 100 3.7±0.3 79 2.2±0.3
D CC+CT 55 5.5±0.5 0.001* 49 2.5±0.3 0.14TT 100 3.7±0.3 79 2.2±0.3
R CC 5 5.4±2.1 0.71 5 2.6±1.0 0.67CT+TT 150 4.3±0.2 123 2.3±0.2
a p-value by Kruskal-Wallis test for genotypic model and Mann-Whitney test for dominant and recessive models;
*p<0.008 (bold font); # 0.008<p<0.05 (italics) (significant without Bonferroni correction); G: genotypic model; D:
dominant model; R: recessive model; LA: last-available follow-up data until 36 months; BAI: Beck Anxiety Inventory;
CDSS: Calgary Depression Rating scale for Schizophrenia; SEM: standard error of the mean
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Supplementary Table S9: Correlation between NRG1 gene expression and RDoC domains at
baseline and 36 months
RDoC domains RDoC construct (scale) Time-point
NRG1 gene expression
N Spearmans rankcorrelation co-efficient p-value
Negative valence
systems
Threat
(sum of BAI scale)
Baseline 168 0.133 0.085
LA 135 0.049 0.575
Loss
(CDSS: item 2)
Baseline 181 -0.057 0.444
LA 146 0.196 0.018*
Cognitive
systems
Visual perception
(SPI-A O4+F1+F2+F3)
Baseline 114 -0.012 0.901
LA 103 -0.099 0.318
Auditory perception
(SPI-A O5+F4+F5)
Baseline 167 0.004 0.963
LA 132 -0.046 0.598
Cognitive control
(SIPS: sum of D1-D4)
Baseline 182 0.051 0.491
LA 145 0.106 0.203
*p<0.05 (bold font); LA: last-available follow-up data until 36 months; RDoC: Research Domain Criteria; BAI: Beck
Anxiety Inventory; CDSS: Calgary Depression Rating scale for Schizophrenia; SPI-A: Schizophrenia Proneness
Instrument-Adult version (≥18 years); SPI-CY: Schizophrenia Proneness Instrument-Child and Youth version (<18
years); SIPS: Structured Interview for Prodromal Symptoms
Supplementary Table S10: NRG1 gene expression in peripheral whole blood across different
phenotypes and power analysis
Clinical phenotypes NRG1 gene expression Effect sizea PoweraN Mean±SEM Mann-Whitney p-value
Converters 23 1.41±0.27 0.892 0.16 0.10Non-converters 58 1.25±0.11
APSS 80 1.36±0.12 0.650 0.16 0.17All other help-seeking 76 1.21±0.09
*p<0.05 (bold font); a t-test; APSS: attenuated positive symptoms syndrome; HR: high risk for psychosis; UHR:
ultra-high risk for psychosis
Supplementary Table S11: NRG1 gene expression in peripheral whole blood across NRG1 SNP
genotypes and models
NRG1 SNP ID NRG1 mRNA expression
Genotypes N Mean±SEM
K-W
p-value Dom model N
Mean±
SEM
M-W
p-value Rec model N
Mean±
SEM
M-W
p-value
rs10503929
CC 7 0.99± 0.15
0.975 CC+ CT 67 1.25± 0.12 0.848
CC 7 0.99± 0.15
0.868CT 60 1.28± 0.14 CT+ TT 165 1.22± 0.07TT 105 1.19± 0.07 TT 105 1.19± 0.07
*p<0.05 (bold font); K-W p-value: Kruskal-Wallis p-value; M-W p-value: Mann-Whitney p-value; Dom model:
dominant model; Rec model: recessive model
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5.4.1 Abstract
Dysfunction of D-amino acid oxidase (DAO) and DAO activator (DAOA)/G72
genes have been linked to neuropsychiatric disorders. The glutamate hypothesis
of schizophrenia has proposed that increased DAO activity leads to decreased
D-serine, which subsequently may lead to N-methyl-D-aspartate (NMDA)
receptor hypofunction. It has been shown that DAOA binds to DAO and
increases its activity. However, there are also studies showing DAOA decreases
DAO activity. Thus, the effect of DAOA on DAO is controversial. We aimed
to understand the effect of DAOA on DAO activity in neuron-like (SH-SY5Y),
astrocyte-like (1321N1), and kidney-like (HEK293) human cell lines. DAO
activity was measured based on the release of hydrogen peroxide and its
interaction with Amplex Red reagent. We found that DAOA increases DAO
activity only in HEK293 cells, but has no effect on DAO activity in SH-SY5Y and
1321N1 cells. This might be because of different signaling pathways, or due to
lower DAO and DAOA expression in SH-SY5Y and 1321N1 cells compared to
HEK293 cells, but also due to different compartmentalization of the proteins. The
lower DAO and DAOA expression in neuron-like SH-SY5Y and astrocyte-like
1321N1 cells might be due to tightly regulated expression, as previously
reported in the human post-mortem brain. Our simulation experiments to
demonstrate the interaction between DAOA and human DAO (hDAO) showed
that hDAO holoenzyme [hDAO with flavine adenine dinucleotide (FAD)]
becomes more flexible and misfolded in the presence of DAOA, whereas DAOA
had no effect on hDAO apoprotein (hDAO without FAD), which indicate that
DAOA inactivates hDAO holoenzyme. Furthermore, patch-clamp analysis
demonstrated no effect of DAOA on NMDA receptor activity in NR1/NR2A
HEK293 cells. In summary, the interaction between DAO and DAOA seems to
be cell type and its biochemical characteristics dependent which still needs to be
elucidated.
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5.4.2 Introduction
The human D-amino acid oxidase (DAO/DAAO) gene is located at chromosome
12q24, and encodes for a ∼39 kDa protein of 347 amino acids (Verrall et al.,
2010). The human DAO activator (DAOA)/G72 gene is a primate specific gene
located at chromosome 13q33, and encodes for a ∼20 kDa protein of 153 amino
acids (Benzel et al., 2008). Previous studies have shown evidence for significant
association of nucleotide variations at DAO and DAOA locus with schizophrenia
and bipolar disorder (Detera-Wadleigh and McMahon, 2006; Allen et al., 2008;
Prata et al., 2008; Gatt et al., 2015). Although the effects of these DAO and DAOA
nucleotide variations on their mRNA and protein expression in schizophrenia is
not yet studied, these genes still remain as candidate genes for schizophrenia
because of their role in the glutamatergic signaling.
DAO is a peroxisomal flavoenzyme. It catalyzes the oxidation of D-amino
acids through concomitant reduction of flavine adenine dinucleotide (FAD),
producing corresponding imino acid, which is then hydrolyzed to yield
ammonia and corresponding α-keto acid. During FAD reoxidation, hydrogen
peroxide is produced (Verrall et al., 2010). FAD binding is weaker in human
DAO (hDAO) compared to DAO from other species, which provides hDAO a
potential means to regulate DAO activity (Caldinelli et al., 2009). DAO protein
and enzymatic activity is present mainly in the human kidney, liver, and brain
(Sasabe et al., 2014; Uhle´n et al., 2015; Jagannath et al., 2017b). In the human
brain, its main substrate is D-serine (Pollegioni et al., 2007; Sacchi et al., 2012).
D-serine serves as a co-agonist at the glycine site of the N-methyl-D-aspartate
(NMDA) receptor. NMDA receptors are glutamate ionotropic receptors which
require both glutamate and co-agonist (D-serine or glycine) to function normally
(Panatier et al., 2006; Henneberger et al., 2010; Papouin et al., 2012). Thus, DAO
can regulate the function of NMDA receptors via D-serine breakdown.
The glutamate hypothesis of schizophrenia is based on the NMDA receptor
hypofunction (Stahl et al., 2007). One possible explanation for NMDA receptor
hypofunction theory proposed in schizophrenia is increased DAO activity
leading to decreased D-serine which subsequently causes hypofunction of
the NMDA receptors. Chumakov and colleagues showed that DAOA binds
to DAO and increases its activity (Chumakov et al., 2002). However, Sacchi
and colleagues showed that DAOA binds to DAO and decreases its activity
(Sacchi et al., 2008). Furthermore, Kvajo and colleagues showed that there
was no interaction between DAO and DAOA (Kvajo et al., 2008). Thus, the
effect of DAOA on DAO is controversial, and yet to be elucidated. Previous
in vitro studies have shown that DAOA localizes in mitochondria and causes
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mitochondrial dysfunction (Kvajo et al., 2008; Sacchi et al., 2011; Otte et al.,
2014). Thus, the exact function of DAOA is not yet completely understood. Since
the microscopic interactions between DAO and DAOA may play an additional
role in DAO activation, in silico molecular dynamics simulations may contribute
in understanding the role of DAOA on DAO activity. Thus, this approach
may contribute to the in vitro insight into the nature and interactions between
these two proteins. In particular, we performed simulations of different DAO
(apoprotein, holoenzyme) forms with and without DAOA, and studied the
stability of DAO in terms of its flexibility, thus verifying one of the above DAO
and DAOA interaction hypotheses.
DAO and DAOA proteins are detected in the human brain with brain region
specificity which is tightly regulated (Jagannath et al., 2017b). DAO has been
shown to interact with DAOA in glial cells (Sacchi et al., 2016). However, DAO is
not solely glial, but it has been reported to be also expressed in neurons (Verrall
et al., 2010). In our study, we used neuron-like SH-SY5Y, astrocyte-like 1321N1,
and kidney-like HEK293 cells to understand the interaction between DAO and
DAOA proteins. We overexpressed DAO and DAOA in these human cell lines
because of the lower endogenous expression of DAO and DAOA mRNA in these
cells (Uhle´n et al., 2015; Rouillard et al., 2016).
Since the interaction between DAO and DAOA is still not clear, we aimed (1) to
understand the effect of DAOA on DAO activity in different types of human cell
lines and (2) to understand the effect of DAOA on NMDA receptor activity in
human cell lines.
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5.4.3 Materials and methods
Cell culture
The human embryonic kidney HEK293 cell line (85120602, Sigma-Aldrich) and
human astrocytoma 1321N1 cell line (86030402, Sigma-Aldrich) were cultured in
Dulbecco’s Modified Eagle Medium (DMEM; 41966029, ThermoFisher scientific)
containing 10% fetal bovine serum (FBS; 10270106, ThermoFisher scientific),
and incubated at 37◦C in a humidified atmosphere of 5% CO2. The human
neuroblastoma SH-SY5Y cell line (CRL-2266, ATCC) was cultured in a 1:1
mixture of DMEM and DMEM/F12 (D8437, Sigma-Aldrich) supplemented with
10% FBS, and incubated at 37◦C in a humidified atmosphere of 5% CO2.
Transient transfection
The human LG72 cDNA (GenBank sequence: AY138546) cloned into the
pEGFPN1 vector was a generous gift from the Institute of Molecular Psychiatry,
University of Bonn, Germany (Otte et al., 2011), and the pEGFPN1 construct
(Takara Clontech) was used as a control plasmid. The human DAO cDNA
(GenBank sequence: BC029057) cloned into pCMV3-c-Myc vector (HG13372-CM,
Sino Biological) and the pCMV3-c-Myc vector (CV014, Sino Biological) were
used for transfection. For all experiments except cell viability, HEK293, 1321N1,
and SH-SY5Y cells were seeded into 6-well plates (3335, Corning) at a density
of 2x105 cells, 5x105, and 1x106 cells in 1 mL growth medium, respectively. The
cells were allowed to adhere for 24 hours. The cells were transfected with 5 µg
of above-mentioned plasmids using Xfect transfection reagent (631317, Takara
Clontech) according to manufacturer’s guidelines. The growth medium was
exchanged 4 hours after transfection. For all experiments, cells were incubated
for 48 hours following transfection.
DAO activity assay
In order to evaluate whether DAOA affects DAO activity, DAO activity
was determined based on the estimation of hydrogen peroxide formation as
previously described (Sikka et al., 2010). The transfected cells were harvested
with 0.05% Trypsin-EDTA (25300054, ThermoFisher Scientific) solution,
transferred to a 15 mL falcon tube, and centrifuged for 5 minutes at 12,000
xg. The cell pellets were homogenized in 100 µL of cold sodium phosphate
buffer (50 mM Na2HPO4, pH 7.4) with 5 mm stainless steel beads (69989,
Qiagen) using the TissueLyser II (Qiagen). In a 384-well optical-bottom
plate (142761, ThermoFisher Scientific), 10 µL of homogenate was added to a
solution of 100 µM Amplex red (A36006, ThermoFisher Scientific), 0.25 U/mL
horseradish peroxidase (10108090001, Sigma-Aldrich), 50 mM D-serine (S4250,
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Sigma-Aldrich), and with or without 10 µM FAD (F6625, Sigma-Aldrich) in a
total volume of 20 µl of sodium phosphate buffer. After 1 hour of incubation at
37◦C, the fluorescence was measured with a Mithras2 LB 943 Multimode Reader
(Berthold technologies) using 544 nm excitation (slit 22 nm) and 590 nm emission
(slit 20 nm) filters. On each plate, we included 3 controls namely, a control
without cell homogenate, a control without D-serine, and a control inhibiting
DAO activity with a DAO inhibitor, 100 µM 6-methyl-benzo[d]isoxazol-3-ol
(027-640-512, MolPort). The fluorescence values of cell homogenates were
calculated by subtracting their fluorescence values from fluorescence values
of control without D-serine. As the wells transfected with control plasmids
(pCMV3-c-Myc and pEGFPN1) showed fluorescence similar to the control
without D-serine, fluorescence values of cells transfected with LG72 and DAO
plasmids were used for analysis.
Cell viability assay
We evaluated cell viability to make sure that the results obtained for DAO activity
were not biased by the sensitivity to different cell lines to transfection. The
viability of transfected cells was determined using CellTiter 96 R© AQueous One
Solution Cell Proliferation Assay (G3582, Promega) according to manufacturer’s
guidelines. HEK293, 1321N1, and SH-SY5Y cells were seeded into 96-well
plates (83.3925, Sarstedt) at a density of 2x104 cells, 5x104, and 1x105 cells in 100
µL growth medium, respectively. They were allowed to adhere for 24 hours
and were transfected with 1.2 µg of plasmids using Xfect transfection reagent
(631317, Takara Clontech) according to manufacturers guidelines. The growth
medium was exchanged 4 hours after transfection. Each transfection condition
was analyzed in triplicates. The cells were incubated for 48 hours following
transfection. Then, 20 µl of CellTiter 96 R© AQueous One Solution Reagent
was added to each well and incubated at 37◦C for 4 hours. The absorbance
was measured at 490 nm using Mithras2 LB 943 Multimode Reader (Berthold
technologies). The absorbance values were corrected by subtracting the average
absorbance from the control wells with no cells.
Simulation setup for hDAO and DAOA interactions
In this work, Molecular Dynamics (MD) simulations were performed. All
MD simulations were carried out using the GROMACS software (Abraham
et al., 2015). In all simulations, the AMBER-14SB and the TIP3P forcefields
(Jorgensen et al., 1983; Maier et al., 2015) were used for the protein and water,
respectively. The simulated conditions were ambient, at a constant temperature
of 300 K, pressure of 1 atm and concentration (NPT ensemble). The simulated
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systems were: hDAO without FAD in water, FAD/hDAO complex in water,
FAD/hDAO/DAOA complex in water, and hDAO/DAOA complex in water.
hDAO without FAD (apoprotein): The hDAO monomer structure was extracted
from the dimer protein data bank (PDB) structure of hDAO (PDB: 2E48), and the
FAD ligand was removed.
FAD/hDAO (holoenzyme) complex: The structure of this complex was obtained
by extracting the hDAO monomer structure from the dimer PDB structure
of hDAO while retaining the FAD ligand. The topology of the complex was
obtained using the AMBER tools and the AMBER-14SB forcefield, after having
created the FAD topology. The FAD topology was obtained using the gaff
forcefield, followed by a geometry optimization using Gaussian package and
the B3LYP/6-31G, constructing the electrostatic potential surface and assigning
charges to atoms using RESP (Bayly et al., 1993).
FAD/hDAO/DAOA complex: The structure of this complex was obtained by
using the patchdock docking server (Schneidman-Duhovny et al., 2005), and
adding constraints on the dimer interface so that DAOA residues 138, 139, 140,
141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153 were within 0.4
nm of any amino acids within 1 nm of hDAO amino acids 37, 138, 163, 185,
188, 191, 193, 194, 195, 196. These contacts have been found to occur in the
hDAO-DAOA complex (Chang et al., 2013). As mentioned earlier, building the
FAD topology and using AMBER tools to combine the topology of FAD, hDAO
and G72 protein, the final complexes topology was obtained. Simulations were
performed using the structure of the best binding pose.
hDAO/DAOA complex: The procedure for constructing the structure of this
complex was the same as the above ones, except the topology of the complex
was obtained by using the AMBER tools for complex’s structure.
DAOA protein: Since there was no available crystal structure for the human
DAOA protein, we obtained its structure by using homology modelling of the
protein sequence with accession number AAN08432. The homology modelling
was performed using the I-TAISER server (Yang and Zhang, 2015). The best
predicted homolog structure was used as the DAOA protein.
NMDA receptor currents using whole-cell patch clamp recording
HEK293 cells stably expressing NMDA receptor subunits NR1 and NR2A
(NR1/NR2A HEK293 cells; B’SYS, Switzerland) were used. They were
cultured in DMEM/F12 (D8437, Sigma-Aldrich) supplemented with 10% FBS
(RNBF7902, ThermoFisher scientific), 1% penicillin/streptomycin (10378016,
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ThermoFisher scientific), 100 µg/mL hygromycin (10687010, ThermoFisher
scientific), 15 µg/mL blasticidin (A1113903, ThermoFisher scientific), 1 µg/mL
puromycin (A1113803, ThermoFisher scientific), and incubated at 37◦C in a
humidified atmosphere of 5% CO2. The cells (2x105 cells/well) were seeded
onto Poly-L-Lysine (P4832, Sigma-Aldrich) coated coverslips placed in 6-well
plates (92412, TPP) and were allowed to adhere for 24 hours. The cells were
transfected with 5 µg of LG72 and control pEGFPN1 plasmids using Xfect
transfection reagent according to manufacturer’s guidelines. The growth
medium was exchanged 4 hours after transfection. Expression of NR1 and NR2A
subunits in the cells were induced 24 hours after transfection using 2.5 µg/mL
tetracycline (T7660, Sigma-Aldrich) in the presence of 50 µM AP5 (ab120003,
abcam). The whole-cell patch clamp recording was performed 48 hours after
transfection at room temperature using Amplifier EPC-10 and Preamplifier
EPC-10 (both, HEKA Electronics). For recording, the coverslips with transfected
or non-transfected cells were placed in a 35-mm culture dish containing 2 mL
of standard bath solution (137 mM sodium chloride, 4 mM potassium chloride,
1.8 mM calcium chloride, 1 mM magnesium chloride, 10 mM HEPES, 10 mM
D-Glucose, pH 7.4 adjusted with sodium hydroxide). The transfected cells
were identified visually by green florescent protein (GFP) fluorescence signal
using inverted microscope IM (Zeiss). The patch pipettes were filled with
pipette solution (130 mM potassium chloride, 1 mM magnesium chloride, 5 mM
magnesium-ATP, 10 mM HEPES, 5 mM EGTA, pH 7.2 adjusted with potassium
hydroxide). After formation of Gigaohm seal between the patch pipettes and
single cell (pipette resistance range: 2.5 MΩ to 6.0 MΩ; seal resistance range: >1
GΩ), the cell membrane across the pipette tip was ruptured to ensure electrical
access to the cell interior (whole-cell patch configuration). In case of poor seal
quality, the process of seal formation was repeated with a different cell and a new
pipette. As soon as a stable seal was established, magnesium-free bath solution
(137 mM sodium chloride, 4 mM potassium chloride, 2.8 mM calcium chloride,
10 mM HEPES, 10 mM D-Glucose, 0.02% Cremophor, pH 7.4 adjusted with
sodium hydroxide) was perfused and NMDA inward currents were measured
upon application of submaximal concentrations of NMDA (100 µM; M3262,
Sigma-Aldrich)/Glycine (5 µM; 410225, Sigma-Aldrich) to patch-clamped cells
for 4 seconds. If the current was too unstable for measurement, another cell
was recorded. During the entire experiment, the membrane potential of the cell
was clamped at -80 mV. We used only data from cells treated with the complete
application protocol for analysis. At least 5 cells were recorded per condition
and three independent experiments were performed. Data was acquired using
PatchMaster (HEKA Electronics, version v2x73 2) software and analyzed using
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Microsoft Excel 2003 software. The NMDA peak current density was calculated
by dividing means of peak current amplitudes (pA) from at least 5 cells by cell
capacitance (pF). The NMDA mean current density was calculated by dividing
means of steady state current amplitudes (pA) from at least 5 cells by cell
capacitance (pF).
Statistical analysis
The results presented in this study are from at least three independent
experiments. IBM R© SPSS R© Statistics (version 23) software was used for
statistical analysis. Shapiro-Wilk test with Lilliefors significance correction was
used to assess the normality of the distribution of NMDA receptor current,
DAO activity and cell viability data. As the NMDA receptor current data was
normally distributed, we used one-way analysis of variance (ANOVA) followed
by post-hoc Bonferroni test to analyze the difference between the groups, and
p < 0.05 was considered statistically significant. As the DAO activity and cell
viability data was also normally distributed, we used independent-samples
t-test to analyze the difference between two groups, and p < 0.05 was considered
statistically significant. GraphPad Prism software (version 6.01) was used to plot
the graphs.
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5.4.4 Results
DAO activity and cell viability in SH-SY5Y cells
To understand the effect of DAOA on DAO activity, SH-SY5Y cells were
transfected with either DAO plasmid alone or both DAO and G72 plasmids. To
achieve DAO-activity signal in SH-SY5Y cells, the addition of 10 µM FAD was
necessary. There were no significant differences in DAO activity between the
two transfection conditions, namely DAO and G72+DAO (Figure 1A). In order
to verify that the non-significant differences in DAO activity between single
(DAO) and double transfection (G72+DAO) conditions is not due to cell death,
we performed cell viability assay. There were no significant differences in cell
viability between the two transfection conditions (Figure 1B).
Figure 1: DAO activity and cell viability in SH-SY5Y cells. (A) DAO activity with the addition of
10 µM FAD across two transfection conditions: DAO and G72+DAO. (B) Cell viability across two
transfection conditions: DAO and G72+DAO. Data is presented as bar graphs with mean±SEM.
Differences between the two transfection conditions was assessed by the independent-samples
t-test (*p<0.05).
DAO activity and cell viability in 1321N1 cells
To verify the results obtained in SH-SY5Y neuroblastoma cells with neuron-like
phenotype, we retested effects of DAOA on DAO activity in the human 1321N1
cells which have an astrocyte-like phenotype. Again, we single and double
transfected 1321N1 cells with DAO plasmid and both DAO and G72 plasmids,
respectively. In contrast to SH-SY5Y cells, DAO activity assay in 1321N1 cells
worked both with and without addition of 10 µM FAD. We did not find any
significant differences in DAO activity without (Figure 2A) and with (Figure 2B)
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addition of 10 µM FAD between the two transfection conditions as well as no
significant differences in cell viability between the two transfection conditions
(Figure 2C).
Figure 2: DAO activity and cell viability in 1321N1 cells. (A) DAO activity without the addition
of 10 µM FAD across two transfection conditions: DAO and G72+DAO. (B) DAO activity with
the addition of 10 µM FAD across two transfection conditions: DAO and G72+DAO. (C) Cell
viability across two transfection conditions: DAO and G72+DAO. Data is presented as bar
graphs with mean±SEM. Differences between the two transfection conditions was assessed by
the independent-samples t-test (*p<0.05).
DAO activity and cell viability in HEK293 cells
To test the tissue related specificity of the results obtained in neuron-glia like
cell lines, we determined the effect of DAOA on DAO activity also in human
HEK293 cells with kidney epithelium-like phenotype. HEK293 cells were
single and double transfected with DAO plasmid and with both DAO and
G72 plasmids, respectively to understand the effect of DAOA on DAO activity.
Similar to 1321N1 cells, DAO activity assay in HEK293 cells worked with and
without addition of 10 µM FAD. In contrast to SH-SY5Y and 1321N1 cells, DAO
activity without (t=3.024, df=10, p=0.013; Figure 3A) and with (t=5.305, df=10,
p=0.0003; Figure 3B) addition of 10 µM FAD was significantly increased in
double transfected HEK293 cells (G72+DAO) compared to the single transfected
(DAO) HEK293 cells. The cell viability assay was performed to confirm that the
differences in DAO activity are not due to cell death. There were no significant
differences in cell viability between the two transfection conditions (Figure 3C).
Although DAO protein was detected at the expected size of 40 kDa in
pEGFPN1+pCMV3-c-Myc and pCMV3-c-Myc transfection conditions in all three
cell lines (data not shown), we could not detect DAO activity signal in these
transfection conditions which might be because the endogenous DAO enzyme is
in FAD unbound inactive state.
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Figure 3: DAO activity and cell viability in HEK293 cells. (A) DAO activity without the addition
of 10 µM FAD across two transfection conditions: DAO and G72+DAO. (B) DAO activity with
the addition of 10 µM FAD across two transfection conditions: DAO and G72+DAO. (C) Cell
viability across two transfection conditions: DAO and G72+DAO. Data is presented as bar
graphs with mean±SEM. Differences between the two transfection conditions was assessed by
the independent-samples t-test (*p<0.05).
In silico interactions between hDAO and DAOA
In order to understand the effect of DAOA protein on the holoenzyme
(FAD/hDAO) and apoprotein (hDAO without FAD) form of the hDAO,
the fluctuations of the Cα atoms of each amino acid were determined. We
found that there was a slight decrease in FAD/hDAO complex flexibility
compared to hDAO without FAD (Figure 4A). Our simulations show that
upon FAD/hDAO/DAOA complex formation, FAD/hDAO become much
more flexible (Figure 4B) and misfolded (Figure 4C) than FAD/hDAO complex
without DAOA. Contrarily, the apoprotein form of the hDAO when in complex
with DAOA, shows much less flexibility (Figure 4B), and retains its folded
structure (Figure 4D).
NMDA receptor currents in NR1/NR2A HEK293 cells
To understand the effect of DAOA on NMDA receptor activity, NR1/NR2A
HEK293 cells were transfected with G72 plasmid. There were no significant
differences in mean NMDA receptor current (Supplementary Figure S1A)
or in peak NMDA receptor current (Supplementary Figure S1B) between all
three conditions namely, G72 transfected, pEGFPN1 plasmid transfected and
non-transfected.
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Figure 4: Fluctuations and 3D conformations of hDAO holoenzyme and apoprotein complex
with DAOA. Room mean square fluctuations of the Cα atom per amino acid (#AA) of (A) the
hDAO without FAD (red), and the FAD/hDAO complex (green), and (B) the hDAO/DAOA
complex (red) and FAD/hDAO/DAOA complex (green). Note that the amino acid index
0-340 corresponds to the hDAO Cα atoms, whereas the index 341-494 corresponds to the Cα
atoms of DAOA amino acids. 3D conformations taken from Molecular Dynamics simulation of
holoenzyme FAD/hDAO/DAOA complex (C) and apoprotein hDAO/DAOA complex (D) with
hDAO in green colour and DAOA in blue colour.
DAO and DAOA mRNA expression in transfected SH-SY5Y, 1321N1, and
HEK293 cells
In order to verify and compare the expression of endogenous and overexpressed
DAO and DAOA mRNA in transfected SH-SY5Y, 1321N1, and HEK293 cells, we
measured the DAO and DAOA mRNA levels using qRT-PCR. We found that
there were no significant differences in DAO mRNA levels between the double
transfection (G72+DAO) and single transfection (DAO) conditions in SH-SY5Y
and 1321N1 cells, but a significantly lower endogenous DAO mRNA levels
in pEGFPN1+pCMV3-c-Myc and pCMV3-c-Myc transfected compared to the
G72+DAO and DAO transfected SH-SY5Y (F=74.91, df=3, p<0.0001) and 1321N1
cells (F=135.98, df=3, p<0.0001; Figure 5A). There was a significant decrease in
DAO mRNA levels in double transfected (G72+DAO) compared to the single
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transfected (DAO) HEK293 cells (Bonferroni test p=0.001), and endogenous
DAO mRNA levels were significantly lower in pEGFPN1+pCMV3-c-Myc
and pCMV3-c-Myc transfected HEK293 cells compared to G72+DAO and
DAO transfected HEK293 cells (F=182.58, df=3, p<0.0001; Figure 5A). We
found that the endogenous DAOA mRNA levels were significantly lower in
DAO, pEGFPN1+pCMV3-c-Myc, pCMV3-c-Myc transfected than G72+DAO
transfected SH-SY5Y (F=3656.23, df=3, p<0.0001), 1321N1 (F=112.39, df=3,
p<0.0001), and HEK293 cells (F=858.86, df=3, p<0.0001; Figure 5B). There were
significant differences in DAO mRNA levels between the three cell lines in
G72+DAO transfection condition (F=213.76, df=2, p<0.0001; Figure 5C), and
DAO mRNA levels were the highest in HEK293 cells compared to the 1321N1
and SH-SY5Y cells in DAO transfection condition (F=222.68, df=2, p<0.0001;
Figure 5D). We found that there were significant differences in DAOA mRNA
levels between the three cell lines both in G72+DAO (F=164.83, df=2, p<0.0001;
Figure 5E) and DAO (F=56.35, df=2, p<0.0001; Figure 5F) transfection conditions.
DAOA mRNA levels were the highest in HEK293 cells followed by intermediate
levels in 1321N1 cells and low levels in SH-SY5Y cells.
DAO and DAOA protein expression in transfected SH-SY5Y, 1321N1, and
HEK293 cells
To verify and compare the overexpression of DAO and DAOA proteins in
transfected SH-SY5Y, 1321N1, and HEK293 cells, we determined DAO and
DAOA proteins using western blot. DAO protein was detected in all three
cell lines at the expected size of 40 kDa in G72+DAO (Figure 6A) and DAO
(Figure 6E) transfection conditions. DAO protein levels were the highest in
1321N1 cells compared to HEK293 and SH-SY5Y cells in G72+DAO (Figure 6B)
and DAO (Figure 6F) transfection conditions. We detected c-Myc-DAO fusion
protein in all three cell lines at the expected size of 41 kDa in G72+DAO
(Figure 6C) and DAO (Figure 6G) transfection conditions. HEK293 cells had
highest c-Myc-DAO fusion protein levels compared to 1321N1 and SH-SY5Y
cells in G72+DAO (Figure 6D) and DAO (Figure 6H) transfection conditions.
DAOA protein was detected in all three cell lines at the expected size of 18
kDa in G72+DAO (Figure 6I) and DAO (Figure 6M) transfection conditions.
DAOA protein levels were the highest in HEK293 cells compared to 1321N1
and SH-SY5Y cells in G72+DAO (Figure 6J) and DAO (Figure 6N) transfection
conditions. GFP-DAOA fusion protein was detected in all three cell lines at the
expected size of 45 kDa in the double transfection with G72+DAO (Figure 6K),
but not in the single transfection with DAO (Figure 6O and 6P). GFP-DAOA
fusion protein levels were the highest in HEK293 cells compared to 1321N1 and
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SH-SY5Y cells in G72+DAO (Figure 6L) transfection condition.
Figure 5: DAO and DAOA mRNA levels in SH-SY5Y, 1321N1 and HEK293 cells across different
transfection conditions. DAO (A) and DAOA (B) mRNA levels across four transfection conditions:
DAO, G72+DAO, pCMV3-c-Myc, and pEGFPN1+ pCMV3-c-Myc in all three cell lines. DAO
mRNA levels in two transfection conditions: G72+DAO (C) and DAO (D). DAOA mRNA levels
in two transfection conditions: G72+DAO (E) and DAO (F). Data is presented as bar graphs with
mean±SEM. Differences in DAO and DAOA mRNA levels between four transfection conditions,
and also between the three cell lines was assessed by one-way ANOVA followed by post-hoc
Bonferroni test (*p<0.05).
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Figure 6: DAO and DAOA protein levels in SH-SY5Y, 1321N1 and HEK293 cells. Representative
western blot images for DAO protein expression levels in three cell lines across two transfection
conditions: G72+DAO (A) and DAO (E), and DAO protein detected at an expected size of 40
kDa. DAO protein levels (arbitrary units) in three cells lines across two transfection conditions:
G72+DAO (B) and DAO (F). Representative western blot images for c-Myc-DAO fusion protein
expression levels in three cell lines across two transfection conditions: G72+DAO (C) and DAO
(G), and c-Myc-DAO fusion protein detected at an expected size of 41 kDa. c-Myc-DAO protein
levels (arbitrary units) in three cells lines across two transfection conditions: G72+DAO (D) and
DAO (H). Representative western blot images for DAOA protein expression levels in three cell
lines across two transfection conditions: G72+DAO (I) and DAO (M), and DAOA protein detected
at an expected size of 18 kDa. DAOA protein levels (arbitrary units) in three cells lines across
two transfection conditions: G72+DAO (J) and DAO (N). Representative western blot images for
GFP-DAOA fusion protein expression levels in three cell lines across two transfection conditions:
G72+DAO (K) and DAO (O), and GFP-DAOA fusion protein detected at an expected size of
45 kDa. GFP-DAOA protein levels (arbitrary units) in three cells lines across two transfection
conditions: G72+DAO (L) and DAO (P).
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5.4.5 Discussion
DAO and DAOA genes are alleged to be involved in pathophysiology
of neuropsychiatric disorders such as schizophrenia and bipolar disorder
(Detera-Wadleigh and McMahon, 2006; Allen et al., 2008; Prata et al., 2008;
Gatt et al., 2015), but the interactions between these genes remains unclear
to date. There are several lines of evidence in humans suggesting NMDA
receptor hypofunction in the pathophysiology of schizophrenia. Healthy
controls manifested primary symptoms of schizophrenia on administration of
NMDA receptor antagonists such as phencyclidine and ketamine (Anis et al.,
1983; Krystal et al., 1994). Patients with NMDA receptor specific antibodies
were reported to be associated with severe psychosis (Dalmau et al., 2008). A
study revealed reduced expression of obligatory NMDA receptor subunit NR1
in post-mortem brains of schizophrenia patients (Weickert et al., 2013), and
reduced D-serine in cerebrospinal fluid of schizophrenia patients (Hashimoto
et al., 2005). Studies have also shown increased DAO activity in brains of
schizophrenia patients compared to the healthy controls (Kapoor et al., 2006;
Burnet et al., 2008; Madeira et al., 2008). There is only one published study
using single-photon emission computed tomography (SPECT) with NMDA
receptor tracer [123I]CNS-1261 which showed lower NMDA receptor binding
in left hippocampus of schizophrenia patients compared to healthy controls
(Pilowsky et al., 2006), however this finding awaits confirmation. Although, the
aforementioned studies provide evidence for NMDA receptor hypofunction in
schizophrenia, it is still not clear what NMDA receptor hypofunction means at
the molecular level. At present there are no drugs on the market to treat the
negative symptoms and cognitive deficits of schizophrenia, and clinical trials
with DAO inhibitors or D-serine have not shown a conclusive or strong effect in
schizophrenia (Smith et al., 2010). Thus, there is an urgent need for new drugs
for the treatment of negative symptoms and cognitive deficits of schizophrenia,
which might be achieved by understanding the interaction between DAO and
DAOA, and their subsequent effect on NMDA receptors. In this study, we
aimed to understand the interaction between DAO and DAOA by determining
the effect of DAOA on DAO and NMDA receptor activity in different types of
human cell lines.
We chose three human cell lines namely, neuron-like SH-SY5Y, astrocyte-like
1321N1 cells, and kidney-like HEK293 cells to verify and compare the effects
of DAOA on DAO activity. We found that DAOA increases the activity of
DAO only in HEK293 cells, but not in the SH-SY5Y and 1321N1 cells. One
possible reason for this result might be because of different signaling pathways
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in kidney-like HEK293 cells versus neuron-like SH-SY5Y and astrocyte-like
1321N1 cells. Moreover, our previous post-mortem study (Jagannath et al.,
2017b) showed that there is a tight transcriptional regulation in DAO and DAOA
expression in the human brain during development and aging, which might
also be the reason that we found no effect of DAOA on DAO activity in the
neuron-like SH-SY5Y and astrocyte-like 1321N1 cells. Chumakov and colleagues
showed that increasing concentrations of recombinant human DAOA protein
causes porcine DAO activation (Chumakov et al., 2002). In the current study, we
found that HEK293 cells overexpressed DAOA mRNA significantly more than in
SH-SY5Y and 1321N1 cells, which might explain why DAO activity increased
only in HEK293 cells when co-transfected with DAOA. A study conducted
using recombinant hDAO and DAOA proteins isolated from E.coli found that
DAOA increases DAO activity (Chang et al., 2013), but a recent study using
recombinant hDAO and DAOA proteins isolated from E.coli found that DAOA
decreases DAO activity (Birolo et al., 2016). Moreover, another study found that
DAOA even decreases DAO activity in human glioblastoma U87 cell line (Sacchi
et al., 2008). However, following the last result, a study conducted in human
glioblastoma U251 cell line, reported that DAOA has no effect on DAO activity
(Kvajo et al., 2008). All these studies performed the DAO activity assay based
on the detection of hydrogen peroxide released from oxidation of D-amino
acids by the DAO enzyme. The differences in results found in these studies
might be because of substrate, cell lines, and enzymatic reaction temperature
used (see summary in Table 1). Chumakov and colleagues used recombinant
human DAOA but recombinant porcine DAO to perform DAO activity assay
with D-serine as substrate and the enzymatic reaction was performed at 30◦C
(Chumakov et al., 2002). However, two independent research groups used
D-alanine as substrate and the assay was performed at 25◦C (Chang et al.,
2013; Birolo et al., 2016). Furthermore, another two groups conducted the DAO
activity assay at room temperature, but Kvajo and colleagues used D-proline
as substrate (Kvajo et al., 2008), while Sacchi and colleagues used D-serine
as substrate (Sacchi et al., 2008). In our study, we used D-serine as substrate
and performed the assay at 37◦C, which corresponds to the human body
temperature. The DAO activity assay conducted with D-proline as substrate
(Kvajo et al., 2008) can be biased because D-proline is also a substrate of human
D-aspartate oxidase (Katane et al., 2015). A study found that DAO shows
lower catalytic efficiency and substrate affinity on the physiological substrate
D-serine compared to D-alanine (Molla et al., 2006b), which might explain the
discrepancies found between studies using these substrates. We found that DAO
activity assay worked in 1321N1 and HEK293 cells even without the addition
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of 10 µM FAD, which might be because of endogenous production of FAD
by these cells. Indeed, FAD co-factor binding was reported to be essential for
the DAO enzyme activity (Molla et al., 2006b). Nevertheless, we found that
addition of 10 µM FAD had no effect on the results obtained comparing to
those obtained without the addition of 10 µM FAD in these two cell lines. In
studies using recombinant DAO and DAOA proteins, two of the studies, which
did not use FAD in DAO activity assay, found DAOA to be a DAO activator
(Chumakov et al., 2002; Chang et al., 2013). However, a recent study with human
recombinant DAO and DAOA proteins, where they added FAD in DAO activity
assay found DAOA to be a DAO inhibitor (Birolo et al., 2016). Thus, additional
studies in a more realistic conditions i.e., human induced pluripotent stem cells
(hiPSC) derived neurons and glia using gene editing tools will be required to
conclusively determine whether DAOA is a DAO activator or inhibitor.
In our simulation experiments, we found that there is a slight decrease in
FAD/hDAO (holoenzyme) complex flexibility compared to the hDAO without
FAD (apoprotein) which indicates that the hDAO holoenzyme is more stable
than the hDAO apoprotein. This result coincides with the previous spectroscopic
evidence of hDAO holoenzyme having slightly higher melting temperature than
the hDAO apoprotein (Caldinelli et al., 2009; Sacchi et al., 2012). Previous studies
based on spectroscopy and proteolysis experiments have shown that DAOA
changes the tertiary structure of FAD/hDAO and leads to decrease in hDAO
holoenzyme form (Caldinelli et al., 2010), which is in line with our simulations
that showed DAOA makes FAD/hDAO more flexible (i.e., less stable) and
misfolded. However, our simulations showed that DAOA had no effect on
hDAO apoprotein structure which corroborates with previous proteolysis
experiments that showed hDAO apoprotein structure is not affected by DAOA
(Caldinelli et al., 2010). The difference in flexibility of hDAO apoprotein and
holoenzyme in complex with DAOA can be explained by the different binding
positions of DAOA. DAOA binds to hDAO holoenzyme much closer to the
FAD binding pocket, which causes an increase in the complex’s fluctuations
(i.e., less stable), compared to the hDAO apoprotein where DAOA binds farther
away from the FAD binding pocket. Thus, our simulations indicate that DAOA
inactivates hDAO holoenzyme and not the hDAO apoprotein. However, we
did not observe the similar inactivating effect of DAOA on DAO activity in our
cell lines which might be due to the fact that in our simulations we used only
hDAO and DAOA proteins in an artificial system. Moreover, as indicated in
our previous postmortem study (Jagannath et al., 2017b), the tight regulation
of DAO and DAOA in the human brain compared to the periphery might
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be an additional reason for the in vitro differences found in neuron-like and
astrocyte-like cells compared to the kidney-like cells.
Accordingly, going one-step forward, we tested whether DAOA overexpression
modulates NMDA receptor activity using induced NR1/NR2A HEK293 cells.
In this study, we did not find an effect of DAOA on NMDA receptor currents
in NR1/NR2A HEK293 cell line, despite our results showing DAOA increases
DAO activity in HEK293 cells. This might be because of several reasons namely;
the endogenous DAO (binding partner of DAOA) in NR1/NR2A HEK293 cell
line is not in an active form leading to no effect on D-serine, unavailability
of D-serine transporters in these NR1/NR2A HEK293 cells to transport the
D-serine extracellularly for its action on NMDA receptors, and the DAOA
transfected NR1/NR2A HEK293 cell line is an artificial model system which
doesn’t recapitulate the human tripartite synapse and the complex signaling
pathways of human neurons and glia. A study conducted in primary cultures
from rat hippocampus using whole cell patch clamp technique showed that
DAO inhibitors lead to increase in NMDA receptor mediated currents (Strick
et al., 2011). To our knowledge, there are no papers showing the effect of
DAOA on NMDA receptor currents in vitro. Thus, future experiments must be
conducted, probably also in a more complex cellular system, to understand the
effect of DAOA on NMDA receptors.
In summary, we found that DAOA increases DAO activity only in kidney-like
HEK293, but not in neuron-like SH-SY5Y and astrocyte-like 1321N1 cells. We
also found no effect of DAOA on NMDA receptor currents in NR1/NR2A
HEK293 cells. As our study was performed using human cell lines, in order to
confirm the tight regulation of DAO and DAOA assumed in the human central
nervous system (CNS), modelling the interactions between DAO and DAOA
proteins in schizophrenia patient specific neuroglial culture i.e., hiPSC derived
neurons and glia co-cultures and comparing them to healthy control derived
neuroglial cultures might further help in settling the debate of DAOA effect on
DAO and NMDA receptor activity..
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5.4.6 Supplementary Information
Supplementary Methods
S1 RNA isolation, cDNA synthesis, and quantification of DAO and DAOA
mRNA levels using qRT-PCR
RNA was isolated from transfected SH-SY5Y, 1321N1, and HEK293 cells
using RNeasy Plus Mini Kit (74136, Qiagen) according to manufacturer’s
guidelines. Firstly, the transfected cells were lysed directly in 6-well plates,
and were disrupted and homogenized in the lysis buffer provided in the kit
using the TissueLyser II (Qiagen). Secondly, the homogenized lysates were
added to the gDNA Eliminator spin column to remove the genomic DNA.
Finally, the lysates were added to the RNeasy spin column and RNA was
eluted. We used a spectrophotometer (NanoVue Plus, GE Healthcare Life
Sciences) to measure RNA concentrations, A260/A280, and A260/A230 ratios.
We reverse transcribed 500 ng of RNA using iScriptTM cDNA Synthesis Kit
(Bio-Rad) as per manufacturer’s protocol. In a subset of samples, negative
controls were prepared with RNA without reverse transcriptase enzyme.
Quantitative real-time reverse transcription-PCR (qRT-PCR) was performed
using cDNA, QuantiFast SYBR Green PCR kit (Qiagen), 1 µM DAO or DAOA
primers, and reference genes [β-actin (ACTB; QT01680476), ribosomal protein
L13a (RPL13A; QT00089915), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; QT01192646), peptidylprolyl isomerase A (PPIA; QT00866137),
and ribosomal RNA (R18S; QT00019936); all from Qiagen]. The DAOA
primer (QT00058863) was purchased from Qiagen, and the DAO primer was
purchased from Microsynth, the sequence of which has been described by
(Verrall et al., 2007) (forward primer: CGCAGACGTGATTGTCAACT; reverse
primer: GGATGATGTACGGGGAATTG). DAO and DAOA mRNA levels were
normalized to the reference genes. LinRegPCR program was used to calculate
the PCR efficiencies (Ruijter et al., 2009), and mean PCR efficiencies for all
studied amplicons were 91-92%. Normalized DAO and DAOA mRNA levels
were quantified using qBASE plus software (Biogazelle) as described in detail
previously (Jagannath et al., 2017b).
S2 Protein isolation, Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blot
Protein was isolated from transfected SH-SY5Y, 1321N1, and HEK293 cells
using radioimmunoprecipitation assay buffer (RIPA; R0278, Sigma-Aldrich)
supplemented with protease inhibitor (04693124001, Sigma-Aldrich) and
phosphatase inhibitor (04906845001, Sigma-Aldrich) as per manufacturer’s
165
Study IV: Supplementary Information
guidelines. The transfected cells were washed twice with ice-cold 1x phosphate
buffered saline (PBS) pH 7.4 (10010015, ThermoFisher Scientific). The cells were
scraped and collected in RIPA buffer, and were incubated for 30 minutes at 4◦C
with constant agitation. The cell lysates were centrifuged at 12000 rpm for 10
minutes at 4◦C, and supernatants were collected. The protein concentration
was determined using the Bradford assay (B6916, Sigma-Aldrich)(Bradford,
1976). Protein lysates (16 µg) were mixed with NuPAGE R© LDS Sample Buffer
(NP0007, ThermoFisher Scientific) and NuPAGE R© Sample Reducing Agent
(NP0009, ThermoFisher Scientific), and heated at 70◦C for 10 minutes. Then,
the lysates were loaded onto NuPAGETM NovexTM 4-12% Bis-Tris Protein Gels
(NP0322BOX, ThermoFisher Scientific), and were subjected to electrophoresis at
180 V for 1 hour in XCell SureLock R© Mini-Cell (ThermoFisher Scientific). The
gels were transferred onto nitrocellulose membranes (IB301002, ThermoFisher
Scientific) using iBlot R© Gel Transfer Device (ThermoFisher Scientific). The
membranes were blocked using 5% non-fat milk (T145.1, Roth) in 1x PBS pH
7.4 with 0.1% Tween-20 (P9416, Sigma-Aldrich) (PBST) for 1 hour at room
temperature (RT). After that, the membranes were incubated with primary
antibodies against DAO (1:500; ab196563, abcam) or DAOA (1:100; ab205502,
abcam) or c-Myc (1:1000; ab32, abcam) or GFP (1:1000; ab1218, abcam) or -tubulin
(1:1000; ab6046, abcam) or vinculin (1:10000; ab129002, abcam) diluted in 5%
non-fat milk-PBST at 4◦C overnight. The membranes were washed thrice with
PBST, and then incubated with anti-rabbit secondary HRP-conjugated antibody
(1:2000; ab97051, abcam) or anti-mouse secondary HRP-conjugated antibody
(1:2000; ab6789, abcam) for 1 hour at RT. The protein bands were visualized
with 20X LumiGLO R© Reagent and 20X Peroxide (7003P, Cell Signaling)
using ChemiDocTM XRS+ System with Image LabTM software (Bio-Rad). The
molecular weight of the detected bands was estimated using Novex R© Sharp
Pre-stained Protein Standard (LC5800, ThermoFisher Scientific). The protein
bands were quantified and were normalized to loading controls (β-tubulin or
vinculin) using the ImageJ software (Schneider et al., 2012).
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Supplementary Figures
Supplementary Figure S1: NMDA receptor currents in NR1/NR2A HEK293 cells. (A) Mean
NMDA receptor current across three transfections conditions: G72, pEGFPN1 plasmid, and
non-transfected (NT). (B) Peak NMDA receptor current across three transfections conditions:
G72, pEGFPN1 plasmid, and non-transfected (NT). Data is presented as bar graphs with
mean±SEM. Differences between the three transfection conditions was assessed by one-way
ANOVA (*p<0.05).
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6. General Discussion
The overall objectives of this thesis were to elucidate the importance of DAO and
DAOA genes in neurodevelopment, the potential of these gene polymorphisms
to emerge as predictive markers for schizophrenia, and the interaction between
these genes. These objectives were achieved by investigating these two genes
of interest using different model systems, namely, spatiotemporal expression
studies of these genes in normal human post-mortem brains, genetic risk and
endophenotype analysis in at-risk for psychosis population, and molecular
interactions between DAO and DAOA in human cell lines. First, the results and
conclusions of each study will be summarised, and then their implications in the
broader context will be discussed.
In the post-mortem study (study I), DAO mRNA levels were found to be higher
in the cerebellum, but DAO protein levels were found to be lower in cerebellum
compared to other brain regions studied (brainstem, amygdala, striatum,
thalamus, frontal cortex), which might suggest post-transcriptional regulation
[e.g., microRNA (miRNA)]. Furthermore, DAOA protein was detected in all
brain regions studied, but DAOA mRNA was not detected in these brain regions,
which might be suggestive of tightly regulated DAOA expression or extremely
localized expression or post-transcriptional regulation (e.g., RNA methylation).
We found that there was a significant positive correlation of DAO mRNA levels
with age till 2 years in cerebellum and amygdala, which might highlight the
importance of this gene during brain development. There was a significant
positive correlation between DAO and DAOA protein levels in all brain regions
studied except frontal cortex, which suggests simultaneous expression of these
proteins, but with this finding, we cannot comment on interactions between
these proteins. There was no significant effect of DAO and DAOA SNPs on their
expression. Moreover, in silico DNA methylation results showed that DAO and
DAOA CpG sites in the cerebellum were significantly more methylated than in
the frontal cortex, which might explain the brain-region specific differential DAO
and DAOA expression. However, we could not correlate the DNA methylation
levels at DAO and DAOA CpG sites with DAO and DAOA expression levels
because we did not measure the DNA methylation in our samples.
In the meta-analysis study (study II), we confirmed that 1 DAO SNP (rs4623951)
out of 8 DAO SNPs studied, and 2 DAOA SNPs (rs778293 and rs3916971)
out of 12 DAOA SNPs studied were found to be significantly associated with
schizophrenia. The C-allele of DAO rs4623951 was found to be protective
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against schizophrenia across all pooled studies [Odds ratio (OR)=0.88, 95%
confidence interval (CI)=0.79-0.98, p=0.02, N=3,143)]. The G-allele of DAOA
rs778293 was to be a risk allele for schizophrenia in Asian patients (OR=1.17,
95% CI=1.08-1.27, p=0.00008, N=6,117), and the T-allele of DAOA rs3916971 was
found to be protective against schizophrenia across all pooled studies (OR=0.84,
95% CI=0.73-0.96, p=0.01, N=1,765). In all these three significant SNPs, there
were no new eligible studies since SzGene meta-analysis (Allen et al., 2008) to be
included in our meta-analysis.
In the at-risk for psychosis study (study III), DAO rs3918347 GA+AA genotype
carriers experienced nominally more auditory perception disturbances (RDoC
cognitive system: auditory perception) than GG genotype carriers (G-allele:
risk for schizophrenia). We found that DAOA rs746187 CC genotype carriers
experienced nominally more hopelessness (RDoC negative valence system: loss)
than CT+TT genotype carriers (T-allele: risk for schizophrenia), and DAOA
rs3916971 TT genotype carriers experienced nominally more visual perception
disturbances (RDoC cognitive system: visual perception) than TC+CC genotype
carriers (T-allele: protective against schizophrenia). These results suggest that
DAO and DAOA SNPs might emerge as predictive markers for endophenotypes
such as hopelessness and perception disturbances in at-risk for psychosis
individuals, only after replication and validation in future studies. Furthermore,
DAO and DAOA SNPs did not emerge as predictive markers for conversion
to schizophrenia-spectrum disorders in at-risk for psychosis individuals at
36 months follow-up. We found that the schizophrenia risk G-allele of DAO
rs3918347 nominally increased the risk for those ultra-high risk (UHR) for
psychosis individuals with attenuated positive symptoms syndrome (APSS). We
could not detect DAO and DAOA mRNA levels in the whole blood of at-risk for
psychosis individuals.
In the cell culture study (study IV), we found that DAOA increased DAO
activity only in human kidney-like HEK293 cells, but DAOA had no effect
on DAO activity in human neuron-like SH-SY5Y and human astrocyte-like
1321N1 cells. This might be because of different signalling pathways, different
compartmentalization of DAO and DAOA proteins and lower DAO and DAOA
overexpressed proteins in 1321N1 and SH-SY5Y cells compared to HEK293
cells. We also found that DAOA had no effect on NMDA receptor activity
in HEK293 cells stably transfected with NMDA receptor subunits NR1 and
NR2A (NR1/NR2A HEK293). This might be because of reasons such as (i) the
endogenous DAO protein might be in an inactive form in NR1/NR2A HEK293
cells leading to no effect on D-serine, (ii) unavailability of D-serine transporters
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in these cells, and (iii) these cells are a simple model that do not recapitulate
the tripartite synapse and its complex signalling. The simulation experiments
showed that DAOA makes human DAO (hDAO) holoenzyme (hDAO with
FAD) more flexible and misfolded than hDAO apoprotein (hDAO without FAD),
which might suggest that DAOA inactivates hDAO. This in silico inactivating
effect of DAOA on DAO was not observed in the cell lines studied, which might
be because the simulations are an artificial system.
DAO and DAOA in neurodevelopment and their dysregulation in
schizophrenia
Human neurodevelopment is a complex and precisely regulated process that
transpires over an extended period of time, during which both structural and
functional changes occur. This process depends on the precise regulation
of gene and protein expression (Kang et al., 2011; Tebbenkamp et al., 2014).
Inherited genetic information, inherited epigenetic marks, and environmental
influences converge at the level of transcriptome that results in cell-type
specific, tissue-specific, spatial and temporal patterns of expression of genes
to guide neurodevelopment. Thus, the transcriptome represents a complex
interplay between genetics and epigenetics, which makes transcriptome studies
valuable as they provide insight into the complex process such as human brain
development (Ziats et al., 2015). In order to understand how putative genes can
contribute to a developmental disorder like schizophrenia, it is important to
study the normal expression pattern and functions of these genes in different
brain regions during the developmental time window of interest. The human
brain transcriptome has unique characteristics such as expression of higher levels
of mRNA transcripts than other species, expression of around 85% of all genes
encoded in the human genome at some point during development, increased
alternative splicing and brain-specific transcript expression, abundance of
non-coding RNAs, and brain region-specific expression (Ziats et al., 2015). We
studied the trajectories of DAO and DAOA expression in the normal human
post-mortem brain from prenatal age to 91 years, which showed that expression
of these genes are age and brain-region specific and these genes are highly
regulated at the level of transcription, which might suggest that these genes
are important for neurodevelopment. Dysregulation of these genes during
neurodevelopment might lead to brain-region specific functional and structural
abnormalities, which might manifest later as schizophrenia.
A post-mortem study reported an increase in DAO mRNA and activity in the
cerebellum, but no change in DAO mRNA in the cerebral cortex of schizophrenia
patients compared to the healthy controls (Kapoor et al., 2006). These cortical and
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cerebellar mRNA findings were replicated in a subsequent study (Verrall et al.,
2007), and DAO immunoreactivity showed trend increase in the cerebellum,
but could not be quantified in the prefrontal cortex of schizophrenia patients
compared to healthy controls. A subsequent study confirmed the increase in
DAO mRNA and DAO activity in the cerebellum of schizophrenia patients
(Burnet et al., 2008). A post-mortem study found no change in DAO protein
levels in the hippocampus and prefrontal cortex of schizophrenia patients
(Bendikov et al., 2007), however, a study found an increase in DAO activity
in the parietal cortex of schizophrenia patients compared to healthy controls
(Madeira et al., 2008). Overall, these data provide clear evidence for increased
DAO in the cerebellum of schizophrenia patients, but the data in other brain
regions is still ambiguous. For many years, the cerebellum has been considered
as a coordinator of motor function. Nevertheless, the cerebellum is also thought
to influence cognition through its connections to the frontal cortex via the
thalamus (cortico-cerebellar-thalamic-cortical network) (Koziol et al., 2014).
Thus, it has been hypothesised that the structural and functional abnormalities
observed in the cerebellum of schizophrenia patients (Bernard and Mittal, 2015;
Moberget et al., 2017) disrupt the cortico-cerebellar-thalamic cortical network
ultimately leading to cortical dysfunction contributing to the cognitive deficits of
schizophrenia (Parker et al., 2014).
An earlier post-mortem study showed an increased DAOA mRNA in the
prefrontal cortex of schizophrenia brains compared to healthy controls
(Korostishevsky et al., 2006), which has not been replicated in the subsequent
study (Benzel et al., 2008). Studies have shown increased DAOA protein levels
in the plasma of schizophrenia compared to healthy controls (Lin et al., 2014;
Akyol et al., 2017), which could not be replicated in a recent study (Ishiwata
et al., 2017). Thus, the role of DAOA in schizophrenia remains elusive. Previous
post-mortem studies showed decreased NMDA receptor subunits NR1, NR2A,
and NR2C mRNA levels (Sokolov, 1998; Beneyto and Meador-Woodruff, 2008;
Weickert et al., 2013) and NR1 protein levels (Weickert et al., 2013) in the frontal
cortex of schizophrenia patients. However, several studies could not replicate
these NMDA receptor subunit mRNA (Akbarian et al., 1996; Le Corre et al., 2000;
Dracheva et al., 2001; Rao et al., 2012) and protein findings (Kristiansen et al.,
2006, 2010; Rao et al., 2012). In summary, the molecular evidence for the NMDA
receptor hypofunction in schizophrenia post-mortem brains remains unclear.
Although the mRNA and protein expression patterns of DAO, DAOA, and
NMDA receptor subunits are ambiguous in the frontal cortex of schizophrenia
patients, this brain region has been implicated in the pathophysiology of
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schizophrenia (Zhou et al., 2015). The prefrontal cortex is involved in executive
functions, such as working memory, attention, and decision making, as well
as emotional processing, including affection, emotion, and social behaviour
(Sakurai et al., 2015). Thus, it has been hypothesised that abnormalities in
prefrontal cortex might manifest as cognitive deficits of schizophrenia, and the
alleged anatomical and functional dysconnectivity between the prefrontal cortex
and other brain regions might contribute to positive and negative symptoms of
schizophrenia (Zhou et al., 2015).
DAO and DAOA gene polymorphisms in schizophrenia
A landmark study in 2002 identified DAO and DAOA as putative risk genes
for schizophrenia (Chumakov et al., 2002). This study identified 4 DAO SNPs
(rs211902, rs3918346, rs3741775, rs3918347) and 6 DAOA SNPs [rs3916965 (M12),
rs3916967 (M14), rs2391191 (M15), rs778293 (M22), rs3918342 (M23), rs1421292
(M24)] to be significantly associated with schizophrenia. This study also found
a marginal epistasis between DAO rs3741775 and DAOA rs778293 SNPs, which
has not been replicated in the later studies (Schumacher et al., 2004; Corvin et al.,
2007b). Subsequently, many genetic studies have investigated the association
of DAO and DAOA SNPs with schizophrenia, these studies were combined
in the SzGene meta-analysis (Allen et al., 2008), which identified 1 DAO SNP
(rs4623951) and 2 DAOA SNPs (rs778293 and rs3916971) to be significantly
associated with schizophrenia. In our meta-analysis, we also found the same
DAO and DAOA SNPs to be significantly associated with schizophrenia due to
the unavailability of new association studies for these SNPs. In our at-risk for
psychosis study, DAO and DAOA SNPs did not emerge as predictive markers
for the transition to schizophrenia-spectrum disorders in at-risk for psychosis
population. Furthermore, DAO and DAOA genes are linked to the glutamate
hypothesis of schizophrenia, which is thought to explain the pathophysiology
underlying negative symptoms and cognitive deficits of schizophrenia better
than the dopamine hypothesis (Frohlich and Van Horn, 2014). Therefore,
we integrated genetic information (DAO and DAOA SNPs) and symptom
dimensions (negative symptoms and cognitive deficits), which is one of the
core principles of the RDoC framework (Cuthbert, 2014). We found DAO and
DAOA SNPs to be associated with symptoms such as hopelessness (RDoC
negative valence system) and perception disturbances (RDoC cognitive system).
Thus, these gene polymorphisms may improve our ability to identify at-risk
for psychosis who will develop some specific symptoms of schizophrenia.
The mechanism underlying genetic association of DAO and DAOA SNPs with
schizophrenia remains unclear. Since the associated DAO and DAOA SNPs are
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in the non-coding region, it is likely that these SNPs exert a pathophysiological
effect by modulating DAO and DAOA expression, which still needs to be
elucidated (Verrall et al., 2010; Sacchi et al., 2016).
DAO and DAOA interactions leading to NMDA receptor hypofunction
In 2002, Chumakov and colleagues identified a primate specific DAOA gene and
showed that DAOA increases DAO activity (Chumakov et al., 2002). Following
this study, many studies reported contradictory results with a positive effect
(Chang et al., 2013), negative effect (Sacchi et al., 2008; Birolo et al., 2016), and
no effect (Kvajo et al., 2008) of DAOA on DAO activity. Thus, there is still no
consensus regarding the effect of DAOA on DAO activity in the field. To our
knowledge, there are no studies to date, which shows the effect of DAOA on
NMDA receptor activity in vitro. In our study, we wanted to determine the effect
of DAOA on DAO and NMDA receptor activity, however, our results were also
inconclusive because of the reasons already discussed.
In addition to regulating DAO activity, DAOA has been reported to be localised
in the mitochondria and modulate mitochondrial function (Kvajo et al., 2008).
A study showed that DAOA binds and impairs the function of mitochondrial
methionine-R-sulfoxide reductase B2 (MSRB2), which is responsible for the
elimination of cellular reactive oxygen species (ROS), ultimately leading to
oxidative stress (Otte et al., 2014). Another recent study also reported a link of
DAOA with ROS production (Wang et al., 2015). Interestingly, mitochondrial
dysfunctions have been implicated in the pathophysiology of schizophrenia
(Park and Park, 2012). Nevertheless, it is still an open question whether DAOA
plays a role in the pathophysiology of schizophrenia via NMDA receptor
hypofunction or via oxidative stress or both. Thus, unravelling the mystery of
DAOA is important with the hope of developing novel pharmacotherapy for
schizophrenia targeting DAOA.
Future perspectives
Despite the fact that this thesis revealed the expression trajectory of DAO
and DAOA during development and aging in the human brain, the role of
DAO and DAOA SNPs and mRNA as predictive markers for transition to
schizophrenia-spectrum disorders and RDoC endophenotypes in at-risk for
psychosis population, and the effect of DAOA on DAO and NMDA receptor
activity in human cell lines, there are still several unanswered questions, which
needs to be addressed in future studies. Future human post-mortem studies
should concentrate on identifying the critical regulators (e.g., non-coding RNA)
of DAO and DAOA expression across different brain regions and ages to
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understand the role of these regulators in the pathophysiology of schizophrenia.
The role of DAO and DAOA genes in neurodevelopment can also be studied
using an in vitro model of human brain development i.e., human induced
pluripotent stem cells (hiPSC) derived three-dimensional organoid culture
system called cerebral organoids (Lancaster et al., 2013). Future genetic studies in
the field of early recognition and intervention of psychosis should concentrate on
increasing the sample size and follow-up period, recruiting more homogeneous
at-risk for psychosis individuals and quantifying DAO and DAOA proteins as
predictive markers for the transition to schizophrenia-spectrum disorders and
RDoC endophenotypes in the plasma of at-risk for psychosis individuals. Studies
should also focus on understanding the effect of schizophrenia associated DAO
and DAOA SNPs on their expression so that eventually the role of these SNPs
in the pathophysiology of schizophrenia can be elucidated. To understand the
effect of DAOA on DAO and NMDA receptor activity, more realistic in vitro
model i.e., hiPSC derived neurons and glia that recapitulate the complexity of
tripartite synapse with the use of gene editing tools, might help in uncovering
the mystery of the effect of DAOA on DAO and NMDA receptor activity.
Despite years of research in the field of schizophrenia, the pathophysiology of
the disorder remains elusive, and the current antipsychotics alleviate mainly the
positive symptoms of schizophrenia. Thus, there is an urgent need for novel
pharmacotherapy that alleviates negative symptoms and cognitive deficits of
schizophrenia. To reach this goal, future studies should focus on elucidating
the pathogenesis of schizophrenia with the hope of identifying new therapeutic
targets for the treatment of schizophrenia.
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